web-scraper-order,web-scraper-start-url,patent_link,patent_link-href,patent_date,patent_abstract,patent_number,patent_assignee,referenced_by_link,referenced_by_link-href,citator_link,citator_link-href,pagination,pagination-href,citator_patent_number,citator_date
1519571925-1,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Sustained release formulation containing an ion-exchange resin,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=100&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3962414.UREF.&Page=Next&OS=ref/3962414&RS=REF/3962414,"4,931,279",1990
1519571930-2,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Bioadhesive compositions and methods of treatment therewith,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=99&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3962414.UREF.&Page=Next&OS=ref/3962414&RS=REF/3962414,"4,983,392",1991
1519571933-3,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Biodegradable ocular implants,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=98&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3962414.UREF.&Page=Next&OS=ref/3962414&RS=REF/3962414,"4,997,652",1991
1519571936-4,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,"Glaucoma formulations comprising an anionic, polysulfonic acid polymer
     having mucomimetic properties and a polystyrene sulfonic polymer",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=97&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3962414.UREF.&Page=Next&OS=ref/3962414&RS=REF/3962414,"5,093,126",1992
1519571938-5,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Biodegradable ocular implants,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=96&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3962414.UREF.&Page=Next&OS=ref/3962414&RS=REF/3962414,"5,164,188",1992
1519571941-6,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,"Method and apparatus for controlled release drug delivery to the cornea
     and anterior chamber of the eye",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=95&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3962414.UREF.&Page=Next&OS=ref/3962414&RS=REF/3962414,"5,185,152",1993
1519571943-7,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Pharmaceutical composition for the treatment of the human eye,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=94&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3962414.UREF.&Page=Next&OS=ref/3962414&RS=REF/3962414,"5,200,180",1993
1519571947-8,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Bioadhesive compositions and methods of treatment therewith,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=93&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3962414.UREF.&Page=Next&OS=ref/3962414&RS=REF/3962414,"5,225,196",1993
1519571949-9,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,"Mirror amide cord factors and mirror thioester cord factors for
     diagnosis of tuberculosis",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=92&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3962414.UREF.&Page=Next&OS=ref/3962414&RS=REF/3962414,"5,399,683",1995
1519571951-10,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Cross-linked alginate transdermal medicine delivery devices,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=91&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3962414.UREF.&Page=Next&OS=ref/3962414&RS=REF/3962414,"5,484,604",1996
1519571953-11,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Films fabricated from mixtures of pectin and poly(vinyl alchohol),http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=90&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3962414.UREF.&Page=Next&OS=ref/3962414&RS=REF/3962414,"5,646,206",1997
1519571956-12,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Device for delivery of substances and methods of use thereof,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=89&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3962414.UREF.&Page=Next&OS=ref/3962414&RS=REF/3962414,"5,681,568",1997
1519571958-13,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Ophthalmic insert and method for sustained release of medication to the eye,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=88&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3962414.UREF.&Page=Next&OS=ref/3962414&RS=REF/3962414,"6,196,993",2001
1519571960-14,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Sustained release ophthalmic formulation,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=87&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3962414.UREF.&Page=Next&OS=ref/3962414&RS=REF/3962414,"6,258,350",2001
1519571962-15,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Method for the management of incontinence,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=86&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3962414.UREF.&Page=Next&OS=ref/3962414&RS=REF/3962414,"6,262,115",2001
1519571965-16,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Stent with collagen,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=85&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3962414.UREF.&Page=Next&OS=ref/3962414&RS=REF/3962414,"6,391,052",2002
1519571968-17,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Microencapsulated compounds and method of preparing same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=84&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3962414.UREF.&Page=Next&OS=ref/3962414&RS=REF/3962414,"6,555,110",2003
1519571970-18,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,"Orally administered dosage forms of GABA analog prodrugs having reduced
     toxicity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=83&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3962414.UREF.&Page=Next&OS=ref/3962414&RS=REF/3962414,"6,833,140",2004
1519571973-19,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Method for the management of incontinence,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=82&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3962414.UREF.&Page=Next&OS=ref/3962414&RS=REF/3962414,"6,919,092",2005
1519571976-20,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Methods and devices for providing prolonged drug therapy,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=81&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3962414.UREF.&Page=Next&OS=ref/3962414&RS=REF/3962414,"6,919,373",2005
1519571979-21,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Methods and devices for providing prolonged drug therapy,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=80&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3962414.UREF.&Page=Next&OS=ref/3962414&RS=REF/3962414,"6,930,129",2005
1519571981-22,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,"Sustained release ophthalmic, otic and nasal suspension",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=79&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3962414.UREF.&Page=Next&OS=ref/3962414&RS=REF/3962414,"7,001,615",2006
1519571984-23,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,"Carbidopa prodrugs and derivatives, and compositions and uses thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=78&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3962414.UREF.&Page=Next&OS=ref/3962414&RS=REF/3962414,"7,101,912",2006
1519571988-24,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,"Acyloxyalkyl carbamate prodrugs, methods of synthesis and use",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=77&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3962414.UREF.&Page=Next&OS=ref/3962414&RS=REF/3962414,"7,109,239",2006
1519571990-25,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,"Platinum-containing compounds exhibiting cytostatic activity, synthesis
     and methods of use",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=76&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3962414.UREF.&Page=Next&OS=ref/3962414&RS=REF/3962414,"7,208,611",2007
1519571994-26,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Methods for synthesis of acyloxyalkyl derivatives of GABA analogs,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=75&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3962414.UREF.&Page=Next&OS=ref/3962414&RS=REF/3962414,"7,232,924",2007
1519571996-27,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,"Acyloxyalkyl carbamate prodrugs, methods of synthesis and use",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=74&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3962414.UREF.&Page=Next&OS=ref/3962414&RS=REF/3962414,"7,300,956",2007
1519571999-28,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,"Levodopa prodrugs, and compositions and uses thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=73&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3962414.UREF.&Page=Next&OS=ref/3962414&RS=REF/3962414,"7,323,585",2008
1519572001-29,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,"Levodopa prodrugs, and compositions and uses thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=72&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3962414.UREF.&Page=Next&OS=ref/3962414&RS=REF/3962414,"7,342,131",2008
1519572004-30,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,"Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis
     and use",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=71&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3962414.UREF.&Page=Next&OS=ref/3962414&RS=REF/3962414,"7,351,740",2008
1519572007-31,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,"Amino acid conjugates providing for sustained systemic concentrations of
     GABA analogues",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=70&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3962414.UREF.&Page=Next&OS=ref/3962414&RS=REF/3962414,"7,420,002",2008
1519572009-32,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Methods for synthesis of acyloxyalkyl derivatives of GABA analogs,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=69&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3962414.UREF.&Page=Next&OS=ref/3962414&RS=REF/3962414,"7,423,169",2008
1519572012-33,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Microencapsulated materials and method of making same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=68&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3962414.UREF.&Page=Next&OS=ref/3962414&RS=REF/3962414,"7,425,543",2008
1519572015-34,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,"Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=67&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3962414.UREF.&Page=Next&OS=ref/3962414&RS=REF/3962414,"7,494,985",2009
1519572017-35,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,"Levodopa prodrugs, and compositions and uses thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=66&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3962414.UREF.&Page=Next&OS=ref/3962414&RS=REF/3962414,"7,534,813",2009
1519572019-36,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,"Levodopa prodrug mesylate, compositions thereof, and uses thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=65&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3962414.UREF.&Page=Next&OS=ref/3962414&RS=REF/3962414,"7,563,821",2009
1519572023-37,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,"Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis,
     and use",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=64&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3962414.UREF.&Page=Next&OS=ref/3962414&RS=REF/3962414,"7,566,738",2009
1519572026-38,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,"Acyloxyalkyl carbamate prodrugs, methods of synthesis and use",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=63&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3962414.UREF.&Page=Next&OS=ref/3962414&RS=REF/3962414,"7,572,830",2009
1519572034-39,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,"Acyloxyalkyl carbamate prodrugs, methods of synthesis and use",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=62&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3962414.UREF.&Page=Next&OS=ref/3962414&RS=REF/3962414,"7,585,996",2009
1519572038-40,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,"Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis
     and use",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=61&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3962414.UREF.&Page=Next&OS=ref/3962414&RS=REF/3962414,"7,592,369",2009
1519572041-41,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,"Amino acid conjugates providing for sustained systemic concentrations of
     GABA analogues",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=60&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3962414.UREF.&Page=Next&OS=ref/3962414&RS=REF/3962414,"7,645,797",2010
1519572044-42,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,"Levodopa prodrugs, and compositions and uses thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=59&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3962414.UREF.&Page=Next&OS=ref/3962414&RS=REF/3962414,"7,671,089",2010
1519572047-43,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Treating urinary incontinence using prodrugs of GABA analogs,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=58&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3962414.UREF.&Page=Next&OS=ref/3962414&RS=REF/3962414,"7,700,652",2010
1519572051-44,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,"Levodopa dimethyl-substituted diester prodrugs compositions, and methods
     of use",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=57&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3962414.UREF.&Page=Next&OS=ref/3962414&RS=REF/3962414,"7,709,527",2010
1519572059-45,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,"Acyloxyalkyl carbamate prodrugs, methods of synthesis and use",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=56&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3962414.UREF.&Page=Next&OS=ref/3962414&RS=REF/3962414,"7,749,985",2010
1519572063-46,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,"Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis
     and use",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=55&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3962414.UREF.&Page=Next&OS=ref/3962414&RS=REF/3962414,"7,777,070",2010
1519572071-47,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,"Catechol protected levodopa diester prodrugs, compositions, and methods of
     use",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=54&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3962414.UREF.&Page=Next&OS=ref/3962414&RS=REF/3962414,"7,829,592",2010
1519572073-48,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,"Levodopa prodrug mesylate, compositions thereof, and uses thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=53&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3962414.UREF.&Page=Next&OS=ref/3962414&RS=REF/3962414,"7,893,105",2011
1519572086-49,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,"Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=52&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3962414.UREF.&Page=Next&OS=ref/3962414&RS=REF/3962414,"7,935,686",2011
1519572090-50,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,"Levodopa prodrugs, and compositions and uses thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=51&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3962414.UREF.&Page=Next&OS=ref/3962414&RS=REF/3962414,"7,956,212",2011
1519572093-51,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,"Levodopa prodrug mesylate, compositions thereof, and uses thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=50&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,,"7,968,597",2011
1519572095-52,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Eye wall anchored fixtures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=49&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,,"7,976,520",2011
1519572098-53,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Antidepressant dosage form,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=48&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,,"8,084,059",2011
1519572100-54,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,"Methods of making decomposable thin films of polyelectrolytes and uses
     thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=47&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,,"8,105,652",2012
1519572105-55,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,"Treating or preventing restless legs syndrome using prodrugs of GABA
     analogs",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=46&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,,"8,114,909",2012
1519572108-56,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Methods and devices for providing prolonged drug therapy,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=45&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,,"8,163,798",2012
1519572112-57,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,"Levodopa prodrugs, and compositions and uses thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=44&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,,"8,163,958",2012
1519572114-58,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Ocular drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=43&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,,"8,167,855",2012
1519572116-59,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,"Levodopa prodrug mesylate, compositions thereof, and uses thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=42&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,,"8,193,242",2012
1519572118-60,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Ocular drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=41&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,,"8,287,504",2012
1519572121-61,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Sustained-release formulations of topiramate,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=40&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,,"8,298,576",2012
1519572123-62,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Sustained-release formulations of topiramate,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=39&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,,"8,298,580",2012
1519572131-63,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,"Levodopa dimethyl-substituted diester prodrugs, compositions, and methods
     of use",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=38&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,,"8,324,272",2012
1519572135-64,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,"Catechol protected levodopa diester prodrugs, compositions, and methods of
     use",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=37&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,,"8,324,273",2012
1519572138-65,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,"Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis
     and use",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=36&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,,"8,372,881",2013
1519572140-66,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Levodopa prodrug mesylate hydrate,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=35&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,,"8,399,513",2013
1519572144-67,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,"Pharmaceutical compositions and oral dosage forms of a levodopa prodrug
     and methods of use",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=34&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,,"8,435,562",2013
1519572148-68,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Methods and devices for providing prolonged drug therapy,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=33&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,,"8,629,179",2014
1519572150-69,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Sustained-release formulations of topiramate,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=32&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,,"8,663,683",2014
1519572153-70,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Ocular drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=31&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,,"8,679,078",2014
1519572157-71,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Ocular insert apparatus and methods,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=30&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,,"8,715,712",2014
1519572159-72,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Levodopa prodrug mesylate hydrate,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=29&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,,"8,722,733",2014
1519572163-73,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,GABA analog prodrug sustained release oral dosage forms,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=28&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,,"8,795,725",2014
1519572165-74,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Punctal plug containing drug formulation,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=27&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,,"8,821,457",2014
1519572167-75,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Sustained-release formulations of topiramate,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=26&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,,"8,877,248",2014
1519572169-76,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Sustained-release formulations of topiramate,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=25&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,,"8,889,191",2014
1519572172-77,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Punctal plugs with directional release,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=24&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,,"8,894,602",2014
1519572176-78,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,GABA analog prodrug sustained release oral dosage forms,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=23&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,,"8,906,412",2014
1519572179-79,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Ocular insert apparatus and methods,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=22&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,,"8,939,948",2015
1519572181-80,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Sustained-release formulations of topiramate,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=21&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,,"8,992,989",2015
1519572183-81,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Methods and devices for providing prolonged drug therapy,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=20&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,,"9,000,038",2015
1519572187-82,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Methods and devices for providing prolonged drug therapy,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=19&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,,"9,029,416",2015
1519572190-83,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Method for forming an ocular drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=18&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,,"9,102,105",2015
1519572192-84,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Methods and devices for providing prolonged drug therapy,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=17&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,,"9,144,549",2015
1519572194-85,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,"Nanospheres encapsulating bioactive material and method for formulation of
     nanospheres",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=16&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,,"9,149,441",2015
1519572197-86,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Controlled delivery of bioactive agents from decomposable films,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=15&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,,"9,198,875",2015
1519572200-87,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,"Prodrugs of gaba analogs, compositions and uses thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=14&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,,"9,238,616",2016
1519572202-88,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Methods of synthesizing a levodopa ester prodrug,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=13&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,,"9,290,445",2016
1519572204-89,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Punctal plugs for controlled release of therapeutic agents,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=12&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,,"9,301,874",2016
1519572206-90,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,"Methods and dosage forms for controlled delivery of paliperidone and
     risperidone",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=11&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,,"9,393,192",2016
1519572209-91,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Self assembled films for protein and drug delivery applications,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=10&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,,"9,393,217",2016
1519572214-92,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Anterior segment drug delivery,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=9&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,,"9,421,126",2016
1519572219-93,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Compositions and methods for nucleic acid delivery,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=8&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,,"9,463,244",2016
1519572228-94,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Sustained-release formulations of topiramate,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=7&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,,"9,549,940",2017
1519572235-95,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Sustained-release formulations of topiramate,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=6&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,,"9,555,004",2017
1519572241-96,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Sustained-release formulations of topiramate,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=5&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,,"9,622,983",2017
1519572250-97,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,"Nucleic acid particles, methods and use thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=4&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,,"9,737,557",2017
1519572259-98,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Topiramate compositions and methods of enhancing its bioavailability,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=3&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,,"9,744,137",2017
1519572266-99,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Ophthalmic system for sustained release of drug to eye,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=2&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,,"9,750,636",2017
1519572276-100,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Structured bioerodible drug delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=623&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"A drug delivery device for the continuous and controlled administration of
     a predetermined therapeutically effective dosage of eye drug to the eye of
     a mamallian patient over a prolonged period of time. The device meters the
     flow of polylactic acid polymer micro-encapsulated eye drug by means of a
     drug release rate controlling material comprised of an anionic polyvalent
     metal cation cross-linked polyelectrolyte. The device bioerodes in the
     biological environment of the patient concurrently with the dispensing or
     at a point in time after the dispensing of the therapeutically desired
     amount of drug.","3,962,414","Alza Corporation
 (Palo Alto, 
CA)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3962414,Polysubunit opioid prodrugs resistant to overdose and abuse,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=1&f=G&l=50&d=PALL&S1=3962414.UREF.&OS=ref/3962414&RS=REF/3962414,,,"9,808,452",2017
1519572317-101,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,"New prosthesis parts, their preparation and their application",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=75&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3982543.UREF.&Page=Next&OS=ref/3982543&RS=REF/3982543,"4,279,249",1981
1519572324-102,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Elastomeric composite material comprising a polypeptide,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=74&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3982543.UREF.&Page=Next&OS=ref/3982543&RS=REF/3982543,"4,474,851",1984
1519572329-103,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Polymers for injection molding of absorbable surgical devices,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=73&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3982543.UREF.&Page=Next&OS=ref/3982543&RS=REF/3982543,"4,523,591",1985
1519572333-104,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Absorbable bone fixation device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=72&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3982543.UREF.&Page=Next&OS=ref/3982543&RS=REF/3982543,"4,539,981",1985
1519572335-105,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Absorbable bone fixation device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=71&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3982543.UREF.&Page=Next&OS=ref/3982543&RS=REF/3982543,"4,550,449",1985
1519572338-106,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Surgical suture coating,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=70&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3982543.UREF.&Page=Next&OS=ref/3982543&RS=REF/3982543,"4,705,820",1987
1519572341-107,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Two-phase compositions for absorbable surgical devices,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=69&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3982543.UREF.&Page=Next&OS=ref/3982543&RS=REF/3982543,"4,744,365",1988
1519572343-108,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Bioabsorbable coating for a surgical article,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=68&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3982543.UREF.&Page=Next&OS=ref/3982543&RS=REF/3982543,"4,788,979",1988
1519572353-109,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Bioabsorbable coating for a surgical article,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=67&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3982543.UREF.&Page=Next&OS=ref/3982543&RS=REF/3982543,"4,791,929",1988
1519572361-110,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Flat braided ligament or tendon implant device having texturized yarns,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=66&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3982543.UREF.&Page=Next&OS=ref/3982543&RS=REF/3982543,"4,792,336",1988
1519572365-111,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Hard tissue substitute composition,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=65&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3982543.UREF.&Page=Next&OS=ref/3982543&RS=REF/3982543,"4,902,649",1990
1519572372-112,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,"Random copolymers of p-dioxanone, lactide and/or glycolide as coating
     polymers for surgical filaments",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=64&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3982543.UREF.&Page=Next&OS=ref/3982543&RS=REF/3982543,"5,076,807",1991
1519572375-113,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Two phase compositions for absorbable surgical devices,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=63&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3982543.UREF.&Page=Next&OS=ref/3982543&RS=REF/3982543,"5,124,103",1992
1519572378-114,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Biodegradable packaging thermoplastics from lactides,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=62&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3982543.UREF.&Page=Next&OS=ref/3982543&RS=REF/3982543,"5,180,765",1993
1519572382-115,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Blends of polyactic acid,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=61&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3982543.UREF.&Page=Next&OS=ref/3982543&RS=REF/3982543,"5,216,050",1993
1519572385-116,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Bioabsorbable melt spun fiber based on glycolide-containing copolymer,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=60&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3982543.UREF.&Page=Next&OS=ref/3982543&RS=REF/3982543,"5,232,648",1993
1519572391-117,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Degradable impact modified polyactic acid,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=59&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3982543.UREF.&Page=Next&OS=ref/3982543&RS=REF/3982543,"5,252,642",1993
1519572393-118,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Method and apparatus for calendering and coating/filling sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=58&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3982543.UREF.&Page=Next&OS=ref/3982543&RS=REF/3982543,"5,312,642",1994
1519572397-119,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Absorbable block copolymers and surgical articles fabricated therefrom,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=57&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3982543.UREF.&Page=Next&OS=ref/3982543&RS=REF/3982543,"5,403,347",1995
1519572405-120,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Resorbable prosthesis,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=56&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3982543.UREF.&Page=Next&OS=ref/3982543&RS=REF/3982543,"5,425,766",1995
1519572415-121,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Absorbable block copolymers and surgical articles fabricated therefrom,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=55&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3982543.UREF.&Page=Next&OS=ref/3982543&RS=REF/3982543,"5,431,679",1995
1519572426-122,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Apparatus for calendering sutures in orthogonal directions,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=54&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3982543.UREF.&Page=Next&OS=ref/3982543&RS=REF/3982543,"5,447,100",1995
1519572430-123,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,"Blends of glycolide and/or lactide polymers and caprolactone and/or
     trimethylene carbonate polymers and absorbable surgical devices made",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=53&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3982543.UREF.&Page=Next&OS=ref/3982543&RS=REF/3982543,"5,475,063",1995
1519572434-124,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Degradable polymer composition,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=52&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3982543.UREF.&Page=Next&OS=ref/3982543&RS=REF/3982543,"5,502,158",1996
1519572439-125,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Absorbable block copolymers and surgical articles fabricated therefrom,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=51&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=3982543.UREF.&Page=Next&OS=ref/3982543&RS=REF/3982543,"5,522,841",1996
1519572441-126,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Apparatus for calendering and coating/filling sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=50&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,,"5,540,773",1996
1519572443-127,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Absorbable block copolymers and surgical articles fabricated therefrom,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=49&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,,"5,554,170",1996
1519572446-128,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Composite bioabsorbable materials and surgical articles made thereform,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=48&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,,"5,578,046",1996
1519572449-129,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Method for making vascular grafts,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=47&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,,"5,584,875",1996
1519572453-130,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Absorbable polymer and surgical articles fabricated therefrom,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=46&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,,"5,618,313",1997
1519572455-131,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Composite bioabsorbable materials and surgical articles made therefrom,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=45&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,,"5,626,611",1997
1519572458-132,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Preparation process of degradable polymer,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=44&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,,"5,637,631",1997
1519572460-133,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Porous flexible sheet for tissue separation,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=43&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,,"5,641,505",1997
1519572463-134,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Impact modified polylactide,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=42&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,,"5,756,651",1998
1519572468-135,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,End use applications of biodegradable polymers,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=41&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,,"5,760,118",1998
1519572474-136,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Degradable polydioxaneone-based materials,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=40&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,,"5,767,222",1998
1519572480-137,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Coating mixture for surgical articles,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=39&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,,"5,786,022",1998
1519572486-138,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Degradable polydioxaneone-based materials,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=38&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,,"5,801,223",1998
1519572492-139,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Process and apparatus for coating surgical sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=37&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,,"5,817,129",1998
1519572497-140,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Impact modified polylactide,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=36&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,,"5,908,918",1999
1519572502-141,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Absorbable polymer blends and surgical articles fabricated therefrom,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=35&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,,"5,997,568",1999
1519572512-142,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Absorbable block copolymers and surgical articles fabricated therefrom,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=34&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,,"6,007,565",1999
1519572517-143,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,"Polymerizable biodegradable polymers including carbonate or dioxanone
     linkages",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=33&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,,"6,083,524",2000
1519572525-144,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Absorbable block copolymers and surgical articles fabricated therefrom,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=32&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,,"6,136,018",2000
1519572531-145,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,"Polymerizable biodegradable polymers including carbonate or dioxanone
     linkages",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=31&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,,"6,177,095",2001
1519572536-146,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Surgical filament construction,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=30&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,,"6,183,499",2001
1519572540-147,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Process and apparatus for coating surgical sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=29&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,,"6,187,095",2001
1519572546-148,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Bioabsorbable suture and method of its manufacture,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=28&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,,"6,191,236",2001
1519572552-149,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Absorbable polymer and surgical articles fabricated therefrom,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=27&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,,"6,206,908",2001
1519572557-150,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,"Blends of glycolide and/or lactide polymers and caprolactone and/or
     trimethylene carbonate polymers and absorabable surgical devices made
     therefrom",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=26&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,,"6,228,954",2001
1519572562-151,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Absorbable block copolymers and surgical articles fabricated therefrom,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=25&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,,"6,277,927",2001
1519572570-152,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Composite materials and surgical articles made therefrom,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=24&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,,"6,315,788",2001
1519572575-153,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,"Bioabsorbable, biocompatible polymers for tissue engineering",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=23&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,,"6,514,515",2003
1519572581-154,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Editing system and editing method,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=22&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,,"6,546,188",2003
1519572588-155,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Polyhydroxyalkanoate compositions having controlled degradation rates,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=21&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,,"6,610,764",2003
1519572591-156,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,High consistency absorbable polymeric resin,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=20&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,,"6,716,932",2004
1519572599-157,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,"Bioabsorbable, biocompatible polymers for tissue engineering",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=19&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,,"6,746,685",2004
1519572609-158,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Polyhydroxyalkanoate compositions having controlled degradation rates,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=18&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,,"6,828,357",2004
1519572615-159,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Polyhydroxyalkanoate compositions having controlled degradation rates,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=17&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,,"6,867,248",2005
1519572624-160,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Polyhydroxyalkanoate compositions having controlled degradation rates,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=16&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,,"6,878,758",2005
1519572631-161,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Sutures and coatings made from therapeutic absorbable glass,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=15&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,,"6,881,766",2005
1519572636-162,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,"Bioabsorbable branched polymers containing units derived from dioxanone
     and medical/surgical devices manufactured therefrom",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=14&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,,"7,097,907",2006
1519572641-163,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,"Polymerizable biodegradable polymers including carbonate or dioxanone
     linkages",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=13&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,,"RE39,713",2007
1519572648-164,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Bioabsorbable branched polymers end-capped with diketene acetals,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=12&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,,"7,321,008",2008
1519572654-165,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Medical devices and applications of polyhydroxyalkanoate polymers,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=11&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,,"7,553,923",2009
1519572661-166,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Method of making a polyhydroxyalkanoate filament,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=10&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,,"7,641,825",2010
1519572666-167,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,"Medical devices containing oriented films of poly-4-hydroxybutyrate and
     copolymers",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=9&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,,"7,943,683",2011
1519572675-168,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Polyhydroxyalkanoate medical textiles and fibers,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=8&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,,"8,034,270",2011
1519572680-169,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Non-curling polyhydroxyalkanoate sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=7&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,,"8,084,125",2011
1519572687-170,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,"Medical devices containing oriented films of poly-4-hydroxybutyrate and
     copolymers",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=6&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,,"8,753,555",2014
1519572692-171,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Process of making polyhydroxyalkanoate medical textiles,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=5&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,,"8,758,657",2014
1519572699-172,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Antimicrobial polymer compositions and the use thereof,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=4&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,,"8,840,876",2014
1519572704-173,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Polyhydroxyalkanoate medical textiles and fibers,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=3&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,,"9,125,719",2015
1519572714-174,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,Method of making a medical textile from polyhydroxyalkanoate fibers,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=2&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,,"9,333,066",2016
1519572726-175,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Reducing capillarity of polyglycolic acid sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=622&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1976,"Useful surgical elements consist of a sterile synthetic copolymer
     containing, by mole percent, about 15 to 85 percent glycolic acid and 85
     to 15 percent lactic acid, which has enhanced tissue absorption as
     compared with polylactic acid and enhanced solubility in organic solvents
     as compared with polyglycolic acid and hence can be cast into sheets
     during preparation and implantation. Such surgical element may be used
     alone or in combination with polyglycolic acid or a coating for
     polyglycolic acid surgical elements. Other comonomers may be introduced
     into the system.","3,982,543","American Cyanamid Company
 (Stamford, 
CT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/3982543,"Methods of orienting multifilament yarn and monofilaments of
     poly-4-hydroxybutyrate and copolymers thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=1&f=G&l=50&d=PALL&S1=3982543.UREF.&OS=ref/3982543&RS=REF/3982543,,,"9,555,155",2017
1519572740-176,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Assimilable hydrophilic prosthesis,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=621&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1980,"A porous, hydrophilic, assimilable prosthesis is formed by the removal of
     solvent, without substantial dimensional change, from a solution of (a),
     an assimilable polymer composed primarily of polymerized units of an alpha
     or beta hydroxy carboxylic acid, preferably but not necessarily those
     having 1 to 4 carbon atoms, and (b), a small amount of a physiologically
     acceptable wetting agent that is sufficient to impart hydrophilicity to
     the prosthesis. The preferred assimilable polymer is a polylactic acid.
     The preferred process for making the prosthesis involves the
     lyophilization of a solution of polylactic acid having a molecular weight
     of at least 100,000, weight average, at a concentration of at least 31/2%
     by weight of the solution of the polylactic acid. A variety of
     physiologically acceptable wetting agents is useful, a preferred class
     being the alkali metal soaps of fatty acids or of alkyl aryl sulfonic
     acids.","4,181,983",null,,http://pdfpiw.uspto.gov/.piw?Docid=04181983&homeurl=http%3A%2F%2Fpatft.uspto.gov%2Fnetacgi%2Fnph-Parser%3FSect1%3DPTO2%2526Sect2%3DHITOFF%2526u%3D%25252Fnetahtml%25252FPTO%25252Fsearch-adv.htm%2526r%3D621%2526f%3DG%2526l%3D50%2526d%3DPTXT%2526s1%3D%252522polylactic%252Bacid%252522.ABTX.%2526p%3D13%2526OS%3DABST%2F%252522polylactic%252Bacid%252522%2526RS%3DABST%2F%252522polylactic%252Bacid%252522&PageNum=&Rtype=&SectionNum=&idkey=NONE&Input=View+first+page,,,null,,,
1519572751-177,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with biologically absorbable outer container,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=620&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1981,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prosthesis. The
     unique construction of the new prosthesis causes the capsule to form at a
     predetermined, controlled distance from the surface thereof. This
     prosthesis is constructed with a first phase or outer temporary component
     and a second phase or inner permanent component. The inner component is a
     container or sac of a flexible, non-absorbable material filled with a
     fluid or gel filler material. The temporary outer component is an outer
     container or cover of a material which is absorbable under the conditions
     of use, and an inert filler material, preferably an absorbable,
     biologically acceptable liquid, e.g. saline solution, filling the space
     between the inner and outer components. The inner component is preferably
     of silicone rubber film and is filled with a silicone gel. The outer
     portion is in the form of a sheet, film or coating of a material which can
     be absorbed in the body after surgical implantation. Suitable materials
     are ones which will be absorbed by phagocytosis or hydrolysis or other
     processes or which can be rendered absorbable by physical or chemical or
     enzymatic treatment or the like, prior to, during, or after surgical
     implantation. These materials include natural, synthetic or semisynthetic
     materials proven useful for surgical sutures and materials such as
     reconstituted collagen, polylactic acid, polyglycolic acid, polyglactin
     910, reconstituted vegetable protein, etc.","4,298,998",null,,http://pdfpiw.uspto.gov/.piw?Docid=04298998&homeurl=http%3A%2F%2Fpatft.uspto.gov%2Fnetacgi%2Fnph-Parser%3FSect1%3DPTO2%2526Sect2%3DHITOFF%2526u%3D%25252Fnetahtml%25252FPTO%25252Fsearch-adv.htm%2526r%3D620%2526f%3DG%2526l%3D50%2526d%3DPTXT%2526s1%3D%252522polylactic%252Bacid%252522.ABTX.%2526p%3D13%2526OS%3DABST%2F%252522polylactic%252Bacid%252522%2526RS%3DABST%2F%252522polylactic%252Bacid%252522&PageNum=&Rtype=&SectionNum=&idkey=NONE&Input=View+first+page,,,null,,,
1519572787-178,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,"Biodegradable organic polymer delivery system for bone morphogenetic
     protein",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=99&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4428082.UREF.&Page=Next&OS=ref/4428082&RS=REF/4428082,"4,563,489",1986
1519572795-179,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Mammary implant,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=98&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4428082.UREF.&Page=Next&OS=ref/4428082&RS=REF/4428082,"4,592,755",1986
1519572799-180,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Collagen coated soft tissue prostheses,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=97&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4428082.UREF.&Page=Next&OS=ref/4428082&RS=REF/4428082,"4,772,285",1988
1519572805-181,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Method for administering interleukin-2,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=96&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4428082.UREF.&Page=Next&OS=ref/4428082&RS=REF/4428082,"4,832,686",1989
1519572811-182,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Stacked breast implant,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=95&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4428082.UREF.&Page=Next&OS=ref/4428082&RS=REF/4428082,"5,236,454",1993
1519572819-183,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Mammary prosthesis,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=94&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4428082.UREF.&Page=Next&OS=ref/4428082&RS=REF/4428082,"5,447,535",1995
1519572825-184,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Orbital implant,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=93&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4428082.UREF.&Page=Next&OS=ref/4428082&RS=REF/4428082,"5,713,955",1998
1519572829-185,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Process for the manufacture of breast prostheses,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=92&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4428082.UREF.&Page=Next&OS=ref/4428082&RS=REF/4428082,"5,738,812",1998
1519572834-186,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Covering for an implantable prosthetic device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=91&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4428082.UREF.&Page=Next&OS=ref/4428082&RS=REF/4428082,"5,779,734",1998
1519572841-187,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Hydraulic foam tissue implant,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=90&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4428082.UREF.&Page=Next&OS=ref/4428082&RS=REF/4428082,"5,824,081",1998
1519572849-188,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Breast enhancer,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=89&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4428082.UREF.&Page=Next&OS=ref/4428082&RS=REF/4428082,"D400,337",1998
1519572856-189,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Multiple section breast prosthesis,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=88&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4428082.UREF.&Page=Next&OS=ref/4428082&RS=REF/4428082,"5,902,335",1999
1519572864-190,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Intervertebral disc nucleus implants and methods,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=87&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4428082.UREF.&Page=Next&OS=ref/4428082&RS=REF/4428082,"6,620,196",2003
1519572869-191,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Bioabsorbable breast implant,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=86&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4428082.UREF.&Page=Next&OS=ref/4428082&RS=REF/4428082,"6,638,308",2003
1519572876-192,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Bioabsorbable breast implant,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=85&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4428082.UREF.&Page=Next&OS=ref/4428082&RS=REF/4428082,"6,881,226",2005
1519572885-193,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Intervertebral disc nucleus implants and methods,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=84&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4428082.UREF.&Page=Next&OS=ref/4428082&RS=REF/4428082,"6,893,466",2005
1519572893-194,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Method and apparatus for delivering an intervertebral disc implant,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=83&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4428082.UREF.&Page=Next&OS=ref/4428082&RS=REF/4428082,"7,204,851",2007
1519572898-195,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Methods for forming and retaining intervertebral disc implants,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=82&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4428082.UREF.&Page=Next&OS=ref/4428082&RS=REF/4428082,"7,503,936",2009
1519572906-196,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Intervertebral disc nucleus implants and methods,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=81&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4428082.UREF.&Page=Next&OS=ref/4428082&RS=REF/4428082,"7,520,900",2009
1519572912-197,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,"Two-layer external breast prosthesis with self-shaping feature and process
     for the manufacture thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=80&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4428082.UREF.&Page=Next&OS=ref/4428082&RS=REF/4428082,"7,575,596",2009
1519572919-198,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Composite intervertebral disc implants and methods for forming the same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=79&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4428082.UREF.&Page=Next&OS=ref/4428082&RS=REF/4428082,"7,618,461",2009
1519572925-199,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Tissue marking implant,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=78&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4428082.UREF.&Page=Next&OS=ref/4428082&RS=REF/4428082,"7,637,948",2009
1519572933-200,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Implantable tissue repair device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=77&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4428082.UREF.&Page=Next&OS=ref/4428082&RS=REF/4428082,"7,819,918",2010
1519572942-201,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Method and apparatus for delivering an intervertebral disc implant,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=76&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4428082.UREF.&Page=Next&OS=ref/4428082&RS=REF/4428082,"7,857,818",2010
1519572945-202,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Tissue marking implant,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=75&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4428082.UREF.&Page=Next&OS=ref/4428082&RS=REF/4428082,"7,871,438",2011
1519572949-203,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Unitary surgical device and method,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=74&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4428082.UREF.&Page=Next&OS=ref/4428082&RS=REF/4428082,"7,871,440",2011
1519572952-204,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Port structures for non-rigid bone plates,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=73&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4428082.UREF.&Page=Next&OS=ref/4428082&RS=REF/4428082,"8,066,750",2011
1519572955-205,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Tissue marking implant,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=72&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4428082.UREF.&Page=Next&OS=ref/4428082&RS=REF/4428082,"8,157,862",2012
1519572958-206,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Plugged tip delivery tube for marker placement,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=71&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4428082.UREF.&Page=Next&OS=ref/4428082&RS=REF/4428082,"8,177,792",2012
1519572960-207,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Modulating buttress saline mammary prosthesis,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=70&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4428082.UREF.&Page=Next&OS=ref/4428082&RS=REF/4428082,"8,202,316",2012
1519572963-208,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Cavity-filling biopsy site markers,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=69&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4428082.UREF.&Page=Next&OS=ref/4428082&RS=REF/4428082,"8,219,182",2012
1519572966-209,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Tissue site markers for in vivo imaging,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=68&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4428082.UREF.&Page=Next&OS=ref/4428082&RS=REF/4428082,"8,224,424",2012
1519572968-210,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Method of utilizing an implant for targeting external beam radiation,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=67&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4428082.UREF.&Page=Next&OS=ref/4428082&RS=REF/4428082,"8,288,745",2012
1519572972-211,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Biopsy tissue marker,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=66&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4428082.UREF.&Page=Next&OS=ref/4428082&RS=REF/4428082,"8,311,610",2012
1519572974-212,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Soft prosthesis shell texturing method,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=65&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4428082.UREF.&Page=Next&OS=ref/4428082&RS=REF/4428082,"8,313,527",2012
1519572977-213,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Marker delivery device with releasable plug,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=64&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4428082.UREF.&Page=Next&OS=ref/4428082&RS=REF/4428082,"8,361,082",2013
1519572980-214,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Biopsy marker with in situ-generated imaging properties,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=63&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4428082.UREF.&Page=Next&OS=ref/4428082&RS=REF/4428082,"8,401,622",2013
1519572983-215,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Breast marker,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=62&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4428082.UREF.&Page=Next&OS=ref/4428082&RS=REF/4428082,"8,437,834",2013
1519572987-216,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Marker or filler forming fluid,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=61&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4428082.UREF.&Page=Next&OS=ref/4428082&RS=REF/4428082,"8,447,386",2013
1519572993-217,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Tissue marking apparatus having drug-eluting tissue marker,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=60&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4428082.UREF.&Page=Next&OS=ref/4428082&RS=REF/4428082,"8,486,028",2013
1519572996-218,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,"Open celled foams, implants including them and processes for making same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=59&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4428082.UREF.&Page=Next&OS=ref/4428082&RS=REF/4428082,"8,487,012",2013
1519572999-219,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Intracorporeal marker and marker delivery device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=58&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4428082.UREF.&Page=Next&OS=ref/4428082&RS=REF/4428082,"8,498,693",2013
1519573002-220,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Soft filled prosthesis shell with discrete fixation surfaces,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=57&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4428082.UREF.&Page=Next&OS=ref/4428082&RS=REF/4428082,"8,506,627",2013
1519573004-221,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Method of utilizing an implant for targeting external beam radiation,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=56&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4428082.UREF.&Page=Next&OS=ref/4428082&RS=REF/4428082,"8,541,764",2013
1519573007-222,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Process for texturing materials,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=55&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4428082.UREF.&Page=Next&OS=ref/4428082&RS=REF/4428082,"8,546,458",2013
1519573010-223,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Apparatus for the percutaneous marking of a lesion,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=54&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4428082.UREF.&Page=Next&OS=ref/4428082&RS=REF/4428082,"8,579,931",2013
1519573013-224,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Fibrous marker and intracorporeal delivery thereof,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=53&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4428082.UREF.&Page=Next&OS=ref/4428082&RS=REF/4428082,"8,626,269",2014
1519573016-225,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Cavity-filling biopsy site markers,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=52&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4428082.UREF.&Page=Next&OS=ref/4428082&RS=REF/4428082,"8,626,270",2014
1519573020-226,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Multi mode imaging marker,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=51&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4428082.UREF.&Page=Next&OS=ref/4428082&RS=REF/4428082,"8,634,899",2014
1519573023-227,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Marker or filler forming fluid,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=50&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,,"8,639,315",2014
1519573027-228,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Tissue marking implant,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=49&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,,"8,668,737",2014
1519573031-229,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Marker delivery device for tissue marker placement,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=48&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,,"8,670,818",2014
1519573034-230,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Methods for creating foam-like texture,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=47&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,,"8,679,279",2014
1519573037-231,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Foam-like materials and methods for producing same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=46&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,,"8,679,570",2014
1519573039-232,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Method of utilizing an implant in a human breast,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=45&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,,"8,680,498",2014
1519573044-233,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,"Porogen compositions, method of making and uses",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=44&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,,"8,685,296",2014
1519573047-234,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Tissue site markers for in vivo imaging,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=43&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,,"8,718,745",2014
1519573050-235,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Plugged tip delivery tube for marker placement,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=42&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,,"8,784,433",2014
1519573053-236,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Surgical methods for breast reconstruction or augmentation,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=41&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,,"8,801,782",2014
1519573058-237,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Tissue marker for intracorporeal site identification,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=40&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,,"D715,442",2014
1519573061-238,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Tissue marker for intracorporeal site identification,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=39&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,,"D715,942",2014
1519573064-239,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Tissue marker for intracorporeal site identification,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=38&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,,"D716,450",2014
1519573067-240,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Tissue marker for intracorporeal site identification,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=37&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,,"D716,451",2014
1519573071-241,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,"Porogen compositions, methods of making and uses",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=36&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,,"8,877,822",2014
1519573075-242,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Fibrous marker and intracorporeal delivery thereof,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=35&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,,"8,880,154",2014
1519573079-243,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,"Porous materials, methods of making and uses",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=34&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,,"8,889,751",2014
1519573081-244,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Implants and methods for manufacturing same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=33&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,,"8,951,596",2015
1519573085-245,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Cavity filling biopsy site markers,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=32&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,,"8,965,486",2015
1519573088-246,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Tissue marking implant,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=31&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,,"9,039,763",2015
1519573091-247,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Biopsy marker with in situ-generated imaging properties,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=30&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,,"9,042,965",2015
1519573094-248,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Marker delivery device with releasable plug,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=29&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,,"9,044,162",2015
1519573097-249,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,"Porous materials, methods of making and uses",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=28&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,,"9,044,897",2015
1519573100-250,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Biocompatible structures and compositions,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=27&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,,"9,072,821",2015
1519573105-251,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Mucosal tissue adhesion via textured surface,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=26&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,,"9,138,308",2015
1519573109-252,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,"Porous materials, methods of making and uses",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=25&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,,"9,138,309",2015
1519573112-253,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Soft prosthesis shell texturing method,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=24&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,,"9,138,310",2015
1519573115-254,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Soft filled prosthesis shell with discrete fixation surfaces,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=23&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,,"9,138,311",2015
1519573118-255,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Deployment of polysaccharide markers for treating a site within a patient,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=22&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,,"9,149,341",2015
1519573121-256,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Methods for creating foam-like texture,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=21&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,,"9,155,613",2015
1519573125-257,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,"Porogen compositions, methods of making and uses",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=20&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,,"9,205,577",2015
1519573128-258,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Cavity-filling biopsy site markers,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=19&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,,"9,237,937",2016
1519573131-259,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Porous bioabsorbable implant,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=18&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,,"9,327,061",2016
1519573133-260,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Therapeutic breast implants,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=17&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,,"9,351,823",2016
1519573136-261,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Soft filled prosthesis shell with discrete fixation surfaces,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=16&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,,"9,393,106",2016
1519573138-262,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Tissue marking implant,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=15&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,,"9,480,554",2016
1519573142-263,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,"Porous materials, methods of making and uses",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=14&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,,"9,522,502",2016
1519573145-264,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Soft filled prosthesis shell with variable texture,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=13&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,,"9,539,086",2017
1519573148-265,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Multiple imaging mode tissue marker,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=12&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,,"9,579,077",2017
1519573151-266,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Apparatus for the percutaneous marking of a lesion,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=11&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,,"9,579,159",2017
1519573155-267,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,"Porogen compositions, methods of making and uses",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=10&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,,"9,593,224",2017
1519573158-268,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Cavity-filling biopsy site markers,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=9&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,,"9,649,093",2017
1519573161-269,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Device and method for making a variable surface breast implant,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=8&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,,"9,688,006",2017
1519573163-270,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Breast implant system,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=7&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,,"9,724,189",2017
1519573166-271,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Fibrous marker and intracorporeal delivery thereof,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=6&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,,"9,801,688",2017
1519573169-272,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Soft filled prosthesis shell with variable texture,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=5&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,,"9,808,338",2017
1519573175-273,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Deployment of polysaccharide markers for treating a site within a patent,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=4&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,,"9,820,824",2017
1519573178-274,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,"Self-contained, self-piercing, side-expelling marking apparatus",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=3&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,,"9,848,956",2017
1519573181-275,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Dual plane breast implant,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=2&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,,"9,848,972",2017
1519573185-276,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Breast prosthesis with filling valve,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=619&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"A newly developed breast prosthesis overcomes the tightness and contracture
     of the fibrous capsule which forms around the existing prostheses. This
     prosthesis is constructed with an outer temporary component and an inner
     permanent component. The inner component is a fluid- or gel-filled
     container or sac of a flexible, non-absorbable material. The temporary
     outer component is a container or cover of a material which is absorbable
     under the conditions of use, and an inert filler material, preferably an
     absorbable, biologically acceptable liquid, e.g. saline solution, filling
     the space between the inner and outer components which is added through a
     valve or tube in the outer cover either at the time of manufacture or at
     the time of implantation. The inner component is preferably of silicone
     rubber film and is filled with a silicone gel. The outer portion is in the
     form of a sheet, film or coating of a material which can be absorbed in
     the body after surgical implantation. The filling valve or tube is also of
     an absorbable material. Suitable materials are ones which will be absorbed
     by phagocytosis or hydrolysis or other processes or which can be rendered
     absorbable by physical or chemical or enzymatic treatment or the like,
     prior to, during, or after surgical implantation. These materials include
     natural, synthetic or semisynthetic materials proven useful for surgical
     sutures and materials such as reconstituted collagen, polylactic acid,
     polyglycolic acid, polyglactin 910, reconstituted vegetable protein, etc.","4,428,082",null,[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4428082,Marker delivery device with releasable plug,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=1&f=G&l=50&d=PALL&S1=4428082.UREF.&OS=ref/4428082&RS=REF/4428082,,,"9,861,294",2018
1519573193-277,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Biodegradable ocular insert for controlled delivery of ophthalmic
     medication",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=618&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1984,"An ocular insert is disclosed that is attachable to the third eyelid of
     animals to provide controlled delivery of ophthalmic medication. The
     insert includes a disc impregnated with medication in controlled-release
     form and a biodegradable spear for attachment of the insert to the third
     eyelid. An insert effective for treatment of infectious bovine
     keratoconjunctivitis comprises a disc impregnated with chloramphenicol
     sodium monosuccinate and a spear of biodegradable polylactic acid which
     provides for retention of the insert in the eye, and consequent
     medication, for up to seven days.","4,439,198","University of Illinois Foundation
 (Urbana, 
IL)",null,,,,,,,
1519573201-278,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Biodegradable organic polymer delivery system for bone morphogenetic
     protein",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=617&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1986,"Disclosed is a biodegradable polylactic acid polymer delivery system for
     delivery of bone morphogenic protein (BMP) to induce formation of new bone
     in viable tissue. The delivery composition is substantially pure BMP in
     combination with a biodegradable polylactic acid polymer and it is
     prepared by admixing the BMP with the biodegradable polymer. The
     composition is implanted in viable tissue where the BMP is slowly released
     and induces formation of new bone.","4,563,489","University of California
 (Berkeley, 
CA)",null,,,,,,,
1519573207-279,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Moldable bone-implant material,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=616&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1987,"A moldable bone-implant material containing between about 65%-95% hard
     filler particles and a binder composed of between about 35%-5% of a
     biocompatible, biodegradable, thermoplastic polymer which has fluidic flow
     properties at or below about 60.degree. C. One preferred binder is
     polylactic acid having a molecular weight between about 400 and 5,000
     daltons, and a preferred hard filler is hydroxylapatite. In use, the
     material is warmed to a temperature which allows molding, and the bone
     site is filled with the moldable material, which then forms a
     contour-fitting, semi-rigid implant. The implant retains its contour fit
     and acquires a rigid final state as the binder in the implant is gradually
     biodegraded and replaced through tissue ingrowth from the surrounding bone
     site.","4,645,503","Orthomatrix Inc.
 (Dublin, 
CA)",,http://pdfpiw.uspto.gov/.piw?Docid=04645503&homeurl=http%3A%2F%2Fpatft.uspto.gov%2Fnetacgi%2Fnph-Parser%3FSect1%3DPTO2%2526Sect2%3DHITOFF%2526u%3D%25252Fnetahtml%25252FPTO%25252Fsearch-adv.htm%2526r%3D616%2526f%3DG%2526l%3D50%2526d%3DPTXT%2526s1%3D%252522polylactic%252Bacid%252522.ABTX.%2526p%3D13%2526OS%3DABST%2F%252522polylactic%252Bacid%252522%2526RS%3DABST%2F%252522polylactic%252Bacid%252522&PageNum=&Rtype=&SectionNum=&idkey=NONE&Input=View+first+page,,,null,,,
1519573227-280,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Preparation process for bioabsorbable polyester,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=100&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4797468.UREF.&Page=Next&OS=ref/4797468&RS=REF/4797468,"5,041,529",1991
1519573231-281,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Polyhydroxy acid films,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=99&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4797468.UREF.&Page=Next&OS=ref/4797468&RS=REF/4797468,"5,076,983",1991
1519573234-282,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Process for preparing cyclic esters using a fluorocarbon,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=98&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4797468.UREF.&Page=Next&OS=ref/4797468&RS=REF/4797468,"5,089,632",1992
1519573237-283,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Process for rapid conversion of oligomers to cyclic esters,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=97&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4797468.UREF.&Page=Next&OS=ref/4797468&RS=REF/4797468,"5,091,544",1992
1519573242-284,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Solvent scrubbing recovery of lactide and other dimeric cyclic esters,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=96&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4797468.UREF.&Page=Next&OS=ref/4797468&RS=REF/4797468,"5,117,008",1992
1519573245-285,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,High yield recycle process for lactide,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=95&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4797468.UREF.&Page=Next&OS=ref/4797468&RS=REF/4797468,"5,136,057",1992
1519573252-286,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=94&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4797468.UREF.&Page=Next&OS=ref/4797468&RS=REF/4797468,"5,142,023",1992
1519573259-287,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,"Process for preparing D,L-Lactide",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=93&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4797468.UREF.&Page=Next&OS=ref/4797468&RS=REF/4797468,"5,149,833",1992
1519573265-288,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Biodegradable packaging thermoplastics from lactides,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=92&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4797468.UREF.&Page=Next&OS=ref/4797468&RS=REF/4797468,"5,180,765",1993
1519573270-289,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Rapid depolymerization of polyhydroxy acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=91&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4797468.UREF.&Page=Next&OS=ref/4797468&RS=REF/4797468,"5,229,528",1993
1519573280-290,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Solventless dimeric cyclic ester distillation process,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=90&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4797468.UREF.&Page=Next&OS=ref/4797468&RS=REF/4797468,"5,236,560",1993
1519573287-291,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=89&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4797468.UREF.&Page=Next&OS=ref/4797468&RS=REF/4797468,"5,247,058",1993
1519573290-292,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=88&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4797468.UREF.&Page=Next&OS=ref/4797468&RS=REF/4797468,"5,247,059",1993
1519573302-293,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=87&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4797468.UREF.&Page=Next&OS=ref/4797468&RS=REF/4797468,"5,258,488",1993
1519573307-294,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Recovery of polyhydroxy acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=86&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4797468.UREF.&Page=Next&OS=ref/4797468&RS=REF/4797468,"5,264,614",1993
1519573326-295,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Preparation of alkyl esters by depolymerization,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=85&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4797468.UREF.&Page=Next&OS=ref/4797468&RS=REF/4797468,"5,264,617",1993
1519573333-296,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Rapid depolymerization of polyhydroxy acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=84&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4797468.UREF.&Page=Next&OS=ref/4797468&RS=REF/4797468,"5,264,626",1993
1519573350-297,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Preparation of amide derivatives of hydroxy acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=83&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4797468.UREF.&Page=Next&OS=ref/4797468&RS=REF/4797468,"5,268,507",1993
1519573357-298,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Continuous process for manufacture of a purified lactide,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=82&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4797468.UREF.&Page=Next&OS=ref/4797468&RS=REF/4797468,"5,274,073",1993
1519573363-299,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Lactide production from dehydration of aqueous lactic acid feed,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=81&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4797468.UREF.&Page=Next&OS=ref/4797468&RS=REF/4797468,"5,274,127",1993
1519573369-300,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Rapidly degradable poly (hydroxyacid) compositions,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=80&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4797468.UREF.&Page=Next&OS=ref/4797468&RS=REF/4797468,"5,278,256",1994
1519573375-301,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Method to produce cyclic esters,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=79&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4797468.UREF.&Page=Next&OS=ref/4797468&RS=REF/4797468,"5,319,107",1994
1519573378-302,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Catalytic production of lactide directly from lactic acid,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=78&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4797468.UREF.&Page=Next&OS=ref/4797468&RS=REF/4797468,"5,332,839",1994
1519573383-303,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,"Melt-stable lactide polymer composition and process for manufacture
     thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=77&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4797468.UREF.&Page=Next&OS=ref/4797468&RS=REF/4797468,"5,338,822",1994
1519573390-304,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,"Continuous process for manufacture of lactide polymers with purification
     by distillation",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=76&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4797468.UREF.&Page=Next&OS=ref/4797468&RS=REF/4797468,"5,357,035",1994
1519573401-305,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Method to produce cyclic esters,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=75&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4797468.UREF.&Page=Next&OS=ref/4797468&RS=REF/4797468,"5,420,304",1995
1519573408-306,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Biodegradable replacement of crystal polystyrene,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=74&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4797468.UREF.&Page=Next&OS=ref/4797468&RS=REF/4797468,"5,424,346",1995
1519573412-307,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,"Paper having a melt-stable lactide polymer coating and process for
     manufacture thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=73&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4797468.UREF.&Page=Next&OS=ref/4797468&RS=REF/4797468,"5,475,080",1995
1519573422-308,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,"Melt-stable amorphous lactide polymer film and process for manufacturing
     thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=72&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4797468.UREF.&Page=Next&OS=ref/4797468&RS=REF/4797468,"5,484,881",1996
1519573425-309,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,"Melt-stable lactide polymer nonwoven fabric and process for manufacture
     thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=71&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4797468.UREF.&Page=Next&OS=ref/4797468&RS=REF/4797468,"5,525,706",1996
1519573429-310,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,"Melt-stable semi-crystalline lactide polymer film and process for
     manufacture thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=70&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4797468.UREF.&Page=Next&OS=ref/4797468&RS=REF/4797468,"5,536,807",1996
1519573432-311,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,"Melt-stable lactide polymer composition and process for manufacture
     thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=69&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4797468.UREF.&Page=Next&OS=ref/4797468&RS=REF/4797468,"5,539,081",1996
1519573437-312,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Process for the production of poly(lactic acid),http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=68&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4797468.UREF.&Page=Next&OS=ref/4797468&RS=REF/4797468,"5,543,494",1996
1519573440-313,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,pH-Modified polymer compositions with enhanced biodegradability,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=67&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4797468.UREF.&Page=Next&OS=ref/4797468&RS=REF/4797468,"5,545,681",1996
1519573443-314,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Degradable polydioxaneone-based materials,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=66&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4797468.UREF.&Page=Next&OS=ref/4797468&RS=REF/4797468,"5,556,895",1996
1519573448-315,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,"Melt-stable amorphous lactide polymer film and process for manufacture
     thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=65&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4797468.UREF.&Page=Next&OS=ref/4797468&RS=REF/4797468,"5,585,191",1996
1519573453-316,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Process for making metalized films and films produced therefrom,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=64&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4797468.UREF.&Page=Next&OS=ref/4797468&RS=REF/4797468,"5,631,066",1997
1519573455-317,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Method for packaging foodstuffs,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=63&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4797468.UREF.&Page=Next&OS=ref/4797468&RS=REF/4797468,"5,639,466",1997
1519573458-318,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,"Paper having a melt-stable lactide polymer coating and process for
     manufacture thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=62&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4797468.UREF.&Page=Next&OS=ref/4797468&RS=REF/4797468,"5,665,474",1997
1519573461-319,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Method to produce and purify cyclic esters,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=61&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4797468.UREF.&Page=Next&OS=ref/4797468&RS=REF/4797468,"5,675,021",1997
1519573464-320,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Purifying cyclic esters by aqueous solvent extraction,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=60&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4797468.UREF.&Page=Next&OS=ref/4797468&RS=REF/4797468,"5,686,630",1997
1519573468-321,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Method to produce cyclic esters,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=59&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4797468.UREF.&Page=Next&OS=ref/4797468&RS=REF/4797468,"5,750,732",1998
1519573471-322,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,"Melt-stable lactide polymer composition and process for manufacture
     thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=58&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4797468.UREF.&Page=Next&OS=ref/4797468&RS=REF/4797468,"5,763,564",1998
1519573474-323,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Degradable polydioxaneone-based materials,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=57&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4797468.UREF.&Page=Next&OS=ref/4797468&RS=REF/4797468,"5,767,222",1998
1519573477-324,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,"Melt-stable semi-crystalline lactide polymer film and process for
     manufacture thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=56&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4797468.UREF.&Page=Next&OS=ref/4797468&RS=REF/4797468,"5,773,562",1998
1519573481-325,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,"Melt-stable amorphous lactide polymer film and process for manufacture
     thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=55&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4797468.UREF.&Page=Next&OS=ref/4797468&RS=REF/4797468,"5,798,436",1998
1519573485-326,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Degradable polydioxaneone-based materials,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=54&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4797468.UREF.&Page=Next&OS=ref/4797468&RS=REF/4797468,"5,801,223",1998
1519573488-327,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,"Melt-stable lactide polymer nonwoven fabric and process for manufacture
     thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=53&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4797468.UREF.&Page=Next&OS=ref/4797468&RS=REF/4797468,"5,807,973",1998
1519573492-328,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,"Paper having a melt-stable lactide polymer coating and process for
     manufacture thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=52&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4797468.UREF.&Page=Next&OS=ref/4797468&RS=REF/4797468,"5,852,166",1998
1519573499-329,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,"Purifying cyclic esters by aqueous solvent extraction and further
     purification",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=51&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=4797468.UREF.&Page=Next&OS=ref/4797468&RS=REF/4797468,"5,856,523",1999
1519573502-330,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Preparation process and purification process of cyclic ester,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=50&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,,"5,900,491",1999
1519573505-331,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,"Melt-stable lactide polymer composition and process for manufacture
     thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=49&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,,"5,981,694",1999
1519573508-332,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=48&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,,"6,005,067",1999
1519573511-333,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,"Melt-stable amorphous lactide polymer film and process for manufacture
     thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=47&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,,"6,005,068",1999
1519573514-334,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Degradable polydioxaneone-based materials,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=46&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,,"6,025,458",2000
1519573517-335,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,"Melt-stable semi-crystalline lactide polymer film and process for
     manufacture thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=45&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,,"6,093,791",2000
1519573520-336,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,"Melt-stable lactide polymer nonwoven fabric and process for manufacture
     thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=44&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,,"6,111,060",2000
1519573523-337,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,"Melt-stable semi-crystalline lactide polymer film and process for
     manufacture thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=43&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,,"6,121,410",2000
1519573527-338,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,"Melt-stable lactide polymer composition and process for manufacture
     thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=42&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,,"6,143,863",2000
1519573530-339,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,"Melt-stable amorphous lactide polymer film and process for manufacture
     thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=41&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,,"6,207,792",2001
1519573533-340,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=40&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,,"6,277,951",2001
1519573535-341,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Melt crystallization purification of lactides,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=39&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,,"6,310,218",2001
1519573538-342,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Degradation control of environmentally degradable disposable materials,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=38&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,,"6,323,307",2001
1519573541-343,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Continuous process for the manufacture of lactide and lactide polymers,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=37&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,,"6,326,458",2001
1519573544-344,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,"Melt-stable lactide polymer nonwoven fabric and process for manufacture
     thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=36&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,,"6,355,772",2002
1519573547-345,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,"Acid end group poly(d,l-lactide-co-glycolide) copolymers high glycolide
     content",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=35&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,,"6,362,308",2002
1519573549-346,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,"Acid end group poly(D,L-lactide-co-glycolide) copolymers with high
     glycolide content",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=34&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,,"6,703,477",2004
1519573551-347,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,"Acid end group poly(D,L-lactide-co-glycolide) copolymers with high
     glycolide content",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=33&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,,"7,074,883",2006
1519573554-348,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Thermoplastic starch for use in melt-extruded substrates,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=32&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,,"7,998,888",2011
1519573557-349,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Water-sensitive film containing thermoplastic polyurethane,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=31&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,,"8,147,965",2012
1519573560-350,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Biodegradable packaging film,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=30&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,,"8,188,185",2012
1519573564-351,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Film formed from a blend of biodegradable aliphatic-aromatic copolyesters,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=29&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,,"8,227,658",2012
1519573567-352,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Polylactic acid fibers,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=28&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,,"8,268,738",2012
1519573569-353,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Polymeric blends and methods of using same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=27&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,,"8,268,913",2012
1519573571-354,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Injection molding material containing starch and plant protein,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=26&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,,"8,283,006",2012
1519573574-355,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Biodegradable and renewable film,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=25&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,,"8,329,601",2012
1519573577-356,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Highly breathable biodegradable films,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=24&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,,"8,334,327",2012
1519573590-357,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Water-sensitive film containing an olefinic elastomer,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=23&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,,"8,338,508",2012
1519573598-358,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Water-sensitive film containing thermoplastic polyurethanes,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=22&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,,"8,445,110",2013
1519573602-359,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Polylactic acid fibers,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=21&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,,"8,461,262",2013
1519573605-360,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Multicomponent biodegradable filaments and nonwoven webs formed therefrom,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=20&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,,"8,518,311",2013
1519573609-361,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,"Polymeric compositions comprising polylactic acid and methods of making
     and using same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=19&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,,"8,545,971",2013
1519573612-362,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Biodegradable aliphatic polyester for use in nonwoven webs,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=18&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,,"8,609,808",2013
1519573621-363,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Molded parts containing a polylactic acid composition,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=17&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,,"8,637,130",2014
1519573626-364,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Biodegradable aliphatic-aromatic copolyester for use in nonwoven webs,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=16&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,,"8,710,172",2014
1519573632-365,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Fragranced biodegradable film,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=15&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,,"8,759,279",2014
1519573636-366,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,"Compatibilized polypropylene and polylactic acid blends and methods of
     making and using same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=14&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,,"8,759,446",2014
1519573644-367,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Fragranced water-sensitive film,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=13&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,,"8,927,617",2015
1519573654-368,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Modified polylactic acid fibers,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=12&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,,"8,936,740",2015
1519573668-369,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,"Composition comprising biodegradable polymers for use in a cosmetic
     composition",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=11&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,,"8,968,787",2015
1519573677-370,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,"Rigid renewable polyester compositions having a high impact strength and
     tensile elongation",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=10&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,,"8,975,305",2015
1519573680-371,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Renewable polyester film having a low modulus and high tensile elongation,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=9&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,,"8,980,964",2015
1519573685-372,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Renewable polyester compositions having a low density,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=8&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,,"9,040,598",2015
1519573688-373,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Biodegradable polylactic acid for use in nonwoven webs,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=7&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,,"9,091,004",2015
1519573692-374,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Film formed from a blend of biodegradable aliphatic-aromatic copolyesters,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=6&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,,"9,150,699",2015
1519573696-375,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Biodegradable aliphatic polyester for use in nonwoven webs,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=5&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,,"9,260,802",2016
1519573699-376,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Biodegradable aliphatic-aromatic copolyester for use in nonwoven webs,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=4&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,,"9,394,629",2016
1519573701-377,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,"Highly purified polylactic acid or a derivative thereof, a salt of the
     same, and purification method thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=3&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,,"9,518,149",2016
1519573704-378,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Renewable polyester compositions having a low density,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=2&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,,"9,518,181",2016
1519573707-379,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Preparation of polylactic acid and copolymers of lactic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=615&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1989,"The invention relates to a method for preparing high molecular polylactic
     acid or copolymers of lactic acids using lactide that is purified by
     extraction with water.","4,797,468","Akzo N.V.
 (Arnhem, 
NL)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4797468,Fragranced water-sensitive film,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=1&f=G&l=50&d=PALL&S1=4797468.UREF.&OS=ref/4797468&RS=REF/4797468,,,"9,617,400",2017
1519573729-380,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid microspheres and process for producing the same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=614&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"Polylactic acid microspheres having an average particle diameter of about
     0.1 to 10 .mu.m which are produced from solution containing a
     physiologically active substance by the solvent-evaporation drying
     process. The microspheres are produced by emulsifying the solution in a
     non-solvent by the aid of ultrasonic wave. The microspheres produce a
     sustained release effect of the physiologically active substance.","4,994,281","Sanraku Incorporated
 (Tokyo, 
JP)


Biomaterials Universe Incorporated
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4994281,Efficient microcapsule preparation and method of use,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=49&f=G&l=50&d=PALL&S1=4994281.UREF.&OS=ref/4994281&RS=REF/4994281,,,"5,238,714",1993
1519573733-381,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid microspheres and process for producing the same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=614&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"Polylactic acid microspheres having an average particle diameter of about
     0.1 to 10 .mu.m which are produced from solution containing a
     physiologically active substance by the solvent-evaporation drying
     process. The microspheres are produced by emulsifying the solution in a
     non-solvent by the aid of ultrasonic wave. The microspheres produce a
     sustained release effect of the physiologically active substance.","4,994,281","Sanraku Incorporated
 (Tokyo, 
JP)


Biomaterials Universe Incorporated
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4994281,Method for stimulating nerve fiber growth,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=48&f=G&l=50&d=PALL&S1=4994281.UREF.&OS=ref/4994281&RS=REF/4994281,,,"5,360,610",1994
1519573737-382,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid microspheres and process for producing the same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=614&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"Polylactic acid microspheres having an average particle diameter of about
     0.1 to 10 .mu.m which are produced from solution containing a
     physiologically active substance by the solvent-evaporation drying
     process. The microspheres are produced by emulsifying the solution in a
     non-solvent by the aid of ultrasonic wave. The microspheres produce a
     sustained release effect of the physiologically active substance.","4,994,281","Sanraku Incorporated
 (Tokyo, 
JP)


Biomaterials Universe Incorporated
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4994281,Microencapsulation process and products therefrom,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=47&f=G&l=50&d=PALL&S1=4994281.UREF.&OS=ref/4994281&RS=REF/4994281,,,"5,407,609",1995
1519573740-383,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid microspheres and process for producing the same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=614&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"Polylactic acid microspheres having an average particle diameter of about
     0.1 to 10 .mu.m which are produced from solution containing a
     physiologically active substance by the solvent-evaporation drying
     process. The microspheres are produced by emulsifying the solution in a
     non-solvent by the aid of ultrasonic wave. The microspheres produce a
     sustained release effect of the physiologically active substance.","4,994,281","Sanraku Incorporated
 (Tokyo, 
JP)


Biomaterials Universe Incorporated
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4994281,Therapeutic and diagnostic use of modified polymeric microcapsules,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=46&f=G&l=50&d=PALL&S1=4994281.UREF.&OS=ref/4994281&RS=REF/4994281,,,"5,484,584",1996
1519573746-384,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid microspheres and process for producing the same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=614&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"Polylactic acid microspheres having an average particle diameter of about
     0.1 to 10 .mu.m which are produced from solution containing a
     physiologically active substance by the solvent-evaporation drying
     process. The microspheres are produced by emulsifying the solution in a
     non-solvent by the aid of ultrasonic wave. The microspheres produce a
     sustained release effect of the physiologically active substance.","4,994,281","Sanraku Incorporated
 (Tokyo, 
JP)


Biomaterials Universe Incorporated
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4994281,Viscous suspensions of controlled-release drug particles,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=45&f=G&l=50&d=PALL&S1=4994281.UREF.&OS=ref/4994281&RS=REF/4994281,,,"5,540,912",1996
1519573751-385,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid microspheres and process for producing the same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=614&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"Polylactic acid microspheres having an average particle diameter of about
     0.1 to 10 .mu.m which are produced from solution containing a
     physiologically active substance by the solvent-evaporation drying
     process. The microspheres are produced by emulsifying the solution in a
     non-solvent by the aid of ultrasonic wave. The microspheres produce a
     sustained release effect of the physiologically active substance.","4,994,281","Sanraku Incorporated
 (Tokyo, 
JP)


Biomaterials Universe Incorporated
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4994281,"Sustained release microsphere preparation containing antipsychotic drug
     and production process thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=44&f=G&l=50&d=PALL&S1=4994281.UREF.&OS=ref/4994281&RS=REF/4994281,,,"5,656,299",1997
1519573758-386,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid microspheres and process for producing the same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=614&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"Polylactic acid microspheres having an average particle diameter of about
     0.1 to 10 .mu.m which are produced from solution containing a
     physiologically active substance by the solvent-evaporation drying
     process. The microspheres are produced by emulsifying the solution in a
     non-solvent by the aid of ultrasonic wave. The microspheres produce a
     sustained release effect of the physiologically active substance.","4,994,281","Sanraku Incorporated
 (Tokyo, 
JP)


Biomaterials Universe Incorporated
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4994281,"Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles
     1,2-benzisothiazoles",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=43&f=G&l=50&d=PALL&S1=4994281.UREF.&OS=ref/4994281&RS=REF/4994281,,,"5,770,231",1998
1519573761-387,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid microspheres and process for producing the same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=614&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"Polylactic acid microspheres having an average particle diameter of about
     0.1 to 10 .mu.m which are produced from solution containing a
     physiologically active substance by the solvent-evaporation drying
     process. The microspheres are produced by emulsifying the solution in a
     non-solvent by the aid of ultrasonic wave. The microspheres produce a
     sustained release effect of the physiologically active substance.","4,994,281","Sanraku Incorporated
 (Tokyo, 
JP)


Biomaterials Universe Incorporated
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4994281,"Tablets or biologically acceptable implants for long-term
     antiinflammatory drug release",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=42&f=G&l=50&d=PALL&S1=4994281.UREF.&OS=ref/4994281&RS=REF/4994281,,,"5,855,915",1999
1519573769-388,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid microspheres and process for producing the same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=614&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"Polylactic acid microspheres having an average particle diameter of about
     0.1 to 10 .mu.m which are produced from solution containing a
     physiologically active substance by the solvent-evaporation drying
     process. The microspheres are produced by emulsifying the solution in a
     non-solvent by the aid of ultrasonic wave. The microspheres produce a
     sustained release effect of the physiologically active substance.","4,994,281","Sanraku Incorporated
 (Tokyo, 
JP)


Biomaterials Universe Incorporated
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4994281,Sustained release microsphere preparation containing antipsychotic drug,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=41&f=G&l=50&d=PALL&S1=4994281.UREF.&OS=ref/4994281&RS=REF/4994281,,,"5,871,778",1999
1519573778-389,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid microspheres and process for producing the same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=614&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"Polylactic acid microspheres having an average particle diameter of about
     0.1 to 10 .mu.m which are produced from solution containing a
     physiologically active substance by the solvent-evaporation drying
     process. The microspheres are produced by emulsifying the solution in a
     non-solvent by the aid of ultrasonic wave. The microspheres produce a
     sustained release effect of the physiologically active substance.","4,994,281","Sanraku Incorporated
 (Tokyo, 
JP)


Biomaterials Universe Incorporated
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4994281,"Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and
     1,2-benzisothiazoles",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=40&f=G&l=50&d=PALL&S1=4994281.UREF.&OS=ref/4994281&RS=REF/4994281,,,"5,965,168",1999
1519573786-390,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid microspheres and process for producing the same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=614&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"Polylactic acid microspheres having an average particle diameter of about
     0.1 to 10 .mu.m which are produced from solution containing a
     physiologically active substance by the solvent-evaporation drying
     process. The microspheres are produced by emulsifying the solution in a
     non-solvent by the aid of ultrasonic wave. The microspheres produce a
     sustained release effect of the physiologically active substance.","4,994,281","Sanraku Incorporated
 (Tokyo, 
JP)


Biomaterials Universe Incorporated
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4994281,"Process for producing drug-containing microspheres by oil-in-water
     evaporation process",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=39&f=G&l=50&d=PALL&S1=4994281.UREF.&OS=ref/4994281&RS=REF/4994281,,,"5,980,947",1999
1519573793-391,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid microspheres and process for producing the same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=614&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"Polylactic acid microspheres having an average particle diameter of about
     0.1 to 10 .mu.m which are produced from solution containing a
     physiologically active substance by the solvent-evaporation drying
     process. The microspheres are produced by emulsifying the solution in a
     non-solvent by the aid of ultrasonic wave. The microspheres produce a
     sustained release effect of the physiologically active substance.","4,994,281","Sanraku Incorporated
 (Tokyo, 
JP)


Biomaterials Universe Incorporated
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4994281,Preparation of particles for inhalation,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=38&f=G&l=50&d=PALL&S1=4994281.UREF.&OS=ref/4994281&RS=REF/4994281,,,"5,985,309",1999
1519573800-392,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid microspheres and process for producing the same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=614&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"Polylactic acid microspheres having an average particle diameter of about
     0.1 to 10 .mu.m which are produced from solution containing a
     physiologically active substance by the solvent-evaporation drying
     process. The microspheres are produced by emulsifying the solution in a
     non-solvent by the aid of ultrasonic wave. The microspheres produce a
     sustained release effect of the physiologically active substance.","4,994,281","Sanraku Incorporated
 (Tokyo, 
JP)


Biomaterials Universe Incorporated
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4994281,"Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and
     1,2-benzisothiazoles",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=37&f=G&l=50&d=PALL&S1=4994281.UREF.&OS=ref/4994281&RS=REF/4994281,,,"6,110,921",2000
1519573804-393,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid microspheres and process for producing the same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=614&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"Polylactic acid microspheres having an average particle diameter of about
     0.1 to 10 .mu.m which are produced from solution containing a
     physiologically active substance by the solvent-evaporation drying
     process. The microspheres are produced by emulsifying the solution in a
     non-solvent by the aid of ultrasonic wave. The microspheres produce a
     sustained release effect of the physiologically active substance.","4,994,281","Sanraku Incorporated
 (Tokyo, 
JP)


Biomaterials Universe Incorporated
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4994281,Aerodynamically light particles for pulmonary drug delivery,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=36&f=G&l=50&d=PALL&S1=4994281.UREF.&OS=ref/4994281&RS=REF/4994281,,,"6,136,295",2000
1519573818-394,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid microspheres and process for producing the same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=614&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"Polylactic acid microspheres having an average particle diameter of about
     0.1 to 10 .mu.m which are produced from solution containing a
     physiologically active substance by the solvent-evaporation drying
     process. The microspheres are produced by emulsifying the solution in a
     non-solvent by the aid of ultrasonic wave. The microspheres produce a
     sustained release effect of the physiologically active substance.","4,994,281","Sanraku Incorporated
 (Tokyo, 
JP)


Biomaterials Universe Incorporated
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4994281,Polyester/carboxylic acid composite materials,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=35&f=G&l=50&d=PALL&S1=4994281.UREF.&OS=ref/4994281&RS=REF/4994281,,,"6,280,772",2001
1519573823-395,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid microspheres and process for producing the same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=614&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"Polylactic acid microspheres having an average particle diameter of about
     0.1 to 10 .mu.m which are produced from solution containing a
     physiologically active substance by the solvent-evaporation drying
     process. The microspheres are produced by emulsifying the solution in a
     non-solvent by the aid of ultrasonic wave. The microspheres produce a
     sustained release effect of the physiologically active substance.","4,994,281","Sanraku Incorporated
 (Tokyo, 
JP)


Biomaterials Universe Incorporated
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4994281,"Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and
     1,2-benzisothiazoles",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=34&f=G&l=50&d=PALL&S1=4994281.UREF.&OS=ref/4994281&RS=REF/4994281,,,"6,368,632",2002
1519573828-396,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid microspheres and process for producing the same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=614&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"Polylactic acid microspheres having an average particle diameter of about
     0.1 to 10 .mu.m which are produced from solution containing a
     physiologically active substance by the solvent-evaporation drying
     process. The microspheres are produced by emulsifying the solution in a
     non-solvent by the aid of ultrasonic wave. The microspheres produce a
     sustained release effect of the physiologically active substance.","4,994,281","Sanraku Incorporated
 (Tokyo, 
JP)


Biomaterials Universe Incorporated
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4994281,"Noscapine and noscapine derivatives, useful as anticancer agents",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=33&f=G&l=50&d=PALL&S1=4994281.UREF.&OS=ref/4994281&RS=REF/4994281,,,"6,376,516",2002
1519573831-397,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid microspheres and process for producing the same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=614&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"Polylactic acid microspheres having an average particle diameter of about
     0.1 to 10 .mu.m which are produced from solution containing a
     physiologically active substance by the solvent-evaporation drying
     process. The microspheres are produced by emulsifying the solution in a
     non-solvent by the aid of ultrasonic wave. The microspheres produce a
     sustained release effect of the physiologically active substance.","4,994,281","Sanraku Incorporated
 (Tokyo, 
JP)


Biomaterials Universe Incorporated
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4994281,Aerodynamically light particles for pulmonary drug delivery,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=32&f=G&l=50&d=PALL&S1=4994281.UREF.&OS=ref/4994281&RS=REF/4994281,,,"6,399,102",2002
1519573834-398,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid microspheres and process for producing the same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=614&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"Polylactic acid microspheres having an average particle diameter of about
     0.1 to 10 .mu.m which are produced from solution containing a
     physiologically active substance by the solvent-evaporation drying
     process. The microspheres are produced by emulsifying the solution in a
     non-solvent by the aid of ultrasonic wave. The microspheres produce a
     sustained release effect of the physiologically active substance.","4,994,281","Sanraku Incorporated
 (Tokyo, 
JP)


Biomaterials Universe Incorporated
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4994281,Microcapsules for administration of neuroactive agents,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=31&f=G&l=50&d=PALL&S1=4994281.UREF.&OS=ref/4994281&RS=REF/4994281,,,"6,517,859",2003
1519573837-399,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid microspheres and process for producing the same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=614&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"Polylactic acid microspheres having an average particle diameter of about
     0.1 to 10 .mu.m which are produced from solution containing a
     physiologically active substance by the solvent-evaporation drying
     process. The microspheres are produced by emulsifying the solution in a
     non-solvent by the aid of ultrasonic wave. The microspheres produce a
     sustained release effect of the physiologically active substance.","4,994,281","Sanraku Incorporated
 (Tokyo, 
JP)


Biomaterials Universe Incorporated
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4994281,"Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and
     1,2-benzisothiazoles",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=30&f=G&l=50&d=PALL&S1=4994281.UREF.&OS=ref/4994281&RS=REF/4994281,,,"6,544,559",2003
1519573840-400,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid microspheres and process for producing the same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=614&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"Polylactic acid microspheres having an average particle diameter of about
     0.1 to 10 .mu.m which are produced from solution containing a
     physiologically active substance by the solvent-evaporation drying
     process. The microspheres are produced by emulsifying the solution in a
     non-solvent by the aid of ultrasonic wave. The microspheres produce a
     sustained release effect of the physiologically active substance.","4,994,281","Sanraku Incorporated
 (Tokyo, 
JP)


Biomaterials Universe Incorporated
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4994281,Microcapsules for administration of neuroactive agents,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=29&f=G&l=50&d=PALL&S1=4994281.UREF.&OS=ref/4994281&RS=REF/4994281,,,"6,565,875",2003
1519573842-401,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid microspheres and process for producing the same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=614&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"Polylactic acid microspheres having an average particle diameter of about
     0.1 to 10 .mu.m which are produced from solution containing a
     physiologically active substance by the solvent-evaporation drying
     process. The microspheres are produced by emulsifying the solution in a
     non-solvent by the aid of ultrasonic wave. The microspheres produce a
     sustained release effect of the physiologically active substance.","4,994,281","Sanraku Incorporated
 (Tokyo, 
JP)


Biomaterials Universe Incorporated
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4994281,"Process for the production of morphologically uniform microcapsules and
     microcapsules that are produced according to this process",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=28&f=G&l=50&d=PALL&S1=4994281.UREF.&OS=ref/4994281&RS=REF/4994281,,,"6,572,894",2003
1519573845-402,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid microspheres and process for producing the same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=614&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"Polylactic acid microspheres having an average particle diameter of about
     0.1 to 10 .mu.m which are produced from solution containing a
     physiologically active substance by the solvent-evaporation drying
     process. The microspheres are produced by emulsifying the solution in a
     non-solvent by the aid of ultrasonic wave. The microspheres produce a
     sustained release effect of the physiologically active substance.","4,994,281","Sanraku Incorporated
 (Tokyo, 
JP)


Biomaterials Universe Incorporated
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4994281,Aerodynamically light particles for pulmonary drug delivery,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=27&f=G&l=50&d=PALL&S1=4994281.UREF.&OS=ref/4994281&RS=REF/4994281,,,"6,635,283",2003
1519573848-403,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid microspheres and process for producing the same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=614&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"Polylactic acid microspheres having an average particle diameter of about
     0.1 to 10 .mu.m which are produced from solution containing a
     physiologically active substance by the solvent-evaporation drying
     process. The microspheres are produced by emulsifying the solution in a
     non-solvent by the aid of ultrasonic wave. The microspheres produce a
     sustained release effect of the physiologically active substance.","4,994,281","Sanraku Incorporated
 (Tokyo, 
JP)


Biomaterials Universe Incorporated
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4994281,Preparation of novel particles for inhalation,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=26&f=G&l=50&d=PALL&S1=4994281.UREF.&OS=ref/4994281&RS=REF/4994281,,,"6,652,837",2003
1519573851-404,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid microspheres and process for producing the same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=614&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"Polylactic acid microspheres having an average particle diameter of about
     0.1 to 10 .mu.m which are produced from solution containing a
     physiologically active substance by the solvent-evaporation drying
     process. The microspheres are produced by emulsifying the solution in a
     non-solvent by the aid of ultrasonic wave. The microspheres produce a
     sustained release effect of the physiologically active substance.","4,994,281","Sanraku Incorporated
 (Tokyo, 
JP)


Biomaterials Universe Incorporated
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4994281,"Delivery systems and methods for noscapine and noscapine derivatives,
     useful as anticancer agents",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=25&f=G&l=50&d=PALL&S1=4994281.UREF.&OS=ref/4994281&RS=REF/4994281,,,"6,673,814",2004
1519573854-405,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid microspheres and process for producing the same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=614&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"Polylactic acid microspheres having an average particle diameter of about
     0.1 to 10 .mu.m which are produced from solution containing a
     physiologically active substance by the solvent-evaporation drying
     process. The microspheres are produced by emulsifying the solution in a
     non-solvent by the aid of ultrasonic wave. The microspheres produce a
     sustained release effect of the physiologically active substance.","4,994,281","Sanraku Incorporated
 (Tokyo, 
JP)


Biomaterials Universe Incorporated
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4994281,Formulation for spray-drying large porous particles,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=24&f=G&l=50&d=PALL&S1=4994281.UREF.&OS=ref/4994281&RS=REF/4994281,,,"6,749,835",2004
1519573859-406,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid microspheres and process for producing the same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=614&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"Polylactic acid microspheres having an average particle diameter of about
     0.1 to 10 .mu.m which are produced from solution containing a
     physiologically active substance by the solvent-evaporation drying
     process. The microspheres are produced by emulsifying the solution in a
     non-solvent by the aid of ultrasonic wave. The microspheres produce a
     sustained release effect of the physiologically active substance.","4,994,281","Sanraku Incorporated
 (Tokyo, 
JP)


Biomaterials Universe Incorporated
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4994281,"Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and
     1,2-benzisothiazoles",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=23&f=G&l=50&d=PALL&S1=4994281.UREF.&OS=ref/4994281&RS=REF/4994281,,,"6,803,055",2004
1519573862-407,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid microspheres and process for producing the same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=614&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"Polylactic acid microspheres having an average particle diameter of about
     0.1 to 10 .mu.m which are produced from solution containing a
     physiologically active substance by the solvent-evaporation drying
     process. The microspheres are produced by emulsifying the solution in a
     non-solvent by the aid of ultrasonic wave. The microspheres produce a
     sustained release effect of the physiologically active substance.","4,994,281","Sanraku Incorporated
 (Tokyo, 
JP)


Biomaterials Universe Incorporated
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4994281,"Induced phase transition method for the production of microparticles
     containing hydrophobic active agents",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=22&f=G&l=50&d=PALL&S1=4994281.UREF.&OS=ref/4994281&RS=REF/4994281,,,"6,899,898",2005
1519573865-408,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid microspheres and process for producing the same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=614&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"Polylactic acid microspheres having an average particle diameter of about
     0.1 to 10 .mu.m which are produced from solution containing a
     physiologically active substance by the solvent-evaporation drying
     process. The microspheres are produced by emulsifying the solution in a
     non-solvent by the aid of ultrasonic wave. The microspheres produce a
     sustained release effect of the physiologically active substance.","4,994,281","Sanraku Incorporated
 (Tokyo, 
JP)


Biomaterials Universe Incorporated
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4994281,Aerodynamically light particles for pulmonary drug delivery,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=21&f=G&l=50&d=PALL&S1=4994281.UREF.&OS=ref/4994281&RS=REF/4994281,,,"6,942,868",2005
1519573868-409,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid microspheres and process for producing the same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=614&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"Polylactic acid microspheres having an average particle diameter of about
     0.1 to 10 .mu.m which are produced from solution containing a
     physiologically active substance by the solvent-evaporation drying
     process. The microspheres are produced by emulsifying the solution in a
     non-solvent by the aid of ultrasonic wave. The microspheres produce a
     sustained release effect of the physiologically active substance.","4,994,281","Sanraku Incorporated
 (Tokyo, 
JP)


Biomaterials Universe Incorporated
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4994281,Stable spray-dried protein formulations,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=20&f=G&l=50&d=PALL&S1=4994281.UREF.&OS=ref/4994281&RS=REF/4994281,,,"6,956,021",2005
1519573871-410,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid microspheres and process for producing the same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=614&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"Polylactic acid microspheres having an average particle diameter of about
     0.1 to 10 .mu.m which are produced from solution containing a
     physiologically active substance by the solvent-evaporation drying
     process. The microspheres are produced by emulsifying the solution in a
     non-solvent by the aid of ultrasonic wave. The microspheres produce a
     sustained release effect of the physiologically active substance.","4,994,281","Sanraku Incorporated
 (Tokyo, 
JP)


Biomaterials Universe Incorporated
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4994281,Particles for inhalation having sustained release properties,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=19&f=G&l=50&d=PALL&S1=4994281.UREF.&OS=ref/4994281&RS=REF/4994281,,,"7,048,908",2006
1519573875-411,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid microspheres and process for producing the same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=614&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"Polylactic acid microspheres having an average particle diameter of about
     0.1 to 10 .mu.m which are produced from solution containing a
     physiologically active substance by the solvent-evaporation drying
     process. The microspheres are produced by emulsifying the solution in a
     non-solvent by the aid of ultrasonic wave. The microspheres produce a
     sustained release effect of the physiologically active substance.","4,994,281","Sanraku Incorporated
 (Tokyo, 
JP)


Biomaterials Universe Incorporated
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4994281,Particles for inhalation having sustained release properties,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=18&f=G&l=50&d=PALL&S1=4994281.UREF.&OS=ref/4994281&RS=REF/4994281,,,"7,052,678",2006
1519573878-412,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid microspheres and process for producing the same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=614&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"Polylactic acid microspheres having an average particle diameter of about
     0.1 to 10 .mu.m which are produced from solution containing a
     physiologically active substance by the solvent-evaporation drying
     process. The microspheres are produced by emulsifying the solution in a
     non-solvent by the aid of ultrasonic wave. The microspheres produce a
     sustained release effect of the physiologically active substance.","4,994,281","Sanraku Incorporated
 (Tokyo, 
JP)


Biomaterials Universe Incorporated
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4994281,"Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and
     1,2-benzisothiazoles",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=17&f=G&l=50&d=PALL&S1=4994281.UREF.&OS=ref/4994281&RS=REF/4994281,,,"7,118,763",2006
1519573881-413,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid microspheres and process for producing the same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=614&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"Polylactic acid microspheres having an average particle diameter of about
     0.1 to 10 .mu.m which are produced from solution containing a
     physiologically active substance by the solvent-evaporation drying
     process. The microspheres are produced by emulsifying the solution in a
     non-solvent by the aid of ultrasonic wave. The microspheres produce a
     sustained release effect of the physiologically active substance.","4,994,281","Sanraku Incorporated
 (Tokyo, 
JP)


Biomaterials Universe Incorporated
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4994281,Particulate compositions for pulmonary delivery,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=16&f=G&l=50&d=PALL&S1=4994281.UREF.&OS=ref/4994281&RS=REF/4994281,,,"7,182,961",2007
1519573885-414,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid microspheres and process for producing the same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=614&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"Polylactic acid microspheres having an average particle diameter of about
     0.1 to 10 .mu.m which are produced from solution containing a
     physiologically active substance by the solvent-evaporation drying
     process. The microspheres are produced by emulsifying the solution in a
     non-solvent by the aid of ultrasonic wave. The microspheres produce a
     sustained release effect of the physiologically active substance.","4,994,281","Sanraku Incorporated
 (Tokyo, 
JP)


Biomaterials Universe Incorporated
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4994281,"Induced phase transition method for the production of microparticles
     containing hydrophilic active agents",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=15&f=G&l=50&d=PALL&S1=4994281.UREF.&OS=ref/4994281&RS=REF/4994281,,,"7,252,842",2007
1519573894-415,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid microspheres and process for producing the same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=614&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"Polylactic acid microspheres having an average particle diameter of about
     0.1 to 10 .mu.m which are produced from solution containing a
     physiologically active substance by the solvent-evaporation drying
     process. The microspheres are produced by emulsifying the solution in a
     non-solvent by the aid of ultrasonic wave. The microspheres produce a
     sustained release effect of the physiologically active substance.","4,994,281","Sanraku Incorporated
 (Tokyo, 
JP)


Biomaterials Universe Incorporated
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4994281,Particulate compositions for pulmonary delivery,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=14&f=G&l=50&d=PALL&S1=4994281.UREF.&OS=ref/4994281&RS=REF/4994281,,,"7,384,649",2008
1519573899-416,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid microspheres and process for producing the same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=614&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"Polylactic acid microspheres having an average particle diameter of about
     0.1 to 10 .mu.m which are produced from solution containing a
     physiologically active substance by the solvent-evaporation drying
     process. The microspheres are produced by emulsifying the solution in a
     non-solvent by the aid of ultrasonic wave. The microspheres produce a
     sustained release effect of the physiologically active substance.","4,994,281","Sanraku Incorporated
 (Tokyo, 
JP)


Biomaterials Universe Incorporated
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4994281,"Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and
     1,2-benzisothiazoles",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=13&f=G&l=50&d=PALL&S1=4994281.UREF.&OS=ref/4994281&RS=REF/4994281,,,"7,547,452",2009
1519573905-417,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid microspheres and process for producing the same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=614&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"Polylactic acid microspheres having an average particle diameter of about
     0.1 to 10 .mu.m which are produced from solution containing a
     physiologically active substance by the solvent-evaporation drying
     process. The microspheres are produced by emulsifying the solution in a
     non-solvent by the aid of ultrasonic wave. The microspheres produce a
     sustained release effect of the physiologically active substance.","4,994,281","Sanraku Incorporated
 (Tokyo, 
JP)


Biomaterials Universe Incorporated
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4994281,Particles for inhalation having sustained release properties,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=12&f=G&l=50&d=PALL&S1=4994281.UREF.&OS=ref/4994281&RS=REF/4994281,,,"7,628,977",2009
1519573909-418,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid microspheres and process for producing the same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=614&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"Polylactic acid microspheres having an average particle diameter of about
     0.1 to 10 .mu.m which are produced from solution containing a
     physiologically active substance by the solvent-evaporation drying
     process. The microspheres are produced by emulsifying the solution in a
     non-solvent by the aid of ultrasonic wave. The microspheres produce a
     sustained release effect of the physiologically active substance.","4,994,281","Sanraku Incorporated
 (Tokyo, 
JP)


Biomaterials Universe Incorporated
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4994281,Particles for inhalation having sustained release properties,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=11&f=G&l=50&d=PALL&S1=4994281.UREF.&OS=ref/4994281&RS=REF/4994281,,,"7,678,364",2010
1519573915-419,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid microspheres and process for producing the same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=614&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"Polylactic acid microspheres having an average particle diameter of about
     0.1 to 10 .mu.m which are produced from solution containing a
     physiologically active substance by the solvent-evaporation drying
     process. The microspheres are produced by emulsifying the solution in a
     non-solvent by the aid of ultrasonic wave. The microspheres produce a
     sustained release effect of the physiologically active substance.","4,994,281","Sanraku Incorporated
 (Tokyo, 
JP)


Biomaterials Universe Incorporated
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4994281,Implantable polymeric device for sustained release of buprenorphine,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=10&f=G&l=50&d=PALL&S1=4994281.UREF.&OS=ref/4994281&RS=REF/4994281,,,"7,736,665",2010
1519573919-420,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid microspheres and process for producing the same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=614&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"Polylactic acid microspheres having an average particle diameter of about
     0.1 to 10 .mu.m which are produced from solution containing a
     physiologically active substance by the solvent-evaporation drying
     process. The microspheres are produced by emulsifying the solution in a
     non-solvent by the aid of ultrasonic wave. The microspheres produce a
     sustained release effect of the physiologically active substance.","4,994,281","Sanraku Incorporated
 (Tokyo, 
JP)


Biomaterials Universe Incorporated
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4994281,Immunomodulatory agent-polymeric compounds,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=9&f=G&l=50&d=PALL&S1=4994281.UREF.&OS=ref/4994281&RS=REF/4994281,,,"8,629,151",2014
1519573921-421,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid microspheres and process for producing the same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=614&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"Polylactic acid microspheres having an average particle diameter of about
     0.1 to 10 .mu.m which are produced from solution containing a
     physiologically active substance by the solvent-evaporation drying
     process. The microspheres are produced by emulsifying the solution in a
     non-solvent by the aid of ultrasonic wave. The microspheres produce a
     sustained release effect of the physiologically active substance.","4,994,281","Sanraku Incorporated
 (Tokyo, 
JP)


Biomaterials Universe Incorporated
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4994281,"Method and device for continuously preparing microspheres, and collection
     unit thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=8&f=G&l=50&d=PALL&S1=4994281.UREF.&OS=ref/4994281&RS=REF/4994281,,,"8,641,900",2014
1519573924-422,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid microspheres and process for producing the same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=614&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"Polylactic acid microspheres having an average particle diameter of about
     0.1 to 10 .mu.m which are produced from solution containing a
     physiologically active substance by the solvent-evaporation drying
     process. The microspheres are produced by emulsifying the solution in a
     non-solvent by the aid of ultrasonic wave. The microspheres produce a
     sustained release effect of the physiologically active substance.","4,994,281","Sanraku Incorporated
 (Tokyo, 
JP)


Biomaterials Universe Incorporated
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4994281,Implantable polymeric device for sustained release of dopamine agonist,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=7&f=G&l=50&d=PALL&S1=4994281.UREF.&OS=ref/4994281&RS=REF/4994281,,,"8,852,623",2014
1519573928-423,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid microspheres and process for producing the same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=614&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"Polylactic acid microspheres having an average particle diameter of about
     0.1 to 10 .mu.m which are produced from solution containing a
     physiologically active substance by the solvent-evaporation drying
     process. The microspheres are produced by emulsifying the solution in a
     non-solvent by the aid of ultrasonic wave. The microspheres produce a
     sustained release effect of the physiologically active substance.","4,994,281","Sanraku Incorporated
 (Tokyo, 
JP)


Biomaterials Universe Incorporated
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4994281,Immunomodulatory agent-polymeric compounds,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=6&f=G&l=50&d=PALL&S1=4994281.UREF.&OS=ref/4994281&RS=REF/4994281,,,"9,006,254",2015
1519573932-424,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid microspheres and process for producing the same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=614&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"Polylactic acid microspheres having an average particle diameter of about
     0.1 to 10 .mu.m which are produced from solution containing a
     physiologically active substance by the solvent-evaporation drying
     process. The microspheres are produced by emulsifying the solution in a
     non-solvent by the aid of ultrasonic wave. The microspheres produce a
     sustained release effect of the physiologically active substance.","4,994,281","Sanraku Incorporated
 (Tokyo, 
JP)


Biomaterials Universe Incorporated
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4994281,Dose selection of adjuvanted synthetic nanocarriers,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=5&f=G&l=50&d=PALL&S1=4994281.UREF.&OS=ref/4994281&RS=REF/4994281,,,"9,066,978",2015
1519573935-425,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid microspheres and process for producing the same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=614&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"Polylactic acid microspheres having an average particle diameter of about
     0.1 to 10 .mu.m which are produced from solution containing a
     physiologically active substance by the solvent-evaporation drying
     process. The microspheres are produced by emulsifying the solution in a
     non-solvent by the aid of ultrasonic wave. The microspheres produce a
     sustained release effect of the physiologically active substance.","4,994,281","Sanraku Incorporated
 (Tokyo, 
JP)


Biomaterials Universe Incorporated
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4994281,Implantable polymeric device for sustained release of dopamine agonist,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=4&f=G&l=50&d=PALL&S1=4994281.UREF.&OS=ref/4994281&RS=REF/4994281,,,"9,278,163",2016
1519573939-426,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid microspheres and process for producing the same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=614&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"Polylactic acid microspheres having an average particle diameter of about
     0.1 to 10 .mu.m which are produced from solution containing a
     physiologically active substance by the solvent-evaporation drying
     process. The microspheres are produced by emulsifying the solution in a
     non-solvent by the aid of ultrasonic wave. The microspheres produce a
     sustained release effect of the physiologically active substance.","4,994,281","Sanraku Incorporated
 (Tokyo, 
JP)


Biomaterials Universe Incorporated
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4994281,Coated particles for sustained-release pharmaceutical administration,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=3&f=G&l=50&d=PALL&S1=4994281.UREF.&OS=ref/4994281&RS=REF/4994281,,,"9,492,388",2016
1519573943-427,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid microspheres and process for producing the same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=614&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"Polylactic acid microspheres having an average particle diameter of about
     0.1 to 10 .mu.m which are produced from solution containing a
     physiologically active substance by the solvent-evaporation drying
     process. The microspheres are produced by emulsifying the solution in a
     non-solvent by the aid of ultrasonic wave. The microspheres produce a
     sustained release effect of the physiologically active substance.","4,994,281","Sanraku Incorporated
 (Tokyo, 
JP)


Biomaterials Universe Incorporated
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4994281,Dose selection of adjuvanted synthetic nanocarriers,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=2&f=G&l=50&d=PALL&S1=4994281.UREF.&OS=ref/4994281&RS=REF/4994281,,,"9,764,031",2017
1519573947-428,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid microspheres and process for producing the same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=614&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"Polylactic acid microspheres having an average particle diameter of about
     0.1 to 10 .mu.m which are produced from solution containing a
     physiologically active substance by the solvent-evaporation drying
     process. The microspheres are produced by emulsifying the solution in a
     non-solvent by the aid of ultrasonic wave. The microspheres produce a
     sustained release effect of the physiologically active substance.","4,994,281","Sanraku Incorporated
 (Tokyo, 
JP)


Biomaterials Universe Incorporated
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/4994281,Immunomodulatory agent-polymeric compounds,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=1&f=G&l=50&d=PALL&S1=4994281.UREF.&OS=ref/4994281&RS=REF/4994281,,,"9,884,112",2018
1519573960-429,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid fiber,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=613&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"A polylactic acid fiber comprises a blend of poly-L-lactic acid and
     poly-D-lactic acid and is improved by spinning and then drawing.","5,010,145","Daicel Chemical Industries, Ltd.
 (Sakai, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5010145,Surgical cable crimp,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=27&f=G&l=50&d=PALL&S1=5010145.UREF.&OS=ref/5010145&RS=REF/5010145,,,"5,476,465",1995
1519573964-430,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid fiber,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=613&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"A polylactic acid fiber comprises a blend of poly-L-lactic acid and
     poly-D-lactic acid and is improved by spinning and then drawing.","5,010,145","Daicel Chemical Industries, Ltd.
 (Sakai, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5010145,Method for producing polylactic acid,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=26&f=G&l=50&d=PALL&S1=5010145.UREF.&OS=ref/5010145&RS=REF/5010145,,,"5,508,378",1996
1519573966-431,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid fiber,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=613&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"A polylactic acid fiber comprises a blend of poly-L-lactic acid and
     poly-D-lactic acid and is improved by spinning and then drawing.","5,010,145","Daicel Chemical Industries, Ltd.
 (Sakai, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5010145,"Nonwoven based on polymers derived from lactic acid, process for
     manufacture and use of such a nonwoven",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=25&f=G&l=50&d=PALL&S1=5010145.UREF.&OS=ref/5010145&RS=REF/5010145,,,"5,985,776",1999
1519573970-432,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid fiber,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=613&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"A polylactic acid fiber comprises a blend of poly-L-lactic acid and
     poly-D-lactic acid and is improved by spinning and then drawing.","5,010,145","Daicel Chemical Industries, Ltd.
 (Sakai, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5010145,Method for manufacturing and treating textiles,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=24&f=G&l=50&d=PALL&S1=5010145.UREF.&OS=ref/5010145&RS=REF/5010145,,,"6,120,558",2000
1519573975-433,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid fiber,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=613&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"A polylactic acid fiber comprises a blend of poly-L-lactic acid and
     poly-D-lactic acid and is improved by spinning and then drawing.","5,010,145","Daicel Chemical Industries, Ltd.
 (Sakai, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5010145,Process for hot stretching braided ligatures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=23&f=G&l=50&d=PALL&S1=5010145.UREF.&OS=ref/5010145&RS=REF/5010145,,,"6,264,674",2001
1519573980-434,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid fiber,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=613&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"A polylactic acid fiber comprises a blend of poly-L-lactic acid and
     poly-D-lactic acid and is improved by spinning and then drawing.","5,010,145","Daicel Chemical Industries, Ltd.
 (Sakai, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5010145,"Melt-stable lactide polymer nonwoven fabric and process for manufacture
     thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=22&f=G&l=50&d=PALL&S1=5010145.UREF.&OS=ref/5010145&RS=REF/5010145,,,"6,355,772",2002
1519573985-435,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid fiber,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=613&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"A polylactic acid fiber comprises a blend of poly-L-lactic acid and
     poly-D-lactic acid and is improved by spinning and then drawing.","5,010,145","Daicel Chemical Industries, Ltd.
 (Sakai, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5010145,Heat bondable biodegradable fiber,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=21&f=G&l=50&d=PALL&S1=5010145.UREF.&OS=ref/5010145&RS=REF/5010145,,,"6,441,267",2002
1519573993-436,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid fiber,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=613&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"A polylactic acid fiber comprises a blend of poly-L-lactic acid and
     poly-D-lactic acid and is improved by spinning and then drawing.","5,010,145","Daicel Chemical Industries, Ltd.
 (Sakai, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5010145,"Degradable polymer fibers; preparation product; and, methods of use",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=20&f=G&l=50&d=PALL&S1=5010145.UREF.&OS=ref/5010145&RS=REF/5010145,,,"6,506,873",2003
1519574007-437,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid fiber,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=613&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"A polylactic acid fiber comprises a blend of poly-L-lactic acid and
     poly-D-lactic acid and is improved by spinning and then drawing.","5,010,145","Daicel Chemical Industries, Ltd.
 (Sakai, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5010145,Heat bondable biodegradable fibers with enhanced adhesion,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=19&f=G&l=50&d=PALL&S1=5010145.UREF.&OS=ref/5010145&RS=REF/5010145,,,"6,509,092",2003
1519574015-438,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid fiber,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=613&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"A polylactic acid fiber comprises a blend of poly-L-lactic acid and
     poly-D-lactic acid and is improved by spinning and then drawing.","5,010,145","Daicel Chemical Industries, Ltd.
 (Sakai, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5010145,Poly(lactic acid) fiber,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=18&f=G&l=50&d=PALL&S1=5010145.UREF.&OS=ref/5010145&RS=REF/5010145,,,"6,761,970",2004
1519574019-439,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid fiber,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=613&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"A polylactic acid fiber comprises a blend of poly-L-lactic acid and
     poly-D-lactic acid and is improved by spinning and then drawing.","5,010,145","Daicel Chemical Industries, Ltd.
 (Sakai, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5010145,Fibers and webs capable of high speed solid state deformation,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=17&f=G&l=50&d=PALL&S1=5010145.UREF.&OS=ref/5010145&RS=REF/5010145,,,"6,770,356",2004
1519574023-440,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid fiber,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=613&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"A polylactic acid fiber comprises a blend of poly-L-lactic acid and
     poly-D-lactic acid and is improved by spinning and then drawing.","5,010,145","Daicel Chemical Industries, Ltd.
 (Sakai, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5010145,Splittable multicomponent polyester fibers,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=16&f=G&l=50&d=PALL&S1=5010145.UREF.&OS=ref/5010145&RS=REF/5010145,,,"6,780,357",2004
1519574027-441,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid fiber,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=613&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"A polylactic acid fiber comprises a blend of poly-L-lactic acid and
     poly-D-lactic acid and is improved by spinning and then drawing.","5,010,145","Daicel Chemical Industries, Ltd.
 (Sakai, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5010145,Fibers formed of a biodegradable polymer and having a low friction surface,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=15&f=G&l=50&d=PALL&S1=5010145.UREF.&OS=ref/5010145&RS=REF/5010145,,,"7,056,580",2006
1519574031-442,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid fiber,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=613&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"A polylactic acid fiber comprises a blend of poly-L-lactic acid and
     poly-D-lactic acid and is improved by spinning and then drawing.","5,010,145","Daicel Chemical Industries, Ltd.
 (Sakai, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5010145,Socket and prosthesis for joint replacement,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=14&f=G&l=50&d=PALL&S1=5010145.UREF.&OS=ref/5010145&RS=REF/5010145,,,"7,909,882",2011
1519574038-443,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid fiber,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=613&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"A polylactic acid fiber comprises a blend of poly-L-lactic acid and
     poly-D-lactic acid and is improved by spinning and then drawing.","5,010,145","Daicel Chemical Industries, Ltd.
 (Sakai, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5010145,Site marker visible under multiple modalities,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=13&f=G&l=50&d=PALL&S1=5010145.UREF.&OS=ref/5010145&RS=REF/5010145,,,"8,060,183",2011
1519574043-444,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid fiber,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=613&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"A polylactic acid fiber comprises a blend of poly-L-lactic acid and
     poly-D-lactic acid and is improved by spinning and then drawing.","5,010,145","Daicel Chemical Industries, Ltd.
 (Sakai, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5010145,Methods for making polylactic acid stereocomplex fibers,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=12&f=G&l=50&d=PALL&S1=5010145.UREF.&OS=ref/5010145&RS=REF/5010145,,,"8,182,725",2012
1519574048-445,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid fiber,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=613&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"A polylactic acid fiber comprises a blend of poly-L-lactic acid and
     poly-D-lactic acid and is improved by spinning and then drawing.","5,010,145","Daicel Chemical Industries, Ltd.
 (Sakai, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5010145,Site marker visable under multiple modalities,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=11&f=G&l=50&d=PALL&S1=5010145.UREF.&OS=ref/5010145&RS=REF/5010145,,,"8,280,486",2012
1519574053-446,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid fiber,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=613&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"A polylactic acid fiber comprises a blend of poly-L-lactic acid and
     poly-D-lactic acid and is improved by spinning and then drawing.","5,010,145","Daicel Chemical Industries, Ltd.
 (Sakai, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5010145,Polylactic acid fiber and manufacturing method thereof,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=10&f=G&l=50&d=PALL&S1=5010145.UREF.&OS=ref/5010145&RS=REF/5010145,,,"8,299,148",2012
1519574057-447,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid fiber,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=613&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"A polylactic acid fiber comprises a blend of poly-L-lactic acid and
     poly-D-lactic acid and is improved by spinning and then drawing.","5,010,145","Daicel Chemical Industries, Ltd.
 (Sakai, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5010145,Screw and method of use,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=9&f=G&l=50&d=PALL&S1=5010145.UREF.&OS=ref/5010145&RS=REF/5010145,,,"8,317,845",2012
1519574061-448,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid fiber,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=613&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"A polylactic acid fiber comprises a blend of poly-L-lactic acid and
     poly-D-lactic acid and is improved by spinning and then drawing.","5,010,145","Daicel Chemical Industries, Ltd.
 (Sakai, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5010145,Site marker visible under multiple modalities,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=8&f=G&l=50&d=PALL&S1=5010145.UREF.&OS=ref/5010145&RS=REF/5010145,,,"8,352,014",2013
1519574065-449,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid fiber,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=613&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"A polylactic acid fiber comprises a blend of poly-L-lactic acid and
     poly-D-lactic acid and is improved by spinning and then drawing.","5,010,145","Daicel Chemical Industries, Ltd.
 (Sakai, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5010145,Process of making conjugate fibers,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=7&f=G&l=50&d=PALL&S1=5010145.UREF.&OS=ref/5010145&RS=REF/5010145,,,"8,377,353",2013
1519574068-450,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid fiber,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=613&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"A polylactic acid fiber comprises a blend of poly-L-lactic acid and
     poly-D-lactic acid and is improved by spinning and then drawing.","5,010,145","Daicel Chemical Industries, Ltd.
 (Sakai, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5010145,Site marker,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=6&f=G&l=50&d=PALL&S1=5010145.UREF.&OS=ref/5010145&RS=REF/5010145,,,"8,433,391",2013
1519574073-451,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid fiber,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=613&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"A polylactic acid fiber comprises a blend of poly-L-lactic acid and
     poly-D-lactic acid and is improved by spinning and then drawing.","5,010,145","Daicel Chemical Industries, Ltd.
 (Sakai, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5010145,Site marker visible under multiple modalities,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=5&f=G&l=50&d=PALL&S1=5010145.UREF.&OS=ref/5010145&RS=REF/5010145,,,"8,442,623",2013
1519574077-452,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid fiber,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=613&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"A polylactic acid fiber comprises a blend of poly-L-lactic acid and
     poly-D-lactic acid and is improved by spinning and then drawing.","5,010,145","Daicel Chemical Industries, Ltd.
 (Sakai, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5010145,Fiber reinforced composite material,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=4&f=G&l=50&d=PALL&S1=5010145.UREF.&OS=ref/5010145&RS=REF/5010145,,,"8,722,783",2014
1519574082-453,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid fiber,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=613&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"A polylactic acid fiber comprises a blend of poly-L-lactic acid and
     poly-D-lactic acid and is improved by spinning and then drawing.","5,010,145","Daicel Chemical Industries, Ltd.
 (Sakai, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5010145,PLA-containing material,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=3&f=G&l=50&d=PALL&S1=5010145.UREF.&OS=ref/5010145&RS=REF/5010145,,,"8,829,097",2014
1519574086-454,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid fiber,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=613&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"A polylactic acid fiber comprises a blend of poly-L-lactic acid and
     poly-D-lactic acid and is improved by spinning and then drawing.","5,010,145","Daicel Chemical Industries, Ltd.
 (Sakai, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5010145,Barrier packaging webs having metallized non-oriented film,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=2&f=G&l=50&d=PALL&S1=5010145.UREF.&OS=ref/5010145&RS=REF/5010145,,,"8,945,702",2015
1519574090-455,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Polylactic acid fiber,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=613&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"A polylactic acid fiber comprises a blend of poly-L-lactic acid and
     poly-D-lactic acid and is improved by spinning and then drawing.","5,010,145","Daicel Chemical Industries, Ltd.
 (Sakai, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5010145,PLA-containing material,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=1&f=G&l=50&d=PALL&S1=5010145.UREF.&OS=ref/5010145&RS=REF/5010145,,,"9,512,303",2016
1519574105-456,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Flexible intramedullary fixation rod,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=612&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1991,"A flexible inramedullary fixation rod for fractured bones is provided
     having a length sufficient to extend a substantial distance on either side
     of a diaphyseal fracture site and a substantially circular core with
     radially disposed fins extending substantially along the full length
     thereof. The radii of the core and fins are such that the rod can pass
     through the bone's medullary canal and engage the inner, or endosteal,
     surface of the bone along line contacts, thereby allowing normal endosteal
     healing and intramedullary revascularization. The rod is constructed of a
     flexible, bio-compatible material, such as titanium, stainless steel,
     resorbable polymers (e.g., polylactic acid) or carbon fiber-polysulfone.
     The radii of the fins are selected to be substantially equal to the
     minimum radius of the medullary canal. The core radius is selected in
     accordance with the Young's and shear moduli associated with the
     bio-compatible material to provide a rod structural rigidity (bending and
     torsional) preferably between 0.1% and 10% of the inherent bone rigidity
     with the relationship between the rod bending and torsional rigidities
     preferably being substantially the same as the corresponding relationship
     for the intact bone. This causes natural stresses (bending and torsional)
     to be maintained at the fracture site, thereby promoting natural and
     therefore stronger healing of the fractured bone.","5,053,035",null,,http://pdfpiw.uspto.gov/.piw?Docid=05053035&homeurl=http%3A%2F%2Fpatft.uspto.gov%2Fnetacgi%2Fnph-Parser%3FSect1%3DPTO2%2526Sect2%3DHITOFF%2526u%3D%25252Fnetahtml%25252FPTO%25252Fsearch-adv.htm%2526r%3D612%2526f%3DG%2526l%3D50%2526d%3DPTXT%2526s1%3D%252522polylactic%252Bacid%252522.ABTX.%2526p%3D13%2526OS%3DABST%2F%252522polylactic%252Bacid%252522%2526RS%3DABST%2F%252522polylactic%252Bacid%252522&PageNum=&Rtype=&SectionNum=&idkey=NONE&Input=View+first+page,,,null,,,
1519574130-457,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,"Noscapine and noscapine derivatives, useful as anticancer agents",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=100&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5100669.UREF.&Page=Next&OS=ref/5100669&RS=REF/5100669,"6,376,516",2002
1519574136-458,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Aerodynamically light particles for pulmonary drug delivery,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=99&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5100669.UREF.&Page=Next&OS=ref/5100669&RS=REF/5100669,"6,399,102",2002
1519574141-459,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Encapsulation of bioactive agents,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=98&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5100669.UREF.&Page=Next&OS=ref/5100669&RS=REF/5100669,"6,406,719",2002
1519574146-460,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Proteinoid carriers and methods for preparation and use thereof,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=97&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5100669.UREF.&Page=Next&OS=ref/5100669&RS=REF/5100669,"6,413,550",2002
1519574149-461,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Formulations and methods for providing prolonged local anesthesia,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=96&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5100669.UREF.&Page=Next&OS=ref/5100669&RS=REF/5100669,"6,426,339",2002
1519574153-462,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Compounds and compositions for delivering active agents,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=95&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5100669.UREF.&Page=Next&OS=ref/5100669&RS=REF/5100669,"6,428,780",2002
1519574157-463,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Method of solubilizing and encapsulating itraconazole,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=94&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5100669.UREF.&Page=Next&OS=ref/5100669&RS=REF/5100669,"6,461,545",2002
1519574161-464,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Polymeric gene delivery,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=93&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5100669.UREF.&Page=Next&OS=ref/5100669&RS=REF/5100669,"6,475,779",2002
1519574165-465,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Formulations and methods for providing prolonged local anesthesia,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=92&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5100669.UREF.&Page=Next&OS=ref/5100669&RS=REF/5100669,"6,514,516",2003
1519574168-466,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Formulations and methods for providing prolonged local anesthesia,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=91&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5100669.UREF.&Page=Next&OS=ref/5100669&RS=REF/5100669,"6,521,259",2003
1519574173-467,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Prolonged anesthesia in joints and body spaces,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=90&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5100669.UREF.&Page=Next&OS=ref/5100669&RS=REF/5100669,"6,534,081",2003
1519574177-468,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Once-a-day controlled release sulfonylurea formulation,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=89&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5100669.UREF.&Page=Next&OS=ref/5100669&RS=REF/5100669,"6,537,578",2003
1519574184-469,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Encapsulation of bioactive agents,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=88&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5100669.UREF.&Page=Next&OS=ref/5100669&RS=REF/5100669,"6,565,777",2003
1519574187-470,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,"Bioactive agent delivering system comprised of microparticles within a
     biodegradable to improve release profiles",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=87&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5100669.UREF.&Page=Next&OS=ref/5100669&RS=REF/5100669,"6,589,549",2003
1519574195-471,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Microencapsulation of drugs by solvent exchange,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=86&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5100669.UREF.&Page=Next&OS=ref/5100669&RS=REF/5100669,"6,599,627",2003
1519574207-472,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Polymeric gene delivery system,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=85&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5100669.UREF.&Page=Next&OS=ref/5100669&RS=REF/5100669,"6,620,617",2003
1519574215-473,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,"Process for preparing biodegradable microspheres containing physiologically
     active agents",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=84&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5100669.UREF.&Page=Next&OS=ref/5100669&RS=REF/5100669,"6,630,156",2003
1519574219-474,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Aerodynamically light particles for pulmonary drug delivery,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=83&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5100669.UREF.&Page=Next&OS=ref/5100669&RS=REF/5100669,"6,635,283",2003
1519574227-475,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Preparation of novel particles for inhalation,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=82&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5100669.UREF.&Page=Next&OS=ref/5100669&RS=REF/5100669,"6,652,837",2003
1519574234-476,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Microencapsulated DNA for vaccination and gene therapy,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=81&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5100669.UREF.&Page=Next&OS=ref/5100669&RS=REF/5100669,"6,667,294",2003
1519574240-477,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,"Delivery systems and methods for noscapine and noscapine derivatives,
     useful as anticancer agents",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=80&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5100669.UREF.&Page=Next&OS=ref/5100669&RS=REF/5100669,"6,673,814",2004
1519574245-478,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Sustained release matrix for high-dose insoluble drugs,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=79&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5100669.UREF.&Page=Next&OS=ref/5100669&RS=REF/5100669,"6,689,386",2004
1519574250-479,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Methods for providing safe local anesthesia,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=78&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5100669.UREF.&Page=Next&OS=ref/5100669&RS=REF/5100669,"6,699,908",2004
1519574253-480,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Composition and method for maintaining blood glucose level,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=77&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5100669.UREF.&Page=Next&OS=ref/5100669&RS=REF/5100669,"6,703,045",2004
1519574262-481,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Sustained release heterodisperse hydrogel systems for insoluble drugs,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=76&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5100669.UREF.&Page=Next&OS=ref/5100669&RS=REF/5100669,"6,726,930",2004
1519574266-482,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Method of making microencapsulated DNA for vaccination and gene therapy,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=75&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5100669.UREF.&Page=Next&OS=ref/5100669&RS=REF/5100669,"6,743,444",2004
1519574269-483,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Formulation for spray-drying large porous particles,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=74&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5100669.UREF.&Page=Next&OS=ref/5100669&RS=REF/5100669,"6,749,835",2004
1519574272-484,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Microencapsulation using ultrasonic atomizers,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=73&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5100669.UREF.&Page=Next&OS=ref/5100669&RS=REF/5100669,"6,767,637",2004
1519574275-485,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Once-a-day controlled release sulfonylurea formulation,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=72&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5100669.UREF.&Page=Next&OS=ref/5100669&RS=REF/5100669,"6,875,793",2005
1519574278-486,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,"Lapachone delivery systems, compositions and uses related thereto",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=71&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5100669.UREF.&Page=Next&OS=ref/5100669&RS=REF/5100669,"6,890,950",2005
1519574281-487,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Compositions for microencapsulation of antigens for use as vaccines,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=70&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5100669.UREF.&Page=Next&OS=ref/5100669&RS=REF/5100669,"6,913,767",2005
1519574284-488,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Formulations and methods for providing prolonged local anesthesia,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=69&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5100669.UREF.&Page=Next&OS=ref/5100669&RS=REF/5100669,"6,921,541",2005
1519574287-489,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Aerodynamically light particles for pulmonary drug delivery,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=68&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5100669.UREF.&Page=Next&OS=ref/5100669&RS=REF/5100669,"6,942,868",2005
1519574290-490,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Stable spray-dried protein formulations,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=67&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5100669.UREF.&Page=Next&OS=ref/5100669&RS=REF/5100669,"6,956,021",2005
1519574295-491,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,"Mixtures of various triblock polyester polyethylene glycol copolymers
     having improved gel properties",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=66&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5100669.UREF.&Page=Next&OS=ref/5100669&RS=REF/5100669,"7,018,645",2006
1519574299-492,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Particles for inhalation having sustained release properties,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=65&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5100669.UREF.&Page=Next&OS=ref/5100669&RS=REF/5100669,"7,048,908",2006
1519574302-493,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Particles for inhalation having sustained release properties,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=64&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5100669.UREF.&Page=Next&OS=ref/5100669&RS=REF/5100669,"7,052,678",2006
1519574306-494,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,"Mixtures of various triblock polyester polyethylene glycol copolymers
     having improved gel properties",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=63&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5100669.UREF.&Page=Next&OS=ref/5100669&RS=REF/5100669,"7,135,190",2006
1519574313-495,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Porous beads and method of production thereof,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=62&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5100669.UREF.&Page=Next&OS=ref/5100669&RS=REF/5100669,"7,153,572",2006
1519574317-496,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Multi-layered microcapsules and method of preparing same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=61&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5100669.UREF.&Page=Next&OS=ref/5100669&RS=REF/5100669,"7,157,102",2007
1519574323-497,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Particulate compositions for pulmonary delivery,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=60&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5100669.UREF.&Page=Next&OS=ref/5100669&RS=REF/5100669,"7,182,961",2007
1519574327-498,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Cyclodextrin-based polymers for therapeutics delivery,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=59&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5100669.UREF.&Page=Next&OS=ref/5100669&RS=REF/5100669,"7,270,808",2007
1519574331-499,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Particulate compositions for pulmonary delivery,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=58&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5100669.UREF.&Page=Next&OS=ref/5100669&RS=REF/5100669,"7,384,649",2008
1519574334-500,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Compounds and compositions for delivering active agents,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=57&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5100669.UREF.&Page=Next&OS=ref/5100669&RS=REF/5100669,"7,417,022",2008
1519574337-501,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Compounds and compositions for delivering active agents,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=56&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5100669.UREF.&Page=Next&OS=ref/5100669&RS=REF/5100669,"7,553,872",2009
1519574340-502,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Particles for inhalation having sustained release properties,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=55&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5100669.UREF.&Page=Next&OS=ref/5100669&RS=REF/5100669,"7,628,977",2009
1519574344-503,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Biodegradable block copolymeric compositions for drug delivery,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=54&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5100669.UREF.&Page=Next&OS=ref/5100669&RS=REF/5100669,"7,649,023",2010
1519574348-504,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,"Protein matrix materials, devices and methods of making and using thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=53&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5100669.UREF.&Page=Next&OS=ref/5100669&RS=REF/5100669,"7,662,409",2010
1519574351-505,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Particles for inhalation having sustained release properties,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=52&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5100669.UREF.&Page=Next&OS=ref/5100669&RS=REF/5100669,"7,678,364",2010
1519574354-506,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Echoing ultrasound atomization and/or mixing system,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=51&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5100669.UREF.&Page=Next&OS=ref/5100669&RS=REF/5100669,"7,753,285",2010
1519574357-507,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Ultrasound pumping apparatus,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=50&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,,"7,780,095",2010
1519574361-508,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Ultrasound apparatus and methods for mixing liquids and coating stents,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=49&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,,"7,896,539",2011
1519574364-509,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Controlled release metformin formulations,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=48&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,,"7,919,116",2011
1519574367-510,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,"Methods and compositons for stimulating neurogenesis and inhibiting
     neuronal degeneration",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=47&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,,"8,039,462",2011
1519574370-511,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,"Methods of inhibiting transendothelial migration of neutrophils and
     monocytes with anti-CD99L2 antibodies",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=46&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,,"8,088,382",2012
1519574373-512,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Process for producing sustained-release composition,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=45&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,,"8,088,726",2012
1519574378-513,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Cyclodextrin-based polymers for therapeutics delivery,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=44&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,,"8,110,179",2012
1519574381-514,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,"Protein biomaterials and biocoacervates and methods of making and using
     thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=43&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,,"8,153,591",2012
1519574386-515,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Cyclodextrin-based polymers for therapeutics delivery,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=42&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,,"8,252,276",2012
1519574390-516,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Zero-order prolonged release coaxial implants,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=41&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,,"8,263,108",2012
1519574396-517,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Cyclodextrin-based polymers for therapeutics delivery,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=40&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,,"8,314,230",2012
1519574398-518,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Biodegradable polymer microparticles and preparation method thereof,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=39&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,,"8,329,856",2012
1519574401-519,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,"Peptidic growth hormone secretagogues analog compounds and preparations
     thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=38&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,,"8,367,620",2013
1519574405-520,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Cyclodextrin-based polymers for therapeutics delivery,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=37&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,,"8,389,499",2013
1519574410-521,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Cyclodextrin-based polymers for therapeutics delivery,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=36&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,,"8,399,431",2013
1519574415-522,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Cyclodextrin-based polymers for therapeutics delivery,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=35&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,,"8,404,662",2013
1519574418-523,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Encapsulated or coated stent systems,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=34&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,,"8,465,537",2013
1519574424-524,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Cyclodextrin-based polymers for therapeutics delivery,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=33&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,,"8,475,781",2013
1519574427-525,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Controlled release metformin formulations,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=32&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,,"8,475,841",2013
1519574431-526,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Cyclodextrin-based polymers for therapeutics delivery,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=31&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,,"8,497,365",2013
1519574436-527,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Cyclodextrin-based polymers for therapeutics delivery,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=30&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,,"8,518,388",2013
1519574443-528,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Mucoadhesive drug delivery devices and methods of making and using thereof,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=29&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,,"8,529,939",2013
1519574447-529,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Cyclodextrin-based polymers for therapeutics delivery,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=28&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,,"8,580,242",2013
1519574452-530,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Cyclodextrin-based polymers for therapeutics delivery,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=27&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,,"8,580,243",2013
1519574459-531,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Cyclodextrin-based polymers for therapeutics delivery,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=26&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,,"8,580,244",2013
1519574468-532,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Cyclodextrin-based polymers for therapeutics delivery,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=25&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,,"8,603,454",2013
1519574474-533,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Cyclodextrin-based polymers for therapeutics delivery,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=24&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,,"8,609,081",2013
1519574481-534,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,"Methods and compositions for stimulating neurogenesis and inhibiting
     neuronal degeneration using isothiazolopyrimidinones",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=23&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,,"8,609,840",2013
1519574486-535,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,"Biomatrix structural containment and fixation systems and methods of use
     thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=22&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,,"8,623,393",2014
1519574495-536,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Biodegradable block copolymeric compositions for drug delivery,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=21&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,,"8,642,666",2014
1519574503-537,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Sustained release matrix systems for highly soluble drugs,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=20&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,,"8,679,535",2014
1519574508-538,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Cyclodextrin-based polymers for therapeutics delivery,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=19&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,,"8,680,202",2014
1519574511-539,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,"Pharmaceutical composition of microspheres for preventing  diabetic foot
     amputation",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=18&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,,"8,741,848",2014
1519574516-540,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,"Protein matrix materials, devices and methods of making and using thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=17&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,,"8,871,267",2014
1519574522-541,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Zero-order prolonged release coaxial implants,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=16&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,,"8,889,174",2014
1519574526-542,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,"Water dispersible compositions and methods of using the water dispersible
     compositions",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=15&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,,"8,906,431",2014
1519574533-543,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,"Process of manufacture of novel drug delivery system: multilayer tablet
     composition of thiazolidinedione and biguanides",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=14&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,,"8,911,781",2014
1519574538-544,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,"Methods and compositions for stimulating neurogenesis and inhibiting
     neuronal degeneration",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=13&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,,"8,999,972",2015
1519574542-545,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,"Methods and compositions for stimulating neurogenesis and inhibiting
     neuronal degeneration using isothiazolopyrimidinones",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=12&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,,"9,096,613",2015
1519574548-546,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Ultrasonic atomization and/or seperation system,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=11&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,,"9,101,949",2015
1519574553-547,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Wound treatments with crosslinked protein amorphous biomaterials,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=10&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,,"9,107,937",2015
1519574559-548,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Biodegradable block copolymeric compositions for drug delivery,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=9&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,,"9,265,836",2016
1519574565-549,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Hemostatic substance with a coating,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=8&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,,"9,289,196",2016
1519574570-550,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,"Methods and compositions for stimulating neurogenesis and inhibiting
     neuronal degeneration",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=7&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,,"9,539,261",2017
1519574575-551,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Cyclodextrin-based polymers for therapeutics delivery,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=6&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,,"9,550,860",2017
1519574578-552,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,"Methods and compositions for stimulating neurogenesis and inhibiting
     neuronal degeneration using isothiazolopyrimidinones",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=5&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,,"9,592,234",2017
1519574583-553,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Polymer drug conjugates with tether groups for controlled drug delivery,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=4&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,,"9,610,360",2017
1519574590-554,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Human iNKT cell activation using glycolipids with altered glycosyl groups,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=3&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,,"9,782,476",2017
1519574596-555,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Method for preparing polymer microparticles by spray process,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=2&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,,"9,850,341",2017
1519574605-556,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Polylactic acid type microspheres containing physiologically active
     substance and process for preparing the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=611&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Microspheres comprising polylactic acid and a water soluble physiologically
     active substance and having a mean particle size of from about 0.01 .mu.m
     to 300 .mu.m, which show not more than 30% of an eluted amount of said
     physiologically active substance based on the content of said
     physiologically active substance in the polylactic acid type microspheres
     after 24 hours in in vitro elution test in phosphate buffer of pH 7.4 at
     37.degree. C., and a process for preparing the same. The polylactic acid
     type microspheres of this invention is advantageous in that the active
     substance can be uniformly incorporated into the microspheres without loss
     of the activity, can gradually release the active substance for a long
     time of period of more than one week.","5,100,669","Biomaterials Universe, Inc.
 (Kyoto, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5100669,Human iNKT cell activation using glycolipids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=1&f=G&l=50&d=PALL&S1=5100669.UREF.&OS=ref/5100669&RS=REF/5100669,,,"9,879,042",2018
1519574636-557,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Pressing having sustained release of active compound,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=610&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Pressing having sustained release of active compound for the oral or
     parenteral administration of medicaments, which contains at least one
     solid pharmaceutical active compound, polylactic acid and a homo- or
     copolymer of D(-)-3-hydroxybutyric acid and processes for its production.","5,128,144","PCD Polymere Gesellschaft m.b.H.
 (Schwechat-Mannsworth, 
AT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5128144,"Implantable controlled release device to deliver drugs directly to an
     internal portion of the body",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=15&f=G&l=50&d=PALL&S1=5128144.UREF.&OS=ref/5128144&RS=REF/5128144,,,"5,773,019",1998
1519574640-558,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Pressing having sustained release of active compound,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=610&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Pressing having sustained release of active compound for the oral or
     parenteral administration of medicaments, which contains at least one
     solid pharmaceutical active compound, polylactic acid and a homo- or
     copolymer of D(-)-3-hydroxybutyric acid and processes for its production.","5,128,144","PCD Polymere Gesellschaft m.b.H.
 (Schwechat-Mannsworth, 
AT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5128144,"Controlled local delivery of chemotherapeutic agents for treating solid
     tumors",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=14&f=G&l=50&d=PALL&S1=5128144.UREF.&OS=ref/5128144&RS=REF/5128144,,,"RE37,410",2001
1519574650-559,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Pressing having sustained release of active compound,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=610&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Pressing having sustained release of active compound for the oral or
     parenteral administration of medicaments, which contains at least one
     solid pharmaceutical active compound, polylactic acid and a homo- or
     copolymer of D(-)-3-hydroxybutyric acid and processes for its production.","5,128,144","PCD Polymere Gesellschaft m.b.H.
 (Schwechat-Mannsworth, 
AT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5128144,Syndiotactic poly(lactic acid),http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=13&f=G&l=50&d=PALL&S1=5128144.UREF.&OS=ref/5128144&RS=REF/5128144,,,"6,608,170",2003
1519574655-560,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Pressing having sustained release of active compound,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=610&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Pressing having sustained release of active compound for the oral or
     parenteral administration of medicaments, which contains at least one
     solid pharmaceutical active compound, polylactic acid and a homo- or
     copolymer of D(-)-3-hydroxybutyric acid and processes for its production.","5,128,144","PCD Polymere Gesellschaft m.b.H.
 (Schwechat-Mannsworth, 
AT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5128144,Pharmaceutical kit comprising midodrine as active drug substance,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=12&f=G&l=50&d=PALL&S1=5128144.UREF.&OS=ref/5128144&RS=REF/5128144,,,"6,761,904",2004
1519574662-561,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Pressing having sustained release of active compound,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=610&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Pressing having sustained release of active compound for the oral or
     parenteral administration of medicaments, which contains at least one
     solid pharmaceutical active compound, polylactic acid and a homo- or
     copolymer of D(-)-3-hydroxybutyric acid and processes for its production.","5,128,144","PCD Polymere Gesellschaft m.b.H.
 (Schwechat-Mannsworth, 
AT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5128144,"Controlled release pharmaceutical composition for oral use containing
     midodrine and/or active metabolite, desglymidodrine",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=11&f=G&l=50&d=PALL&S1=5128144.UREF.&OS=ref/5128144&RS=REF/5128144,,,"7,070,803",2006
1519574667-562,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Pressing having sustained release of active compound,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=610&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Pressing having sustained release of active compound for the oral or
     parenteral administration of medicaments, which contains at least one
     solid pharmaceutical active compound, polylactic acid and a homo- or
     copolymer of D(-)-3-hydroxybutyric acid and processes for its production.","5,128,144","PCD Polymere Gesellschaft m.b.H.
 (Schwechat-Mannsworth, 
AT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5128144,Medical devices and applications of polyhydroxyalkanoate polymers,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=10&f=G&l=50&d=PALL&S1=5128144.UREF.&OS=ref/5128144&RS=REF/5128144,,,"7,553,923",2009
1519574674-563,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Pressing having sustained release of active compound,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=610&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Pressing having sustained release of active compound for the oral or
     parenteral administration of medicaments, which contains at least one
     solid pharmaceutical active compound, polylactic acid and a homo- or
     copolymer of D(-)-3-hydroxybutyric acid and processes for its production.","5,128,144","PCD Polymere Gesellschaft m.b.H.
 (Schwechat-Mannsworth, 
AT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5128144,Method of making a polyhydroxyalkanoate filament,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=9&f=G&l=50&d=PALL&S1=5128144.UREF.&OS=ref/5128144&RS=REF/5128144,,,"7,641,825",2010
1519574680-564,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Pressing having sustained release of active compound,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=610&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Pressing having sustained release of active compound for the oral or
     parenteral administration of medicaments, which contains at least one
     solid pharmaceutical active compound, polylactic acid and a homo- or
     copolymer of D(-)-3-hydroxybutyric acid and processes for its production.","5,128,144","PCD Polymere Gesellschaft m.b.H.
 (Schwechat-Mannsworth, 
AT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5128144,"Medical devices containing oriented films of poly-4-hydroxybutyrate and
     copolymers",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=8&f=G&l=50&d=PALL&S1=5128144.UREF.&OS=ref/5128144&RS=REF/5128144,,,"7,943,683",2011
1519574687-565,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Pressing having sustained release of active compound,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=610&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Pressing having sustained release of active compound for the oral or
     parenteral administration of medicaments, which contains at least one
     solid pharmaceutical active compound, polylactic acid and a homo- or
     copolymer of D(-)-3-hydroxybutyric acid and processes for its production.","5,128,144","PCD Polymere Gesellschaft m.b.H.
 (Schwechat-Mannsworth, 
AT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5128144,Polyhydroxyalkanoate medical textiles and fibers,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=7&f=G&l=50&d=PALL&S1=5128144.UREF.&OS=ref/5128144&RS=REF/5128144,,,"8,034,270",2011
1519574692-566,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Pressing having sustained release of active compound,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=610&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Pressing having sustained release of active compound for the oral or
     parenteral administration of medicaments, which contains at least one
     solid pharmaceutical active compound, polylactic acid and a homo- or
     copolymer of D(-)-3-hydroxybutyric acid and processes for its production.","5,128,144","PCD Polymere Gesellschaft m.b.H.
 (Schwechat-Mannsworth, 
AT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5128144,Non-curling polyhydroxyalkanoate sutures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=6&f=G&l=50&d=PALL&S1=5128144.UREF.&OS=ref/5128144&RS=REF/5128144,,,"8,084,125",2011
1519574698-567,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Pressing having sustained release of active compound,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=610&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Pressing having sustained release of active compound for the oral or
     parenteral administration of medicaments, which contains at least one
     solid pharmaceutical active compound, polylactic acid and a homo- or
     copolymer of D(-)-3-hydroxybutyric acid and processes for its production.","5,128,144","PCD Polymere Gesellschaft m.b.H.
 (Schwechat-Mannsworth, 
AT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5128144,"Medical devices containing oriented films of poly-4-hydroxybutyrate and
     copolymers",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=5&f=G&l=50&d=PALL&S1=5128144.UREF.&OS=ref/5128144&RS=REF/5128144,,,"8,753,555",2014
1519574702-568,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Pressing having sustained release of active compound,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=610&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Pressing having sustained release of active compound for the oral or
     parenteral administration of medicaments, which contains at least one
     solid pharmaceutical active compound, polylactic acid and a homo- or
     copolymer of D(-)-3-hydroxybutyric acid and processes for its production.","5,128,144","PCD Polymere Gesellschaft m.b.H.
 (Schwechat-Mannsworth, 
AT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5128144,Process of making polyhydroxyalkanoate medical textiles,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=4&f=G&l=50&d=PALL&S1=5128144.UREF.&OS=ref/5128144&RS=REF/5128144,,,"8,758,657",2014
1519574705-569,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Pressing having sustained release of active compound,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=610&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Pressing having sustained release of active compound for the oral or
     parenteral administration of medicaments, which contains at least one
     solid pharmaceutical active compound, polylactic acid and a homo- or
     copolymer of D(-)-3-hydroxybutyric acid and processes for its production.","5,128,144","PCD Polymere Gesellschaft m.b.H.
 (Schwechat-Mannsworth, 
AT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5128144,Polyhydroxyalkanoate medical textiles and fibers,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=3&f=G&l=50&d=PALL&S1=5128144.UREF.&OS=ref/5128144&RS=REF/5128144,,,"9,125,719",2015
1519574711-570,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Pressing having sustained release of active compound,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=610&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Pressing having sustained release of active compound for the oral or
     parenteral administration of medicaments, which contains at least one
     solid pharmaceutical active compound, polylactic acid and a homo- or
     copolymer of D(-)-3-hydroxybutyric acid and processes for its production.","5,128,144","PCD Polymere Gesellschaft m.b.H.
 (Schwechat-Mannsworth, 
AT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5128144,Method of making a medical textile from polyhydroxyalkanoate fibers,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=2&f=G&l=50&d=PALL&S1=5128144.UREF.&OS=ref/5128144&RS=REF/5128144,,,"9,333,066",2016
1519574716-571,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Pressing having sustained release of active compound,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=610&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Pressing having sustained release of active compound for the oral or
     parenteral administration of medicaments, which contains at least one
     solid pharmaceutical active compound, polylactic acid and a homo- or
     copolymer of D(-)-3-hydroxybutyric acid and processes for its production.","5,128,144","PCD Polymere Gesellschaft m.b.H.
 (Schwechat-Mannsworth, 
AT)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5128144,"Methods of orienting multifilament yarn and monofilaments of
     poly-4-hydroxybutyrate and copolymers thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=1&f=G&l=50&d=PALL&S1=5128144.UREF.&OS=ref/5128144&RS=REF/5128144,,,"9,555,155",2017
1519574764-572,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Threaded interbody spinal fusion implant,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=100&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5133755.UREF.&Page=Next&OS=ref/5133755&RS=REF/5133755,"8,057,475",2011
1519574777-573,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Apparatus and systems for membraneless separation of fluids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=99&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5133755.UREF.&Page=Next&OS=ref/5133755&RS=REF/5133755,"8,083,706",2011
1519574790-574,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,"Systems and methods of microfluidic membraneless exchange using filtration
     of extraction outlet streams",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=98&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5133755.UREF.&Page=Next&OS=ref/5133755&RS=REF/5133755,"8,092,684",2012
1519574800-575,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,"Systems and methods of microfluidic membraneless exchange using filtration
     of extraction outlet streams",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=97&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5133755.UREF.&Page=Next&OS=ref/5133755&RS=REF/5133755,"8,097,153",2012
1519574807-576,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,"Systems and methods of microfluidic membraneless exchange using filtration
     of extraction outlet streams",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=96&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5133755.UREF.&Page=Next&OS=ref/5133755&RS=REF/5133755,"8,097,162",2012
1519574816-577,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Medical device with tensionably attached remodelable material,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=95&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5133755.UREF.&Page=Next&OS=ref/5133755&RS=REF/5133755,"8,128,682",2012
1519574821-578,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,"Biomimetic composition reinforced by a polyelectrolytic complex of
     hyaluronic acid and chitosan",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=94&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5133755.UREF.&Page=Next&OS=ref/5133755&RS=REF/5133755,"8,137,696",2012
1519574826-579,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Instrumentation kit for delivering viscous bone filler material,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=93&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5133755.UREF.&Page=Next&OS=ref/5133755&RS=REF/5133755,"8,147,500",2012
1519574831-580,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Attachment of absorbable tissue scaffolds to fixation devices,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=92&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5133755.UREF.&Page=Next&OS=ref/5133755&RS=REF/5133755,"8,187,326",2012
1519574835-581,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,System and methods for spinal fusion,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=91&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5133755.UREF.&Page=Next&OS=ref/5133755&RS=REF/5133755,"8,187,334",2012
1519574839-582,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Threaded frusto-conical spinal implants,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=90&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5133755.UREF.&Page=Next&OS=ref/5133755&RS=REF/5133755,"8,226,652",2012
1519574845-583,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Systems and methods for spinal fusion,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=89&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5133755.UREF.&Page=Next&OS=ref/5133755&RS=REF/5133755,"8,246,686",2012
1519574855-584,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,"Systems and methods of microfluidic membraneless exchange using filtration
     of extraction outlet streams",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=88&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5133755.UREF.&Page=Next&OS=ref/5133755&RS=REF/5133755,"8,257,593",2012
1519574864-585,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Method and apparatus for performing spine surgery,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=87&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5133755.UREF.&Page=Next&OS=ref/5133755&RS=REF/5133755,"8,287,597",2012
1519574875-586,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Composite mixer,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=86&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5133755.UREF.&Page=Next&OS=ref/5133755&RS=REF/5133755,"8,308,340",2012
1519574881-587,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,"Device and methods for sequential, regional delivery of multiple cytotoxic
     agents and directed assembly of wound repair tissues",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=85&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5133755.UREF.&Page=Next&OS=ref/5133755&RS=REF/5133755,"8,314,084",2012
1519574888-588,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Intervertebral implant,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=84&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5133755.UREF.&Page=Next&OS=ref/5133755&RS=REF/5133755,"D671,645",2012
1519574895-589,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Total disc replacement system and related methods,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=83&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5133755.UREF.&Page=Next&OS=ref/5133755&RS=REF/5133755,"8,328,851",2012
1519574906-590,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Systems and methods for spinal fusion,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=82&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5133755.UREF.&Page=Next&OS=ref/5133755&RS=REF/5133755,"8,361,156",2013
1519574912-591,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Device for regeneration of articular cartilage and other tissue,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=81&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5133755.UREF.&Page=Next&OS=ref/5133755&RS=REF/5133755,"8,403,996",2013
1519574920-592,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Light polarizer,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=80&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5133755.UREF.&Page=Next&OS=ref/5133755&RS=REF/5133755,"8,411,230",2013
1519574924-593,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Stackable spinal support system,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=79&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5133755.UREF.&Page=Next&OS=ref/5133755&RS=REF/5133755,"8,460,384",2013
1519574928-594,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Fenestrated wound repair scaffold,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=78&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5133755.UREF.&Page=Next&OS=ref/5133755&RS=REF/5133755,"8,460,691",2013
1519574931-595,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,"Systems and methods of microfluidic membraneless exchange using filtration
     of extraction outlet streams",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=77&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5133755.UREF.&Page=Next&OS=ref/5133755&RS=REF/5133755,"8,470,180",2013
1519574935-596,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Stackable spinal support system,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=76&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5133755.UREF.&Page=Next&OS=ref/5133755&RS=REF/5133755,"8,475,496",2013
1519574942-597,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Systems and methods for membraneless dialysis,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=75&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5133755.UREF.&Page=Next&OS=ref/5133755&RS=REF/5133755,"8,491,516",2013
1519574952-598,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,"Fluid separation devices, systems and methods",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=74&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5133755.UREF.&Page=Next&OS=ref/5133755&RS=REF/5133755,"8,496,606",2013
1519574959-599,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Implantable putty material,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=73&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5133755.UREF.&Page=Next&OS=ref/5133755&RS=REF/5133755,"8,497,236",2013
1519574963-600,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Systems and methods for spinal fusion,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=72&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5133755.UREF.&Page=Next&OS=ref/5133755&RS=REF/5133755,"8,574,301",2013
1519574968-601,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Systems and methods for spinal fusion,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=71&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5133755.UREF.&Page=Next&OS=ref/5133755&RS=REF/5133755,"8,608,804",2013
1519574976-602,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Bone void fillers,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=70&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5133755.UREF.&Page=Next&OS=ref/5133755&RS=REF/5133755,"8,613,938",2013
1519574980-603,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Spinal fusion implant and related methods,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=69&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5133755.UREF.&Page=Next&OS=ref/5133755&RS=REF/5133755,"8,623,088",2014
1519574985-604,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,System and methods for spinal fusion,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=68&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5133755.UREF.&Page=Next&OS=ref/5133755&RS=REF/5133755,"8,673,005",2014
1519574992-605,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Spinal implants,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=67&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5133755.UREF.&Page=Next&OS=ref/5133755&RS=REF/5133755,"8,679,118",2014
1519574996-606,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Systems and methods for spinal fusion,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=66&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5133755.UREF.&Page=Next&OS=ref/5133755&RS=REF/5133755,"8,685,105",2014
1519575004-607,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Composition and process for bone growth and repair,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=65&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5133755.UREF.&Page=Next&OS=ref/5133755&RS=REF/5133755,"8,690,874",2014
1519575009-608,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Method for making a porous polymeric material,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=64&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5133755.UREF.&Page=Next&OS=ref/5133755&RS=REF/5133755,"8,697,108",2014
1519575015-609,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Bone growth particles and osteoinductive composition thereof,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=63&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5133755.UREF.&Page=Next&OS=ref/5133755&RS=REF/5133755,"8,742,072",2014
1519575022-610,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Fully synthetic implantable multi-phased scaffold,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=62&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5133755.UREF.&Page=Next&OS=ref/5133755&RS=REF/5133755,"8,753,391",2014
1519575027-611,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Foam-formed collagen strand,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=61&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5133755.UREF.&Page=Next&OS=ref/5133755&RS=REF/5133755,"8,790,699",2014
1519575038-612,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Resorbable polymeric device for localized drug delivery,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=60&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5133755.UREF.&Page=Next&OS=ref/5133755&RS=REF/5133755,"8,795,242",2014
1519575045-613,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Tissue scaffold,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=59&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5133755.UREF.&Page=Next&OS=ref/5133755&RS=REF/5133755,"8,796,015",2014
1519575052-614,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,"At least partially resorbable reticulated elastomeric matrix elements and
     methods of making same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=58&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5133755.UREF.&Page=Next&OS=ref/5133755&RS=REF/5133755,"8,801,801",2014
1519575056-615,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,"Multi-phased, biodegradable and osteointegrative composite scaffold for
     biological fixation of musculoskeletal soft tissue of bone",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=57&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5133755.UREF.&Page=Next&OS=ref/5133755&RS=REF/5133755,"8,802,122",2014
1519575063-616,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Systems and methods for spinal fusion,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=56&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5133755.UREF.&Page=Next&OS=ref/5133755&RS=REF/5133755,"8,814,940",2014
1519575070-617,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,"Biomimmetic nanofiber scaffold for soft tissue and soft tissue-to-bone
     repair, augmentation and replacement",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=55&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5133755.UREF.&Page=Next&OS=ref/5133755&RS=REF/5133755,"8,864,843",2014
1519575074-618,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Total disc replacement system and related methods,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=54&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5133755.UREF.&Page=Next&OS=ref/5133755&RS=REF/5133755,"8,870,960",2014
1519575078-619,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Methods and apparatus for performing spine surgery,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=53&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5133755.UREF.&Page=Next&OS=ref/5133755&RS=REF/5133755,"8,920,500",2014
1519575082-620,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Intervertebral implant,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=52&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5133755.UREF.&Page=Next&OS=ref/5133755&RS=REF/5133755,"D721,808",2015
1519575088-621,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Porous osteoimplant,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=51&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5133755.UREF.&Page=Next&OS=ref/5133755&RS=REF/5133755,"9,034,356",2015
1519575093-622,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Spinal fusion implant,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=50&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,,"D731,063",2015
1519575098-623,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,"At least partially resorbable reticulated elastomeric matrix elements and
     methods of making same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=49&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,,"9,050,176",2015
1519575105-624,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Methods for collagen processing and products using processed collagen,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=48&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,,"9,056,151",2015
1519575109-625,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Stackable spinal support system,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=47&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,,"9,101,484",2015
1519575117-626,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Spinal fusion implant,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=46&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,,"D741,488",2015
1519575125-627,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Total disc replacement system and related methods,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=45&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,,"9,168,149",2015
1519575138-628,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Implants and methods for spinal fusion,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=44&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,,"9,168,152",2015
1519575146-629,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Systems and methods for spinal fusion,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=43&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,,"9,180,021",2015
1519575155-630,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,System and methods for spinal fusion,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=42&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,,"9,186,261",2015
1519575161-631,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Methods and apparatus for performing spine surgery,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=41&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,,"9,192,482",2015
1519575171-632,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Expandable spinal fusion implants and related methods,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=40&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,,"9,198,765",2015
1519575183-633,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Instrumentation kit for delivering viscous bone filler material,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=39&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,,"9,277,944",2016
1519575193-634,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Spinal fusion implant,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=38&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,,"D754,346",2016
1519575201-635,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Spinal fusion implant,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=37&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,,"9,320,614",2016
1519575205-636,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,In-situ formed intervertebral fusion device and method,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=36&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,,"9,333,091",2016
1519575209-637,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Method and apparatus for performing spine surgery,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=35&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,,"9,351,845",2016
1519575219-638,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Intervertebral implant,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=34&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,,"D759,248",2016
1519575225-639,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Vertebral body replacement,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=33&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,,"9,387,090",2016
1519575231-640,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Spinal fusion implant,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=32&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,,"9,387,091",2016
1519575236-641,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Implantable medical devices,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=31&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,,"9,399,086",2016
1519575242-642,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,"Multi-phased, biodegradable and oesteointegrative composite scaffold for
     biological fixation of musculoskeletal soft tissue to bone",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=30&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,,"9,427,495",2016
1519575246-643,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,In-situ formed intervertebral fusion device and method,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=29&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,,"9,439,776",2016
1519575250-644,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,In-situ formed intervertebral fusion device and method,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=28&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,,"9,439,777",2016
1519575256-645,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Tissue scaffold,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=27&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,,"9,440,007",2016
1519575262-646,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Systems and methods for spinal fusion,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=26&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,,"9,474,627",2016
1519575266-647,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Intervertebral implant,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=25&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,,"D770,045",2016
1519575269-648,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,System and methods for spinal fusion,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=24&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,,"9,486,329",2016
1519575272-649,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Non-soft tissue repair,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=23&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,,"9,526,539",2016
1519575276-650,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Total disc replacement system and related methods,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=22&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,,"9,610,171",2017
1519575284-651,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Vertebral body replacement,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=21&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,,"9,636,233",2017
1519575297-652,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Tissue scaffold,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=20&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,,"9,642,943",2017
1519575305-653,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Expandable spinal fusion implants and related methods,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=19&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,,"9,655,744",2017
1519575310-654,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Intervertebral implant,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=18&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,,"D788,308",2017
1519575314-655,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Vertebral body replacement,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=17&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,,"9,687,357",2017
1519575321-656,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Intervertebral implant,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=16&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,,"D791,949",2017
1519575325-657,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Spinal fusion implant,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=15&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,,"9,713,538",2017
1519575334-658,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,In-situ formed intervertebral fusion device and method,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=14&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,,"9,724,207",2017
1519575346-659,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Method of in-situ formation of an intervertebral fusion device,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=13&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,,"9,730,803",2017
1519575354-660,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Spinal fusion implant,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=12&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,,"9,737,413",2017
1519575359-661,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Systems and methods for spinal fusion,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=11&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,,"9,744,053",2017
1519575363-662,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Biphasic implant device providing gradient,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=10&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,,"9,744,123",2017
1519575367-663,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Methods and apparatus for performing spine surgery,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=9&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,,"9,757,246",2017
1519575371-664,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Spinal fusion implant,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=8&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,,"D797,934",2017
1519575374-665,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Foam-formed collagen strand,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=7&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,,"9,771,410",2017
1519575380-666,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,In-situ formed intervertebral fusion device and method,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=6&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,,"9,788,963",2017
1519575384-667,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,Aspirating implants and method of bony regeneration,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=5&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,,"9,801,725",2017
1519575392-668,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,In-situ formed intervertebral fusion device and method,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=4&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,,"9,801,729",2017
1519575398-669,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,In-situ formed intervertebral fusion device and method,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=3&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,,"9,808,351",2017
1519575404-670,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,In-situ formed intervertebral fusion device and method,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=2&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,,"9,814,589",2017
1519575413-671,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Method and apparatus for diodegradable, osteogenic, bone graft
     substitute device",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=609&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Device and method for treating mammalian bone deficiencies, defects, voids
     and conformational discontinuities produced by congenital deformities,
     osseous and/or soft tissue pathology, traumatic injuries and functional
     atrophy is described. The device is a one piece molded body member
     composed of four substances, each of which contributes to the device, a
     specific requirement (or requirements) for osteogenesis and/or
     osteoneogenesis. Taken as a whole, the functions of these device
     constituents are integrated into a single body member which, when
     implanted into a bone defect, has the capacity to restore functional
     architecture and mechanical integrity, initiate osteoinduction and
     osteogenesis, and maintain the biological processes of bone formation and
     remodeling while the host organism is simultaneously biodegrading the body
     member. The ultimate result of the functioning is formation of healthy,
     viable bone tissue where there was not bone before, while, simultaneously,
     the entire device is hydrolyzed and completely metabolized by the host
     organism. The device comprises four disparate elements: polylactic acid,
     hyaluronic acid bone morphogenetic protein and bone derived growth factor.
     Working together, these elements provide the following five biological
     functions prerequisite to the processes of osteoneogenesis: structural
     competence (polylactic acid), chemotaxis (hyaluronic acid),
     electronegative field (hyaluronic acid and physical-chemical
     electrokinetic events), osteoinduction (bone morphogenetic protein), and
     osteogenesis (bone derived growth factor).","5,133,755","THM Biomedical, Inc.
 (Duluth, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5133755,In-situ formed intervertebral fusion device and method,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=1&f=G&l=50&d=PALL&S1=5133755.UREF.&OS=ref/5133755&RS=REF/5133755,,,"9,814,590",2017
1519575425-672,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,High yield recycle process for lactide,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=608&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Processes are described for recovering lactic acid from impure lactide and
     the residue produced in the depolymerization of polylactic acid to
     lactide. Lactic acid is recovered from the impure lactide by a dual
     solvent extraction process and, from the polylactic acid residue by
     hydrolysis. The lactic acid recovered from the impure lactide and the
     depolymerization residue is recycled to provide for a high yield lactide
     process.","5,136,057","E. I. Du Pont de Nemours and Company
 (Wilmington, 
DE)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5136057,Rapidly degradable poly (hydroxyacid) compositions,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=20&f=G&l=50&d=PALL&S1=5136057.UREF.&OS=ref/5136057&RS=REF/5136057,,,"5,278,256",1994
1519575428-673,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,High yield recycle process for lactide,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=608&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Processes are described for recovering lactic acid from impure lactide and
     the residue produced in the depolymerization of polylactic acid to
     lactide. Lactic acid is recovered from the impure lactide by a dual
     solvent extraction process and, from the polylactic acid residue by
     hydrolysis. The lactic acid recovered from the impure lactide and the
     depolymerization residue is recycled to provide for a high yield lactide
     process.","5,136,057","E. I. Du Pont de Nemours and Company
 (Wilmington, 
DE)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5136057,"Melt-stable lactide polymer composition and process for manufacture
     thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=19&f=G&l=50&d=PALL&S1=5136057.UREF.&OS=ref/5136057&RS=REF/5136057,,,"5,338,822",1994
1519575438-674,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,High yield recycle process for lactide,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=608&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Processes are described for recovering lactic acid from impure lactide and
     the residue produced in the depolymerization of polylactic acid to
     lactide. Lactic acid is recovered from the impure lactide by a dual
     solvent extraction process and, from the polylactic acid residue by
     hydrolysis. The lactic acid recovered from the impure lactide and the
     depolymerization residue is recycled to provide for a high yield lactide
     process.","5,136,057","E. I. Du Pont de Nemours and Company
 (Wilmington, 
DE)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5136057,"Continuous process for manufacture of lactide polymers with purification
     by distillation",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=18&f=G&l=50&d=PALL&S1=5136057.UREF.&OS=ref/5136057&RS=REF/5136057,,,"5,357,035",1994
1519575443-675,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,High yield recycle process for lactide,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=608&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Processes are described for recovering lactic acid from impure lactide and
     the residue produced in the depolymerization of polylactic acid to
     lactide. Lactic acid is recovered from the impure lactide by a dual
     solvent extraction process and, from the polylactic acid residue by
     hydrolysis. The lactic acid recovered from the impure lactide and the
     depolymerization residue is recycled to provide for a high yield lactide
     process.","5,136,057","E. I. Du Pont de Nemours and Company
 (Wilmington, 
DE)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5136057,Integrated process for the manufacture of lactide,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=17&f=G&l=50&d=PALL&S1=5136057.UREF.&OS=ref/5136057&RS=REF/5136057,,,"5,521,278",1996
1519575450-676,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,High yield recycle process for lactide,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=608&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Processes are described for recovering lactic acid from impure lactide and
     the residue produced in the depolymerization of polylactic acid to
     lactide. Lactic acid is recovered from the impure lactide by a dual
     solvent extraction process and, from the polylactic acid residue by
     hydrolysis. The lactic acid recovered from the impure lactide and the
     depolymerization residue is recycled to provide for a high yield lactide
     process.","5,136,057","E. I. Du Pont de Nemours and Company
 (Wilmington, 
DE)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5136057,"Melt-stable lactide polymer nonwoven fabric and process for manufacture
     thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=16&f=G&l=50&d=PALL&S1=5136057.UREF.&OS=ref/5136057&RS=REF/5136057,,,"5,525,706",1996
1519575456-677,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,High yield recycle process for lactide,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=608&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Processes are described for recovering lactic acid from impure lactide and
     the residue produced in the depolymerization of polylactic acid to
     lactide. Lactic acid is recovered from the impure lactide by a dual
     solvent extraction process and, from the polylactic acid residue by
     hydrolysis. The lactic acid recovered from the impure lactide and the
     depolymerization residue is recycled to provide for a high yield lactide
     process.","5,136,057","E. I. Du Pont de Nemours and Company
 (Wilmington, 
DE)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5136057,Purifying cyclic esters by aqueous solvent extraction,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=15&f=G&l=50&d=PALL&S1=5136057.UREF.&OS=ref/5136057&RS=REF/5136057,,,"5,686,630",1997
1519575462-678,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,High yield recycle process for lactide,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=608&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Processes are described for recovering lactic acid from impure lactide and
     the residue produced in the depolymerization of polylactic acid to
     lactide. Lactic acid is recovered from the impure lactide by a dual
     solvent extraction process and, from the polylactic acid residue by
     hydrolysis. The lactic acid recovered from the impure lactide and the
     depolymerization residue is recycled to provide for a high yield lactide
     process.","5,136,057","E. I. Du Pont de Nemours and Company
 (Wilmington, 
DE)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5136057,"Melt-stable lactide polymer nonwoven fabric and process for manufacture
     thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=14&f=G&l=50&d=PALL&S1=5136057.UREF.&OS=ref/5136057&RS=REF/5136057,,,"5,807,973",1998
1519575468-679,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,High yield recycle process for lactide,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=608&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Processes are described for recovering lactic acid from impure lactide and
     the residue produced in the depolymerization of polylactic acid to
     lactide. Lactic acid is recovered from the impure lactide by a dual
     solvent extraction process and, from the polylactic acid residue by
     hydrolysis. The lactic acid recovered from the impure lactide and the
     depolymerization residue is recycled to provide for a high yield lactide
     process.","5,136,057","E. I. Du Pont de Nemours and Company
 (Wilmington, 
DE)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5136057,"Purifying cyclic esters by aqueous solvent extraction and further
     purification",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=13&f=G&l=50&d=PALL&S1=5136057.UREF.&OS=ref/5136057&RS=REF/5136057,,,"5,856,523",1999
1519575476-680,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,High yield recycle process for lactide,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=608&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Processes are described for recovering lactic acid from impure lactide and
     the residue produced in the depolymerization of polylactic acid to
     lactide. Lactic acid is recovered from the impure lactide by a dual
     solvent extraction process and, from the polylactic acid residue by
     hydrolysis. The lactic acid recovered from the impure lactide and the
     depolymerization residue is recycled to provide for a high yield lactide
     process.","5,136,057","E. I. Du Pont de Nemours and Company
 (Wilmington, 
DE)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5136057,Process for the recovery of lactic acid,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=12&f=G&l=50&d=PALL&S1=5136057.UREF.&OS=ref/5136057&RS=REF/5136057,,,"5,959,144",1999
1519575483-681,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,High yield recycle process for lactide,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=608&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Processes are described for recovering lactic acid from impure lactide and
     the residue produced in the depolymerization of polylactic acid to
     lactide. Lactic acid is recovered from the impure lactide by a dual
     solvent extraction process and, from the polylactic acid residue by
     hydrolysis. The lactic acid recovered from the impure lactide and the
     depolymerization residue is recycled to provide for a high yield lactide
     process.","5,136,057","E. I. Du Pont de Nemours and Company
 (Wilmington, 
DE)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5136057,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=11&f=G&l=50&d=PALL&S1=5136057.UREF.&OS=ref/5136057&RS=REF/5136057,,,"6,005,067",1999
1519575490-682,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,High yield recycle process for lactide,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=608&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Processes are described for recovering lactic acid from impure lactide and
     the residue produced in the depolymerization of polylactic acid to
     lactide. Lactic acid is recovered from the impure lactide by a dual
     solvent extraction process and, from the polylactic acid residue by
     hydrolysis. The lactic acid recovered from the impure lactide and the
     depolymerization residue is recycled to provide for a high yield lactide
     process.","5,136,057","E. I. Du Pont de Nemours and Company
 (Wilmington, 
DE)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5136057,"Melt-stable lactide polymer nonwoven fabric and process for manufacture
     thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=10&f=G&l=50&d=PALL&S1=5136057.UREF.&OS=ref/5136057&RS=REF/5136057,,,"6,111,060",2000
1519575496-683,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,High yield recycle process for lactide,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=608&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Processes are described for recovering lactic acid from impure lactide and
     the residue produced in the depolymerization of polylactic acid to
     lactide. Lactic acid is recovered from the impure lactide by a dual
     solvent extraction process and, from the polylactic acid residue by
     hydrolysis. The lactic acid recovered from the impure lactide and the
     depolymerization residue is recycled to provide for a high yield lactide
     process.","5,136,057","E. I. Du Pont de Nemours and Company
 (Wilmington, 
DE)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5136057,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=9&f=G&l=50&d=PALL&S1=5136057.UREF.&OS=ref/5136057&RS=REF/5136057,,,"6,277,951",2001
1519575500-684,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,High yield recycle process for lactide,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=608&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Processes are described for recovering lactic acid from impure lactide and
     the residue produced in the depolymerization of polylactic acid to
     lactide. Lactic acid is recovered from the impure lactide by a dual
     solvent extraction process and, from the polylactic acid residue by
     hydrolysis. The lactic acid recovered from the impure lactide and the
     depolymerization residue is recycled to provide for a high yield lactide
     process.","5,136,057","E. I. Du Pont de Nemours and Company
 (Wilmington, 
DE)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5136057,"Melt-stable lactide polymer nonwoven fabric and process for manufacture
     thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=8&f=G&l=50&d=PALL&S1=5136057.UREF.&OS=ref/5136057&RS=REF/5136057,,,"6,355,772",2002
1519575505-685,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,High yield recycle process for lactide,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=608&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Processes are described for recovering lactic acid from impure lactide and
     the residue produced in the depolymerization of polylactic acid to
     lactide. Lactic acid is recovered from the impure lactide by a dual
     solvent extraction process and, from the polylactic acid residue by
     hydrolysis. The lactic acid recovered from the impure lactide and the
     depolymerization residue is recycled to provide for a high yield lactide
     process.","5,136,057","E. I. Du Pont de Nemours and Company
 (Wilmington, 
DE)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5136057,Continuous process for preparing lactic acid,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=7&f=G&l=50&d=PALL&S1=5136057.UREF.&OS=ref/5136057&RS=REF/5136057,,,"6,509,179",2003
1519575509-686,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,High yield recycle process for lactide,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=608&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Processes are described for recovering lactic acid from impure lactide and
     the residue produced in the depolymerization of polylactic acid to
     lactide. Lactic acid is recovered from the impure lactide by a dual
     solvent extraction process and, from the polylactic acid residue by
     hydrolysis. The lactic acid recovered from the impure lactide and the
     depolymerization residue is recycled to provide for a high yield lactide
     process.","5,136,057","E. I. Du Pont de Nemours and Company
 (Wilmington, 
DE)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5136057,Azeotropic distillation of cyclic esters of hydroxy organic acids,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=6&f=G&l=50&d=PALL&S1=5136057.UREF.&OS=ref/5136057&RS=REF/5136057,,,"6,984,293",2006
1519575516-687,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,High yield recycle process for lactide,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=608&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Processes are described for recovering lactic acid from impure lactide and
     the residue produced in the depolymerization of polylactic acid to
     lactide. Lactic acid is recovered from the impure lactide by a dual
     solvent extraction process and, from the polylactic acid residue by
     hydrolysis. The lactic acid recovered from the impure lactide and the
     depolymerization residue is recycled to provide for a high yield lactide
     process.","5,136,057","E. I. Du Pont de Nemours and Company
 (Wilmington, 
DE)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5136057,Polymeric materials from renewable resources,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=5&f=G&l=50&d=PALL&S1=5136057.UREF.&OS=ref/5136057&RS=REF/5136057,,,"7,723,461",2010
1519575523-688,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,High yield recycle process for lactide,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=608&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Processes are described for recovering lactic acid from impure lactide and
     the residue produced in the depolymerization of polylactic acid to
     lactide. Lactic acid is recovered from the impure lactide by a dual
     solvent extraction process and, from the polylactic acid residue by
     hydrolysis. The lactic acid recovered from the impure lactide and the
     depolymerization residue is recycled to provide for a high yield lactide
     process.","5,136,057","E. I. Du Pont de Nemours and Company
 (Wilmington, 
DE)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5136057,Chemical recycling of PLA by hydrolysis,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=4&f=G&l=50&d=PALL&S1=5136057.UREF.&OS=ref/5136057&RS=REF/5136057,,,"8,431,683",2013
1519575527-689,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,High yield recycle process for lactide,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=608&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Processes are described for recovering lactic acid from impure lactide and
     the residue produced in the depolymerization of polylactic acid to
     lactide. Lactic acid is recovered from the impure lactide by a dual
     solvent extraction process and, from the polylactic acid residue by
     hydrolysis. The lactic acid recovered from the impure lactide and the
     depolymerization residue is recycled to provide for a high yield lactide
     process.","5,136,057","E. I. Du Pont de Nemours and Company
 (Wilmington, 
DE)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5136057,Method for stereospecifically recycling a PLA polymer mixture,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=3&f=G&l=50&d=PALL&S1=5136057.UREF.&OS=ref/5136057&RS=REF/5136057,,,"8,614,338",2013
1519575531-690,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,High yield recycle process for lactide,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=608&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Processes are described for recovering lactic acid from impure lactide and
     the residue produced in the depolymerization of polylactic acid to
     lactide. Lactic acid is recovered from the impure lactide by a dual
     solvent extraction process and, from the polylactic acid residue by
     hydrolysis. The lactic acid recovered from the impure lactide and the
     depolymerization residue is recycled to provide for a high yield lactide
     process.","5,136,057","E. I. Du Pont de Nemours and Company
 (Wilmington, 
DE)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5136057,"Process for the preparation of L-lactide of high chemical yield and
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=2&f=G&l=50&d=PALL&S1=5136057.UREF.&OS=ref/5136057&RS=REF/5136057,,,"8,895,760",2014
1519575534-691,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,High yield recycle process for lactide,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=608&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"Processes are described for recovering lactic acid from impure lactide and
     the residue produced in the depolymerization of polylactic acid to
     lactide. Lactic acid is recovered from the impure lactide by a dual
     solvent extraction process and, from the polylactic acid residue by
     hydrolysis. The lactic acid recovered from the impure lactide and the
     depolymerization residue is recycled to provide for a high yield lactide
     process.","5,136,057","E. I. Du Pont de Nemours and Company
 (Wilmington, 
DE)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5136057,Quality test for polymerizable lactic acid and method for producing same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=1&f=G&l=50&d=PALL&S1=5136057.UREF.&OS=ref/5136057&RS=REF/5136057,,,"9,416,222",2016
1519575547-692,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=607&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,142,023","Cargill, Incorporated
 (Minnetonka, 
MN)",,http://pdfpiw.uspto.gov/.piw?Docid=05142023&homeurl=http%3A%2F%2Fpatft.uspto.gov%2Fnetacgi%2Fnph-Parser%3FSect1%3DPTO2%2526Sect2%3DHITOFF%2526u%3D%25252Fnetahtml%25252FPTO%25252Fsearch-adv.htm%2526r%3D607%2526f%3DG%2526l%3D50%2526d%3DPTXT%2526s1%3D%252522polylactic%252Bacid%252522.ABTX.%2526p%3D13%2526OS%3DABST%2F%252522polylactic%252Bacid%252522%2526RS%3DABST%2F%252522polylactic%252Bacid%252522&PageNum=&Rtype=&SectionNum=&idkey=NONE&Input=View+first+page,,,null,,,
1519575570-693,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Resorbable urethral stent and apparatus for its insertion,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=606&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1992,"A resorbable stent, particularly adapted for implantation in the penile
     urethra, comprises a helical coil formed from a filament of a
     biocompatible, biodegradable material that is resiliently deformable. The
     stent is compressible from a first diameter to a smaller second diameter,
     and restores itself substantially to its first diameter by its own
     resiliency when the compressing force is removed. Polymers of polylactic
     acid and polyglycolic acid are preferred materials. A device for inserting
     the stent has a first embodiment that includes a retractable sheath
     surrounding a rotatable rod journaled in a stationary bushing. The stent
     is mounted on the rod and the bushing so that relative rotation of the rod
     and bushing compresses the stent by coiling it more tightly. The sheath is
     inserted into the urethra with the stent compressed inside of it, and the
     retracted. The rod and bushing are then relatively rotated so as to uncoil
     the stent, which is restored to its first diameter. A shearing sleeve is
     actuated to detach the stent from the rod and the bushing. A second
     embodiment includes a plunger on which the stent is detachably mounted.
     The plunger is inserted through the sheath, thereby compressing the stent.
     When the stent is discharged through the distal end of the sheath into the
     urethra, the stent resiliently restores itself to its first diameter.","5,160,341","Advanced Surgical Intervention, Inc.
 (San Clemente, 
CA)",,http://pdfpiw.uspto.gov/.piw?Docid=05160341&homeurl=http%3A%2F%2Fpatft.uspto.gov%2Fnetacgi%2Fnph-Parser%3FSect1%3DPTO2%2526Sect2%3DHITOFF%2526u%3D%25252Fnetahtml%25252FPTO%25252Fsearch-adv.htm%2526r%3D606%2526f%3DG%2526l%3D50%2526d%3DPTXT%2526s1%3D%252522polylactic%252Bacid%252522.ABTX.%2526p%3D13%2526OS%3DABST%2F%252522polylactic%252Bacid%252522%2526RS%3DABST%2F%252522polylactic%252Bacid%252522&PageNum=&Rtype=&SectionNum=&idkey=NONE&Input=View+first+page,,,null,,,
1519575601-694,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,High polymer network,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=605&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A degradable polymer network obtained by adding from 0.2 to 10 parts by
     weight of a foaming agent to 100 parts by weight of a polylactic acid-base
     resin composition comprising from 80 to 100% by weight of polylactic acid
     or a lactic acid-hydroxycarboxylic acid copolymer and from 0 to 20% by
     weight of a plasticizer, conducting melt-foaming extrusion of resulting
     mixture, and opening the foam cells in the extrudate. The high polymer
     network is characterized in suitable flexibility and hydrolyzability and
     thus useful as a material for absorbing oils and body fluids, screens for
     sunlight, heat-insulating materials, filter media and packaging materials;
     and does not accumulate as industrial wastes because of hydrolyzability in
     the natural environment, even though abandoned after use.","5,223,546","Mitsui Toatsu Chemicals, Inc.
 (Tokyo, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5223546,Porous film,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=29&f=G&l=50&d=PALL&S1=5223546.UREF.&OS=ref/5223546&RS=REF/5223546,,,"5,405,887",1995
1519575609-695,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,High polymer network,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=605&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A degradable polymer network obtained by adding from 0.2 to 10 parts by
     weight of a foaming agent to 100 parts by weight of a polylactic acid-base
     resin composition comprising from 80 to 100% by weight of polylactic acid
     or a lactic acid-hydroxycarboxylic acid copolymer and from 0 to 20% by
     weight of a plasticizer, conducting melt-foaming extrusion of resulting
     mixture, and opening the foam cells in the extrudate. The high polymer
     network is characterized in suitable flexibility and hydrolyzability and
     thus useful as a material for absorbing oils and body fluids, screens for
     sunlight, heat-insulating materials, filter media and packaging materials;
     and does not accumulate as industrial wastes because of hydrolyzability in
     the natural environment, even though abandoned after use.","5,223,546","Mitsui Toatsu Chemicals, Inc.
 (Tokyo, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5223546,Recyclable thermoplastic foam with a high glass transition temperature II,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=28&f=G&l=50&d=PALL&S1=5223546.UREF.&OS=ref/5223546&RS=REF/5223546,,,"5,407,966",1995
1519575615-696,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,High polymer network,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=605&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A degradable polymer network obtained by adding from 0.2 to 10 parts by
     weight of a foaming agent to 100 parts by weight of a polylactic acid-base
     resin composition comprising from 80 to 100% by weight of polylactic acid
     or a lactic acid-hydroxycarboxylic acid copolymer and from 0 to 20% by
     weight of a plasticizer, conducting melt-foaming extrusion of resulting
     mixture, and opening the foam cells in the extrudate. The high polymer
     network is characterized in suitable flexibility and hydrolyzability and
     thus useful as a material for absorbing oils and body fluids, screens for
     sunlight, heat-insulating materials, filter media and packaging materials;
     and does not accumulate as industrial wastes because of hydrolyzability in
     the natural environment, even though abandoned after use.","5,223,546","Mitsui Toatsu Chemicals, Inc.
 (Tokyo, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5223546,Degradable foam and use of same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=27&f=G&l=50&d=PALL&S1=5223546.UREF.&OS=ref/5223546&RS=REF/5223546,,,"5,447,962",1995
1519575619-697,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,High polymer network,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=605&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A degradable polymer network obtained by adding from 0.2 to 10 parts by
     weight of a foaming agent to 100 parts by weight of a polylactic acid-base
     resin composition comprising from 80 to 100% by weight of polylactic acid
     or a lactic acid-hydroxycarboxylic acid copolymer and from 0 to 20% by
     weight of a plasticizer, conducting melt-foaming extrusion of resulting
     mixture, and opening the foam cells in the extrudate. The high polymer
     network is characterized in suitable flexibility and hydrolyzability and
     thus useful as a material for absorbing oils and body fluids, screens for
     sunlight, heat-insulating materials, filter media and packaging materials;
     and does not accumulate as industrial wastes because of hydrolyzability in
     the natural environment, even though abandoned after use.","5,223,546","Mitsui Toatsu Chemicals, Inc.
 (Tokyo, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5223546,"Melt-stable amorphous lactide polymer film and process for manufacturing
     thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=26&f=G&l=50&d=PALL&S1=5223546.UREF.&OS=ref/5223546&RS=REF/5223546,,,"5,484,881",1996
1519575629-698,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,High polymer network,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=605&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A degradable polymer network obtained by adding from 0.2 to 10 parts by
     weight of a foaming agent to 100 parts by weight of a polylactic acid-base
     resin composition comprising from 80 to 100% by weight of polylactic acid
     or a lactic acid-hydroxycarboxylic acid copolymer and from 0 to 20% by
     weight of a plasticizer, conducting melt-foaming extrusion of resulting
     mixture, and opening the foam cells in the extrudate. The high polymer
     network is characterized in suitable flexibility and hydrolyzability and
     thus useful as a material for absorbing oils and body fluids, screens for
     sunlight, heat-insulating materials, filter media and packaging materials;
     and does not accumulate as industrial wastes because of hydrolyzability in
     the natural environment, even though abandoned after use.","5,223,546","Mitsui Toatsu Chemicals, Inc.
 (Tokyo, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5223546,"Melt-stable semi-crystalline lactide polymer film and process for
     manufacture thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=25&f=G&l=50&d=PALL&S1=5223546.UREF.&OS=ref/5223546&RS=REF/5223546,,,"5,536,807",1996
1519575638-699,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,High polymer network,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=605&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A degradable polymer network obtained by adding from 0.2 to 10 parts by
     weight of a foaming agent to 100 parts by weight of a polylactic acid-base
     resin composition comprising from 80 to 100% by weight of polylactic acid
     or a lactic acid-hydroxycarboxylic acid copolymer and from 0 to 20% by
     weight of a plasticizer, conducting melt-foaming extrusion of resulting
     mixture, and opening the foam cells in the extrudate. The high polymer
     network is characterized in suitable flexibility and hydrolyzability and
     thus useful as a material for absorbing oils and body fluids, screens for
     sunlight, heat-insulating materials, filter media and packaging materials;
     and does not accumulate as industrial wastes because of hydrolyzability in
     the natural environment, even though abandoned after use.","5,223,546","Mitsui Toatsu Chemicals, Inc.
 (Tokyo, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5223546,Method for packaging foodstuffs,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=24&f=G&l=50&d=PALL&S1=5223546.UREF.&OS=ref/5223546&RS=REF/5223546,,,"5,639,466",1997
1519575646-700,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,High polymer network,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=605&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A degradable polymer network obtained by adding from 0.2 to 10 parts by
     weight of a foaming agent to 100 parts by weight of a polylactic acid-base
     resin composition comprising from 80 to 100% by weight of polylactic acid
     or a lactic acid-hydroxycarboxylic acid copolymer and from 0 to 20% by
     weight of a plasticizer, conducting melt-foaming extrusion of resulting
     mixture, and opening the foam cells in the extrudate. The high polymer
     network is characterized in suitable flexibility and hydrolyzability and
     thus useful as a material for absorbing oils and body fluids, screens for
     sunlight, heat-insulating materials, filter media and packaging materials;
     and does not accumulate as industrial wastes because of hydrolyzability in
     the natural environment, even though abandoned after use.","5,223,546","Mitsui Toatsu Chemicals, Inc.
 (Tokyo, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5223546,Process for preparing rigid polyurethane foams,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=23&f=G&l=50&d=PALL&S1=5223546.UREF.&OS=ref/5223546&RS=REF/5223546,,,"5,736,588",1998
1519575652-701,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,High polymer network,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=605&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A degradable polymer network obtained by adding from 0.2 to 10 parts by
     weight of a foaming agent to 100 parts by weight of a polylactic acid-base
     resin composition comprising from 80 to 100% by weight of polylactic acid
     or a lactic acid-hydroxycarboxylic acid copolymer and from 0 to 20% by
     weight of a plasticizer, conducting melt-foaming extrusion of resulting
     mixture, and opening the foam cells in the extrudate. The high polymer
     network is characterized in suitable flexibility and hydrolyzability and
     thus useful as a material for absorbing oils and body fluids, screens for
     sunlight, heat-insulating materials, filter media and packaging materials;
     and does not accumulate as industrial wastes because of hydrolyzability in
     the natural environment, even though abandoned after use.","5,223,546","Mitsui Toatsu Chemicals, Inc.
 (Tokyo, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5223546,"Melt-stable amorphous lactide polymer film and process for manufacture
     thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=22&f=G&l=50&d=PALL&S1=5223546.UREF.&OS=ref/5223546&RS=REF/5223546,,,"5,798,436",1998
1519575658-702,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,High polymer network,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=605&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A degradable polymer network obtained by adding from 0.2 to 10 parts by
     weight of a foaming agent to 100 parts by weight of a polylactic acid-base
     resin composition comprising from 80 to 100% by weight of polylactic acid
     or a lactic acid-hydroxycarboxylic acid copolymer and from 0 to 20% by
     weight of a plasticizer, conducting melt-foaming extrusion of resulting
     mixture, and opening the foam cells in the extrudate. The high polymer
     network is characterized in suitable flexibility and hydrolyzability and
     thus useful as a material for absorbing oils and body fluids, screens for
     sunlight, heat-insulating materials, filter media and packaging materials;
     and does not accumulate as industrial wastes because of hydrolyzability in
     the natural environment, even though abandoned after use.","5,223,546","Mitsui Toatsu Chemicals, Inc.
 (Tokyo, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5223546,Multicomponent fiber,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=21&f=G&l=50&d=PALL&S1=5223546.UREF.&OS=ref/5223546&RS=REF/5223546,,,"5,952,088",1999
1519575662-703,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,High polymer network,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=605&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A degradable polymer network obtained by adding from 0.2 to 10 parts by
     weight of a foaming agent to 100 parts by weight of a polylactic acid-base
     resin composition comprising from 80 to 100% by weight of polylactic acid
     or a lactic acid-hydroxycarboxylic acid copolymer and from 0 to 20% by
     weight of a plasticizer, conducting melt-foaming extrusion of resulting
     mixture, and opening the foam cells in the extrudate. The high polymer
     network is characterized in suitable flexibility and hydrolyzability and
     thus useful as a material for absorbing oils and body fluids, screens for
     sunlight, heat-insulating materials, filter media and packaging materials;
     and does not accumulate as industrial wastes because of hydrolyzability in
     the natural environment, even though abandoned after use.","5,223,546","Mitsui Toatsu Chemicals, Inc.
 (Tokyo, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5223546,"Melt-stable amorphous lactide polymer film and process for manufacture
     thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=20&f=G&l=50&d=PALL&S1=5223546.UREF.&OS=ref/5223546&RS=REF/5223546,,,"6,005,068",1999
1519575665-704,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,High polymer network,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=605&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A degradable polymer network obtained by adding from 0.2 to 10 parts by
     weight of a foaming agent to 100 parts by weight of a polylactic acid-base
     resin composition comprising from 80 to 100% by weight of polylactic acid
     or a lactic acid-hydroxycarboxylic acid copolymer and from 0 to 20% by
     weight of a plasticizer, conducting melt-foaming extrusion of resulting
     mixture, and opening the foam cells in the extrudate. The high polymer
     network is characterized in suitable flexibility and hydrolyzability and
     thus useful as a material for absorbing oils and body fluids, screens for
     sunlight, heat-insulating materials, filter media and packaging materials;
     and does not accumulate as industrial wastes because of hydrolyzability in
     the natural environment, even though abandoned after use.","5,223,546","Mitsui Toatsu Chemicals, Inc.
 (Tokyo, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5223546,Investment casting composition and method for making the same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=19&f=G&l=50&d=PALL&S1=5223546.UREF.&OS=ref/5223546&RS=REF/5223546,,,"6,051,619",2000
1519575674-705,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,High polymer network,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=605&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A degradable polymer network obtained by adding from 0.2 to 10 parts by
     weight of a foaming agent to 100 parts by weight of a polylactic acid-base
     resin composition comprising from 80 to 100% by weight of polylactic acid
     or a lactic acid-hydroxycarboxylic acid copolymer and from 0 to 20% by
     weight of a plasticizer, conducting melt-foaming extrusion of resulting
     mixture, and opening the foam cells in the extrudate. The high polymer
     network is characterized in suitable flexibility and hydrolyzability and
     thus useful as a material for absorbing oils and body fluids, screens for
     sunlight, heat-insulating materials, filter media and packaging materials;
     and does not accumulate as industrial wastes because of hydrolyzability in
     the natural environment, even though abandoned after use.","5,223,546","Mitsui Toatsu Chemicals, Inc.
 (Tokyo, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5223546,Synthetic fiber,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=18&f=G&l=50&d=PALL&S1=5223546.UREF.&OS=ref/5223546&RS=REF/5223546,,,"6,135,987",2000
1519575684-706,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,High polymer network,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=605&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A degradable polymer network obtained by adding from 0.2 to 10 parts by
     weight of a foaming agent to 100 parts by weight of a polylactic acid-base
     resin composition comprising from 80 to 100% by weight of polylactic acid
     or a lactic acid-hydroxycarboxylic acid copolymer and from 0 to 20% by
     weight of a plasticizer, conducting melt-foaming extrusion of resulting
     mixture, and opening the foam cells in the extrudate. The high polymer
     network is characterized in suitable flexibility and hydrolyzability and
     thus useful as a material for absorbing oils and body fluids, screens for
     sunlight, heat-insulating materials, filter media and packaging materials;
     and does not accumulate as industrial wastes because of hydrolyzability in
     the natural environment, even though abandoned after use.","5,223,546","Mitsui Toatsu Chemicals, Inc.
 (Tokyo, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5223546,"Disposable articles having biodegradable nonwovens with improved fluid
     management properties",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=17&f=G&l=50&d=PALL&S1=5223546.UREF.&OS=ref/5223546&RS=REF/5223546,,,"6,194,483",2001
1519575696-707,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,High polymer network,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=605&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A degradable polymer network obtained by adding from 0.2 to 10 parts by
     weight of a foaming agent to 100 parts by weight of a polylactic acid-base
     resin composition comprising from 80 to 100% by weight of polylactic acid
     or a lactic acid-hydroxycarboxylic acid copolymer and from 0 to 20% by
     weight of a plasticizer, conducting melt-foaming extrusion of resulting
     mixture, and opening the foam cells in the extrudate. The high polymer
     network is characterized in suitable flexibility and hydrolyzability and
     thus useful as a material for absorbing oils and body fluids, screens for
     sunlight, heat-insulating materials, filter media and packaging materials;
     and does not accumulate as industrial wastes because of hydrolyzability in
     the natural environment, even though abandoned after use.","5,223,546","Mitsui Toatsu Chemicals, Inc.
 (Tokyo, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5223546,Fluid-jet false-twisting method and product,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=16&f=G&l=50&d=PALL&S1=5223546.UREF.&OS=ref/5223546&RS=REF/5223546,,,"6,195,975",2001
1519575702-708,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,High polymer network,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=605&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A degradable polymer network obtained by adding from 0.2 to 10 parts by
     weight of a foaming agent to 100 parts by weight of a polylactic acid-base
     resin composition comprising from 80 to 100% by weight of polylactic acid
     or a lactic acid-hydroxycarboxylic acid copolymer and from 0 to 20% by
     weight of a plasticizer, conducting melt-foaming extrusion of resulting
     mixture, and opening the foam cells in the extrudate. The high polymer
     network is characterized in suitable flexibility and hydrolyzability and
     thus useful as a material for absorbing oils and body fluids, screens for
     sunlight, heat-insulating materials, filter media and packaging materials;
     and does not accumulate as industrial wastes because of hydrolyzability in
     the natural environment, even though abandoned after use.","5,223,546","Mitsui Toatsu Chemicals, Inc.
 (Tokyo, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5223546,Biodegradable nonwovens with improved fluid management properties,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=15&f=G&l=50&d=PALL&S1=5223546.UREF.&OS=ref/5223546&RS=REF/5223546,,,"6,197,860",2001
1519575709-709,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,High polymer network,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=605&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A degradable polymer network obtained by adding from 0.2 to 10 parts by
     weight of a foaming agent to 100 parts by weight of a polylactic acid-base
     resin composition comprising from 80 to 100% by weight of polylactic acid
     or a lactic acid-hydroxycarboxylic acid copolymer and from 0 to 20% by
     weight of a plasticizer, conducting melt-foaming extrusion of resulting
     mixture, and opening the foam cells in the extrudate. The high polymer
     network is characterized in suitable flexibility and hydrolyzability and
     thus useful as a material for absorbing oils and body fluids, screens for
     sunlight, heat-insulating materials, filter media and packaging materials;
     and does not accumulate as industrial wastes because of hydrolyzability in
     the natural environment, even though abandoned after use.","5,223,546","Mitsui Toatsu Chemicals, Inc.
 (Tokyo, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5223546,"Biodegradable polylactide nonwovens with improved fluid management
     properties",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=14&f=G&l=50&d=PALL&S1=5223546.UREF.&OS=ref/5223546&RS=REF/5223546,,,"6,201,068",2001
1519575718-710,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,High polymer network,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=605&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A degradable polymer network obtained by adding from 0.2 to 10 parts by
     weight of a foaming agent to 100 parts by weight of a polylactic acid-base
     resin composition comprising from 80 to 100% by weight of polylactic acid
     or a lactic acid-hydroxycarboxylic acid copolymer and from 0 to 20% by
     weight of a plasticizer, conducting melt-foaming extrusion of resulting
     mixture, and opening the foam cells in the extrudate. The high polymer
     network is characterized in suitable flexibility and hydrolyzability and
     thus useful as a material for absorbing oils and body fluids, screens for
     sunlight, heat-insulating materials, filter media and packaging materials;
     and does not accumulate as industrial wastes because of hydrolyzability in
     the natural environment, even though abandoned after use.","5,223,546","Mitsui Toatsu Chemicals, Inc.
 (Tokyo, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5223546,"Melt-stable amorphous lactide polymer film and process for manufacture
     thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=13&f=G&l=50&d=PALL&S1=5223546.UREF.&OS=ref/5223546&RS=REF/5223546,,,"6,207,792",2001
1519575724-711,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,High polymer network,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=605&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A degradable polymer network obtained by adding from 0.2 to 10 parts by
     weight of a foaming agent to 100 parts by weight of a polylactic acid-base
     resin composition comprising from 80 to 100% by weight of polylactic acid
     or a lactic acid-hydroxycarboxylic acid copolymer and from 0 to 20% by
     weight of a plasticizer, conducting melt-foaming extrusion of resulting
     mixture, and opening the foam cells in the extrudate. The high polymer
     network is characterized in suitable flexibility and hydrolyzability and
     thus useful as a material for absorbing oils and body fluids, screens for
     sunlight, heat-insulating materials, filter media and packaging materials;
     and does not accumulate as industrial wastes because of hydrolyzability in
     the natural environment, even though abandoned after use.","5,223,546","Mitsui Toatsu Chemicals, Inc.
 (Tokyo, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5223546,"Disposable articles having biodegradable nonwovens with improved fluid
     management properties",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=12&f=G&l=50&d=PALL&S1=5223546.UREF.&OS=ref/5223546&RS=REF/5223546,,,"6,245,831",2001
1519575732-712,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,High polymer network,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=605&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A degradable polymer network obtained by adding from 0.2 to 10 parts by
     weight of a foaming agent to 100 parts by weight of a polylactic acid-base
     resin composition comprising from 80 to 100% by weight of polylactic acid
     or a lactic acid-hydroxycarboxylic acid copolymer and from 0 to 20% by
     weight of a plasticizer, conducting melt-foaming extrusion of resulting
     mixture, and opening the foam cells in the extrudate. The high polymer
     network is characterized in suitable flexibility and hydrolyzability and
     thus useful as a material for absorbing oils and body fluids, screens for
     sunlight, heat-insulating materials, filter media and packaging materials;
     and does not accumulate as industrial wastes because of hydrolyzability in
     the natural environment, even though abandoned after use.","5,223,546","Mitsui Toatsu Chemicals, Inc.
 (Tokyo, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5223546,Synthetic fiber,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=11&f=G&l=50&d=PALL&S1=5223546.UREF.&OS=ref/5223546&RS=REF/5223546,,,"6,261,677",2001
1519575738-713,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,High polymer network,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=605&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A degradable polymer network obtained by adding from 0.2 to 10 parts by
     weight of a foaming agent to 100 parts by weight of a polylactic acid-base
     resin composition comprising from 80 to 100% by weight of polylactic acid
     or a lactic acid-hydroxycarboxylic acid copolymer and from 0 to 20% by
     weight of a plasticizer, conducting melt-foaming extrusion of resulting
     mixture, and opening the foam cells in the extrudate. The high polymer
     network is characterized in suitable flexibility and hydrolyzability and
     thus useful as a material for absorbing oils and body fluids, screens for
     sunlight, heat-insulating materials, filter media and packaging materials;
     and does not accumulate as industrial wastes because of hydrolyzability in
     the natural environment, even though abandoned after use.","5,223,546","Mitsui Toatsu Chemicals, Inc.
 (Tokyo, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5223546,"Biodegradable polylactide nonwovens with improved fluid management
     properties",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=10&f=G&l=50&d=PALL&S1=5223546.UREF.&OS=ref/5223546&RS=REF/5223546,,,"6,268,434",2001
1519575743-714,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,High polymer network,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=605&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A degradable polymer network obtained by adding from 0.2 to 10 parts by
     weight of a foaming agent to 100 parts by weight of a polylactic acid-base
     resin composition comprising from 80 to 100% by weight of polylactic acid
     or a lactic acid-hydroxycarboxylic acid copolymer and from 0 to 20% by
     weight of a plasticizer, conducting melt-foaming extrusion of resulting
     mixture, and opening the foam cells in the extrudate. The high polymer
     network is characterized in suitable flexibility and hydrolyzability and
     thus useful as a material for absorbing oils and body fluids, screens for
     sunlight, heat-insulating materials, filter media and packaging materials;
     and does not accumulate as industrial wastes because of hydrolyzability in
     the natural environment, even though abandoned after use.","5,223,546","Mitsui Toatsu Chemicals, Inc.
 (Tokyo, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5223546,"Disposable absorbent product having biodisintegratable nonwovens with
     improved fluid management properties",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=9&f=G&l=50&d=PALL&S1=5223546.UREF.&OS=ref/5223546&RS=REF/5223546,,,"6,306,782",2001
1519575747-715,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,High polymer network,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=605&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A degradable polymer network obtained by adding from 0.2 to 10 parts by
     weight of a foaming agent to 100 parts by weight of a polylactic acid-base
     resin composition comprising from 80 to 100% by weight of polylactic acid
     or a lactic acid-hydroxycarboxylic acid copolymer and from 0 to 20% by
     weight of a plasticizer, conducting melt-foaming extrusion of resulting
     mixture, and opening the foam cells in the extrudate. The high polymer
     network is characterized in suitable flexibility and hydrolyzability and
     thus useful as a material for absorbing oils and body fluids, screens for
     sunlight, heat-insulating materials, filter media and packaging materials;
     and does not accumulate as industrial wastes because of hydrolyzability in
     the natural environment, even though abandoned after use.","5,223,546","Mitsui Toatsu Chemicals, Inc.
 (Tokyo, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5223546,Biodisintegratable nonwovens with improved fluid management properties,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=8&f=G&l=50&d=PALL&S1=5223546.UREF.&OS=ref/5223546&RS=REF/5223546,,,"6,309,988",2001
1519575751-716,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,High polymer network,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=605&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A degradable polymer network obtained by adding from 0.2 to 10 parts by
     weight of a foaming agent to 100 parts by weight of a polylactic acid-base
     resin composition comprising from 80 to 100% by weight of polylactic acid
     or a lactic acid-hydroxycarboxylic acid copolymer and from 0 to 20% by
     weight of a plasticizer, conducting melt-foaming extrusion of resulting
     mixture, and opening the foam cells in the extrudate. The high polymer
     network is characterized in suitable flexibility and hydrolyzability and
     thus useful as a material for absorbing oils and body fluids, screens for
     sunlight, heat-insulating materials, filter media and packaging materials;
     and does not accumulate as industrial wastes because of hydrolyzability in
     the natural environment, even though abandoned after use.","5,223,546","Mitsui Toatsu Chemicals, Inc.
 (Tokyo, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5223546,Degradation control of environmentally degradable disposable materials,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=7&f=G&l=50&d=PALL&S1=5223546.UREF.&OS=ref/5223546&RS=REF/5223546,,,"6,323,307",2001
1519575754-717,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,High polymer network,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=605&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A degradable polymer network obtained by adding from 0.2 to 10 parts by
     weight of a foaming agent to 100 parts by weight of a polylactic acid-base
     resin composition comprising from 80 to 100% by weight of polylactic acid
     or a lactic acid-hydroxycarboxylic acid copolymer and from 0 to 20% by
     weight of a plasticizer, conducting melt-foaming extrusion of resulting
     mixture, and opening the foam cells in the extrudate. The high polymer
     network is characterized in suitable flexibility and hydrolyzability and
     thus useful as a material for absorbing oils and body fluids, screens for
     sunlight, heat-insulating materials, filter media and packaging materials;
     and does not accumulate as industrial wastes because of hydrolyzability in
     the natural environment, even though abandoned after use.","5,223,546","Mitsui Toatsu Chemicals, Inc.
 (Tokyo, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5223546,Methods for making a thermoplastic composition and fibers including same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=6&f=G&l=50&d=PALL&S1=5223546.UREF.&OS=ref/5223546&RS=REF/5223546,,,"6,475,418",2002
1519575761-718,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,High polymer network,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=605&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A degradable polymer network obtained by adding from 0.2 to 10 parts by
     weight of a foaming agent to 100 parts by weight of a polylactic acid-base
     resin composition comprising from 80 to 100% by weight of polylactic acid
     or a lactic acid-hydroxycarboxylic acid copolymer and from 0 to 20% by
     weight of a plasticizer, conducting melt-foaming extrusion of resulting
     mixture, and opening the foam cells in the extrudate. The high polymer
     network is characterized in suitable flexibility and hydrolyzability and
     thus useful as a material for absorbing oils and body fluids, screens for
     sunlight, heat-insulating materials, filter media and packaging materials;
     and does not accumulate as industrial wastes because of hydrolyzability in
     the natural environment, even though abandoned after use.","5,223,546","Mitsui Toatsu Chemicals, Inc.
 (Tokyo, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5223546,Methods for making a biodegradable thermoplastic composition,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=5&f=G&l=50&d=PALL&S1=5223546.UREF.&OS=ref/5223546&RS=REF/5223546,,,"6,544,455",2003
1519575765-719,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,High polymer network,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=605&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A degradable polymer network obtained by adding from 0.2 to 10 parts by
     weight of a foaming agent to 100 parts by weight of a polylactic acid-base
     resin composition comprising from 80 to 100% by weight of polylactic acid
     or a lactic acid-hydroxycarboxylic acid copolymer and from 0 to 20% by
     weight of a plasticizer, conducting melt-foaming extrusion of resulting
     mixture, and opening the foam cells in the extrudate. The high polymer
     network is characterized in suitable flexibility and hydrolyzability and
     thus useful as a material for absorbing oils and body fluids, screens for
     sunlight, heat-insulating materials, filter media and packaging materials;
     and does not accumulate as industrial wastes because of hydrolyzability in
     the natural environment, even though abandoned after use.","5,223,546","Mitsui Toatsu Chemicals, Inc.
 (Tokyo, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5223546,"Poly(L-lactide-co-glycolide) copolymers, methods for making and using same,
     and devices containing same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=4&f=G&l=50&d=PALL&S1=5223546.UREF.&OS=ref/5223546&RS=REF/5223546,,,"6,747,121",2004
1519575772-720,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,High polymer network,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=605&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A degradable polymer network obtained by adding from 0.2 to 10 parts by
     weight of a foaming agent to 100 parts by weight of a polylactic acid-base
     resin composition comprising from 80 to 100% by weight of polylactic acid
     or a lactic acid-hydroxycarboxylic acid copolymer and from 0 to 20% by
     weight of a plasticizer, conducting melt-foaming extrusion of resulting
     mixture, and opening the foam cells in the extrudate. The high polymer
     network is characterized in suitable flexibility and hydrolyzability and
     thus useful as a material for absorbing oils and body fluids, screens for
     sunlight, heat-insulating materials, filter media and packaging materials;
     and does not accumulate as industrial wastes because of hydrolyzability in
     the natural environment, even though abandoned after use.","5,223,546","Mitsui Toatsu Chemicals, Inc.
 (Tokyo, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5223546,Method of preparing a star polymer macromonomer,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=3&f=G&l=50&d=PALL&S1=5223546.UREF.&OS=ref/5223546&RS=REF/5223546,,,"8,378,041",2013
1519575783-721,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,High polymer network,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=605&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A degradable polymer network obtained by adding from 0.2 to 10 parts by
     weight of a foaming agent to 100 parts by weight of a polylactic acid-base
     resin composition comprising from 80 to 100% by weight of polylactic acid
     or a lactic acid-hydroxycarboxylic acid copolymer and from 0 to 20% by
     weight of a plasticizer, conducting melt-foaming extrusion of resulting
     mixture, and opening the foam cells in the extrudate. The high polymer
     network is characterized in suitable flexibility and hydrolyzability and
     thus useful as a material for absorbing oils and body fluids, screens for
     sunlight, heat-insulating materials, filter media and packaging materials;
     and does not accumulate as industrial wastes because of hydrolyzability in
     the natural environment, even though abandoned after use.","5,223,546","Mitsui Toatsu Chemicals, Inc.
 (Tokyo, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5223546,Macromonomers for preparation of degradable polymers and model networks,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=2&f=G&l=50&d=PALL&S1=5223546.UREF.&OS=ref/5223546&RS=REF/5223546,,,"8,895,673",2014
1519575792-722,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,High polymer network,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=605&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A degradable polymer network obtained by adding from 0.2 to 10 parts by
     weight of a foaming agent to 100 parts by weight of a polylactic acid-base
     resin composition comprising from 80 to 100% by weight of polylactic acid
     or a lactic acid-hydroxycarboxylic acid copolymer and from 0 to 20% by
     weight of a plasticizer, conducting melt-foaming extrusion of resulting
     mixture, and opening the foam cells in the extrudate. The high polymer
     network is characterized in suitable flexibility and hydrolyzability and
     thus useful as a material for absorbing oils and body fluids, screens for
     sunlight, heat-insulating materials, filter media and packaging materials;
     and does not accumulate as industrial wastes because of hydrolyzability in
     the natural environment, even though abandoned after use.","5,223,546","Mitsui Toatsu Chemicals, Inc.
 (Tokyo, 
JP)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5223546,Macromonomers for preparation of degradable polymers and model networks,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=1&f=G&l=50&d=PALL&S1=5223546.UREF.&OS=ref/5223546&RS=REF/5223546,,,"9,200,097",2015
1519575804-723,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,Process for preparing a degradable high polymer network,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=604&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A degradable polymer network obtained by adding from 0.2 to 10 parts by
     weight of a foaming agent to 100 parts by weight of a polylactic acid-base
     resin composition comprising from 80 to 100% by weight of polylactic acid
     or a lactic acid-hydroxycarboxylic acid copolymer and from 0 to 20% by
     weight of a plasticizer, conducting melt-foaming extrusion of resulting
     mixture, and opening the foam cells in the extrudate. The high polymer
     network is characterized in suitable flexibility and hydrolyzability and
     thus useful as a material for absorbing of oils and body fluids, screens
     for sunlight, heat-insulating materials, filter media and packaging
     materials; and does not accumulate as industrial wastes because of
     hydrolyzability in the natural environment, even though abandoned after
     use.","5,238,968","Mitsui Toatsu Chemicals, Inc.
 (Tokyo, 
JP)",null,,,,,,,
1519575833-724,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=603&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,247,058","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247058,Lactide polymerization,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=46&f=G&l=50&d=PALL&S1=5247058.UREF.&OS=ref/5247058&RS=REF/5247058,,,"5,357,034",1994
1519575839-725,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=603&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,247,058","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247058,"Continuous process for manufacture of lactide polymers with purification
     by distillation",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=45&f=G&l=50&d=PALL&S1=5247058.UREF.&OS=ref/5247058&RS=REF/5247058,,,"5,357,035",1994
1519575846-726,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=603&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,247,058","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247058,Integrated process for the manufacture of lactide,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=44&f=G&l=50&d=PALL&S1=5247058.UREF.&OS=ref/5247058&RS=REF/5247058,,,"5,521,278",1996
1519575853-727,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=603&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,247,058","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247058,"Viscosity-modified lactide polymer composition and process for
     manufacture thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=43&f=G&l=50&d=PALL&S1=5247058.UREF.&OS=ref/5247058&RS=REF/5247058,,,"5,594,095",1997
1519575860-728,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=603&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,247,058","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247058,"Viscosity-modified lactide polymer composition and process for
     manufacture thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=42&f=G&l=50&d=PALL&S1=5247058.UREF.&OS=ref/5247058&RS=REF/5247058,,,"5,798,435",1998
1519575868-729,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=603&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,247,058","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247058,"Viscosity-modified lactide polymer composition and process for
     manufacture thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=41&f=G&l=50&d=PALL&S1=5247058.UREF.&OS=ref/5247058&RS=REF/5247058,,,"5,998,552",1999
1519575877-730,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=603&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,247,058","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247058,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=40&f=G&l=50&d=PALL&S1=5247058.UREF.&OS=ref/5247058&RS=REF/5247058,,,"6,005,067",1999
1519575881-731,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=603&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,247,058","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247058,Lactic acid processing methods arrangements and products,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=39&f=G&l=50&d=PALL&S1=5247058.UREF.&OS=ref/5247058&RS=REF/5247058,,,"6,229,046",2001
1519575889-732,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=603&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,247,058","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247058,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=38&f=G&l=50&d=PALL&S1=5247058.UREF.&OS=ref/5247058&RS=REF/5247058,,,"6,277,951",2001
1519575895-733,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=603&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,247,058","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247058,"Viscosity-modified lactide polymer composition and process for manufacture
     thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=37&f=G&l=50&d=PALL&S1=5247058.UREF.&OS=ref/5247058&RS=REF/5247058,,,"6,291,597",2001
1519575900-734,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=603&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,247,058","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247058,"Lactic acid processing; methods; arrangements; and, product",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=36&f=G&l=50&d=PALL&S1=5247058.UREF.&OS=ref/5247058&RS=REF/5247058,,,"6,320,077",2001
1519575908-735,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=603&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,247,058","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247058,Low PH lactic acid fermentation,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=35&f=G&l=50&d=PALL&S1=5247058.UREF.&OS=ref/5247058&RS=REF/5247058,,,"6,475,759",2002
1519575913-736,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=603&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,247,058","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247058,"Lactic acid processing; methods; arrangements; and, products",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=34&f=G&l=50&d=PALL&S1=5247058.UREF.&OS=ref/5247058&RS=REF/5247058,,,"6,534,679",2003
1519575921-737,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=603&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,247,058","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247058,"Lactic acid processing; methods; arrangements; and, products",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=33&f=G&l=50&d=PALL&S1=5247058.UREF.&OS=ref/5247058&RS=REF/5247058,,,"7,144,977",2006
1519575926-738,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=603&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,247,058","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247058,"Lactobacillus strains and use thereof in fermentation for L-lactic acid
     production",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=32&f=G&l=50&d=PALL&S1=5247058.UREF.&OS=ref/5247058&RS=REF/5247058,,,"7,300,787",2007
1519575934-739,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=603&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,247,058","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247058,Biodegradable netting,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=31&f=G&l=50&d=PALL&S1=5247058.UREF.&OS=ref/5247058&RS=REF/5247058,,,"7,326,659",2008
1519575937-740,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=603&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,247,058","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247058,Polymeric materials from renewable resources,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=30&f=G&l=50&d=PALL&S1=5247058.UREF.&OS=ref/5247058&RS=REF/5247058,,,"7,723,461",2010
1519575941-741,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=603&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,247,058","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247058,Process for crystallising amorphous plastic granulates,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=29&f=G&l=50&d=PALL&S1=5247058.UREF.&OS=ref/5247058&RS=REF/5247058,,,"7,771,493",2010
1519575943-742,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=603&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,247,058","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247058,PLA film with good sliding and antistatic properties,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=28&f=G&l=50&d=PALL&S1=5247058.UREF.&OS=ref/5247058&RS=REF/5247058,,,"7,914,881",2011
1519575949-743,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=603&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,247,058","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247058,Photobioreactor systems positioned on bodies of water,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=27&f=G&l=50&d=PALL&S1=5247058.UREF.&OS=ref/5247058&RS=REF/5247058,,,"7,980,024",2011
1519575956-744,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=603&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,247,058","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247058,PLA film comprising good antistatic properties,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=26&f=G&l=50&d=PALL&S1=5247058.UREF.&OS=ref/5247058&RS=REF/5247058,,,"8,101,271",2012
1519575967-745,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=603&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,247,058","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247058,"Photobioreactor systems and methods for treating CO.sub.2-enriched gas and
     producing biomass",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=25&f=G&l=50&d=PALL&S1=5247058.UREF.&OS=ref/5247058&RS=REF/5247058,,,"8,110,395",2012
1519575976-746,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=603&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,247,058","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247058,Simultaneously drawn opaque film made of PLA,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=24&f=G&l=50&d=PALL&S1=5247058.UREF.&OS=ref/5247058&RS=REF/5247058,,,"8,231,978",2012
1519575983-747,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=603&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,247,058","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247058,"Photobioreactor cell culture systems, methods for preconditioning
     photosynthetic organisms, and cultures of photosynthetic organisms
     produced thereby",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=23&f=G&l=50&d=PALL&S1=5247058.UREF.&OS=ref/5247058&RS=REF/5247058,,,"8,507,253",2013
1519575991-748,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=603&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,247,058","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247058,"Photobioreactor systems and methods for treating CO.sub.2-enriched gas and
     producing biomass",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=22&f=G&l=50&d=PALL&S1=5247058.UREF.&OS=ref/5247058&RS=REF/5247058,,,"8,507,264",2013
1519575995-749,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=603&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,247,058","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247058,Recovery of lactic acid values from a meso-lactide stream,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=21&f=G&l=50&d=PALL&S1=5247058.UREF.&OS=ref/5247058&RS=REF/5247058,,,"8,552,209",2013
1519576002-750,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=603&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,247,058","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247058,Process for producing aqueous dispersions of thermoplastic polyesters,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=20&f=G&l=50&d=PALL&S1=5247058.UREF.&OS=ref/5247058&RS=REF/5247058,,,"8,604,101",2013
1519576012-751,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=603&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,247,058","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247058,Methods for producing lactide with recycle of meso-lactide,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=19&f=G&l=50&d=PALL&S1=5247058.UREF.&OS=ref/5247058&RS=REF/5247058,,,"8,674,056",2014
1519576024-752,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=603&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,247,058","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247058,Simultaneously drawn opaque film made of PLA,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=18&f=G&l=50&d=PALL&S1=5247058.UREF.&OS=ref/5247058&RS=REF/5247058,,,"8,790,786",2014
1519576034-753,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=603&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,247,058","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247058,Photobioreactor systems positioned on bodies of water,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=17&f=G&l=50&d=PALL&S1=5247058.UREF.&OS=ref/5247058&RS=REF/5247058,,,"8,859,262",2014
1519576038-754,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=603&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,247,058","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247058,"Photobioreactor systems and methods for treating CO2-enriched gas and
     producing biomass",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=16&f=G&l=50&d=PALL&S1=5247058.UREF.&OS=ref/5247058&RS=REF/5247058,,,"8,877,488",2014
1519576041-755,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=603&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,247,058","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247058,Recovery of lactic acid values from a meso-lactide stream,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=15&f=G&l=50&d=PALL&S1=5247058.UREF.&OS=ref/5247058&RS=REF/5247058,,,"9,035,076",2015
1519576050-756,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=603&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,247,058","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247058,"Polylactic acid preparation method, polylactic acid resin prepared using
     the method, resin composition comprising the polylactic acid resin, and
     catalyst system for preparing polylactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=14&f=G&l=50&d=PALL&S1=5247058.UREF.&OS=ref/5247058&RS=REF/5247058,,,"9,234,075",2016
1519576059-757,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=603&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,247,058","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247058,Packaging for UV sterilization,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=13&f=G&l=50&d=PALL&S1=5247058.UREF.&OS=ref/5247058&RS=REF/5247058,,,"9,309,018",2016
1519576064-758,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=603&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,247,058","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247058,Array for processing materials,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=12&f=G&l=50&d=PALL&S1=5247058.UREF.&OS=ref/5247058&RS=REF/5247058,,,"9,334,518",2016
1519576070-759,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=603&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,247,058","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247058,Processing materials,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=11&f=G&l=50&d=PALL&S1=5247058.UREF.&OS=ref/5247058&RS=REF/5247058,,,"9,371,550",2016
1519576075-760,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=603&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,247,058","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247058,Reconfigureable processing enclosures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=10&f=G&l=50&d=PALL&S1=5247058.UREF.&OS=ref/5247058&RS=REF/5247058,,,"9,388,442",2016
1519576079-761,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=603&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,247,058","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247058,Array for processing materials,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=9&f=G&l=50&d=PALL&S1=5247058.UREF.&OS=ref/5247058&RS=REF/5247058,,,"9,464,334",2016
1519576084-762,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=603&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,247,058","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247058,Methods for treating lignocellulosic materials,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=8&f=G&l=50&d=PALL&S1=5247058.UREF.&OS=ref/5247058&RS=REF/5247058,,,"9,493,851",2016
1519576089-763,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=603&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,247,058","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247058,Controlling process gases,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=7&f=G&l=50&d=PALL&S1=5247058.UREF.&OS=ref/5247058&RS=REF/5247058,,,"9,611,516",2017
1519576097-764,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=603&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,247,058","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247058,Methods for treating lignocellulosic materials,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=6&f=G&l=50&d=PALL&S1=5247058.UREF.&OS=ref/5247058&RS=REF/5247058,,,"9,631,246",2017
1519576105-765,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=603&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,247,058","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247058,Methods for treating lignocellulosic materials,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=5&f=G&l=50&d=PALL&S1=5247058.UREF.&OS=ref/5247058&RS=REF/5247058,,,"9,650,687",2017
1519576109-766,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=603&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,247,058","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247058,Yeast having improved productivity and method of producing product,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=4&f=G&l=50&d=PALL&S1=5247058.UREF.&OS=ref/5247058&RS=REF/5247058,,,"9,701,988",2017
1519576118-767,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=603&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,247,058","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247058,Array for processing materials,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=3&f=G&l=50&d=PALL&S1=5247058.UREF.&OS=ref/5247058&RS=REF/5247058,,,"9,708,761",2017
1519576124-768,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=603&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,247,058","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247058,Methods for treating lignocellulosic materials,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=2&f=G&l=50&d=PALL&S1=5247058.UREF.&OS=ref/5247058&RS=REF/5247058,,,"9,783,861",2017
1519576133-769,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=603&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,247,058","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247058,Processing materials,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=1&f=G&l=50&d=PALL&S1=5247058.UREF.&OS=ref/5247058&RS=REF/5247058,,,"9,816,231",2017
1519576180-770,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,High porosity fractures and methods of creating high porosity fractures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=100&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5247059.UREF.&Page=Next&OS=ref/5247059&RS=REF/5247059,"7,281,580",2007
1519576187-771,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,"Methods of hydraulic fracturing and of propping fractures in subterranean
     formations",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=99&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5247059.UREF.&Page=Next&OS=ref/5247059&RS=REF/5247059,"7,281,581",2007
1519576198-772,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,"Carbon foam particulates and methods of using carbon foam particulates in
     subterranean applications",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=98&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5247059.UREF.&Page=Next&OS=ref/5247059&RS=REF/5247059,"7,299,869",2007
1519576203-773,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,Methods for controlling particulate migration,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=97&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5247059.UREF.&Page=Next&OS=ref/5247059&RS=REF/5247059,"7,299,875",2007
1519576207-774,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,"Lactobacillus strains and use thereof in fermentation for L-lactic acid
     production",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=96&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5247059.UREF.&Page=Next&OS=ref/5247059&RS=REF/5247059,"7,300,787",2007
1519576211-775,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,Compositions and methods for particulate consolidation,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=95&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5247059.UREF.&Page=Next&OS=ref/5247059&RS=REF/5247059,"7,306,037",2007
1519576216-776,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,"Methods relating to maintaining the structural integrity of deviated well
     bores",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=94&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5247059.UREF.&Page=Next&OS=ref/5247059&RS=REF/5247059,"7,318,473",2008
1519576220-777,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,"Methods and compositions for controlling formation fines and reducing
     proppant flow-back",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=93&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5247059.UREF.&Page=Next&OS=ref/5247059&RS=REF/5247059,"7,318,474",2008
1519576222-778,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,Biodegradable netting,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=92&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5247059.UREF.&Page=Next&OS=ref/5247059&RS=REF/5247059,"7,326,659",2008
1519576226-779,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,Methods for fracturing subterranean wells,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=91&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5247059.UREF.&Page=Next&OS=ref/5247059&RS=REF/5247059,"7,334,635",2008
1519576230-780,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,Methods of creating high-porosity propped fractures using reticulated foam,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=90&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5247059.UREF.&Page=Next&OS=ref/5247059&RS=REF/5247059,"7,334,636",2008
1519576235-781,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,Methods of stabilizing surfaces of subterranean formations,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=89&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5247059.UREF.&Page=Next&OS=ref/5247059&RS=REF/5247059,"7,343,973",2008
1519576241-782,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,"Methods for mitigating the production of water from subterranean
     formations",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=88&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5247059.UREF.&Page=Next&OS=ref/5247059&RS=REF/5247059,"7,345,011",2008
1519576249-783,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,Methods of preparing and using coated particulates,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=87&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5247059.UREF.&Page=Next&OS=ref/5247059&RS=REF/5247059,"7,350,571",2008
1519576258-784,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,"Self-degrading cement compositions and methods of using self-degrading
     cement compositions in subterranean formations",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=86&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5247059.UREF.&Page=Next&OS=ref/5247059&RS=REF/5247059,"7,353,876",2008
1519576264-785,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,Methods of controlling sand and water production in subterranean zones,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=85&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5247059.UREF.&Page=Next&OS=ref/5247059&RS=REF/5247059,"7,398,825",2008
1519576273-786,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,Methods of coating particulates,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=84&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5247059.UREF.&Page=Next&OS=ref/5247059&RS=REF/5247059,"7,407,010",2008
1519576282-787,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,"Remediation of subterranean formations using vibrational waves and
     consolidating agents",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=83&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5247059.UREF.&Page=Next&OS=ref/5247059&RS=REF/5247059,"7,413,010",2008
1519576293-788,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,"Methods and compositions for inducing tip screenouts in frac-packing
     operations",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=82&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5247059.UREF.&Page=Next&OS=ref/5247059&RS=REF/5247059,"7,413,017",2008
1519576299-789,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,Methods of controlled acidization in a wellbore,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=81&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5247059.UREF.&Page=Next&OS=ref/5247059&RS=REF/5247059,"7,431,088",2008
1519576306-790,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,"Methods for controlling migration of particulates in a subterranean
     formation",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=80&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5247059.UREF.&Page=Next&OS=ref/5247059&RS=REF/5247059,"7,448,451",2008
1519576312-791,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,"Methods and compositions relating to the control of the rates of
     acid-generating compounds in acidizing operations",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=79&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5247059.UREF.&Page=Next&OS=ref/5247059&RS=REF/5247059,"7,455,112",2008
1519576320-792,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,Methods of modifying particulate surfaces to affect acidic sites thereon,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=78&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5247059.UREF.&Page=Next&OS=ref/5247059&RS=REF/5247059,"7,461,697",2008
1519576327-793,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,Treatment fluids and methods of use in subterranean formations,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=77&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5247059.UREF.&Page=Next&OS=ref/5247059&RS=REF/5247059,"7,475,728",2009
1519576333-794,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,"Delayed tackifying compositions and associated methods involving
     controlling particulate migration",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=76&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5247059.UREF.&Page=Next&OS=ref/5247059&RS=REF/5247059,"7,484,564",2009
1519576338-795,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,"Methods of isolating zones in subterranean formations using self-degrading
     cement compositions",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=75&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5247059.UREF.&Page=Next&OS=ref/5247059&RS=REF/5247059,"7,497,258",2009
1519576347-796,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,Methods of degrading filter cakes in a subterranean formation,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=74&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5247059.UREF.&Page=Next&OS=ref/5247059&RS=REF/5247059,"7,497,278",2009
1519576353-797,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,"Methods of enhancing uniform placement of a resin in a subterranean
     formation",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=73&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5247059.UREF.&Page=Next&OS=ref/5247059&RS=REF/5247059,"7,500,521",2009
1519576362-798,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,"Fracturing fluids comprising degradable diverting agents and methods of
     use in subterranean formations",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=72&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5247059.UREF.&Page=Next&OS=ref/5247059&RS=REF/5247059,"7,506,689",2009
1519576371-799,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,On-the-fly preparation of proppant and its use in subterranean operations,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=71&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5247059.UREF.&Page=Next&OS=ref/5247059&RS=REF/5247059,"7,541,318",2009
1519576376-800,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,"Acidic treatment fluids comprising scleroglucan and/or diutan and
     associated methods",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=70&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5247059.UREF.&Page=Next&OS=ref/5247059&RS=REF/5247059,"7,547,665",2009
1519576383-801,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,"In-situ filter cake degradation compositions and methods of use in
     subterranean formations",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=69&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5247059.UREF.&Page=Next&OS=ref/5247059&RS=REF/5247059,"7,553,800",2009
1519576390-802,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,High porosity fractures and methods of creating high porosity fractures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=68&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5247059.UREF.&Page=Next&OS=ref/5247059&RS=REF/5247059,"7,571,767",2009
1519576397-803,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,"Delayed tackifying compositions and associated methods involving
     controlling particulate migration",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=67&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5247059.UREF.&Page=Next&OS=ref/5247059&RS=REF/5247059,"7,595,280",2009
1519576404-804,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,"Filter cake degradation compositions and methods of use in subterranean
     operations",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=66&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5247059.UREF.&Page=Next&OS=ref/5247059&RS=REF/5247059,"7,598,208",2009
1519576411-805,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,"Degradable particulates as friction reducers for the flow of solid
     particulates and associated methods of use",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=65&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5247059.UREF.&Page=Next&OS=ref/5247059&RS=REF/5247059,"7,608,566",2009
1519576419-806,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,Degradable surfactants and methods for use,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=64&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5247059.UREF.&Page=Next&OS=ref/5247059&RS=REF/5247059,"7,608,567",2009
1519576428-807,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,"Acidic treatment fluids comprising scleroglucan and/or diutan and
     associated methods",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=63&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5247059.UREF.&Page=Next&OS=ref/5247059&RS=REF/5247059,"7,621,334",2009
1519576436-808,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,"Kickoff plugs comprising a self-degrading cement in subterranean well
     bores",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=62&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5247059.UREF.&Page=Next&OS=ref/5247059&RS=REF/5247059,"7,637,319",2009
1519576440-809,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,"Methods of directional drilling and forming kickoff plugs using
     self-degrading cement in subterranean well bores",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=61&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5247059.UREF.&Page=Next&OS=ref/5247059&RS=REF/5247059,"7,640,985",2010
1519576447-810,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,Methods of degrading filter cakes in subterranean formations,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=60&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5247059.UREF.&Page=Next&OS=ref/5247059&RS=REF/5247059,"7,648,946",2010
1519576458-811,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,Degradable surfactants and methods for use,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=59&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5247059.UREF.&Page=Next&OS=ref/5247059&RS=REF/5247059,"7,662,753",2010
1519576468-812,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,Methods of cleaning sand control screens and gravel packs,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=58&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5247059.UREF.&Page=Next&OS=ref/5247059&RS=REF/5247059,"7,665,517",2010
1519576477-813,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,Method of stabilizing unconsolidated formation for sand control,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=57&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5247059.UREF.&Page=Next&OS=ref/5247059&RS=REF/5247059,"7,673,686",2010
1519576486-814,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,"Treatment fluids and methods of forming degradable filter cakes comprising
     aliphatic polyester and their use in subterranean formations",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=56&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5247059.UREF.&Page=Next&OS=ref/5247059&RS=REF/5247059,"7,674,753",2010
1519576493-815,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,Degradable surfactants and methods for use,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=55&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5247059.UREF.&Page=Next&OS=ref/5247059&RS=REF/5247059,"7,677,315",2010
1519576500-816,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,Drill-in fluids and associated methods,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=54&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5247059.UREF.&Page=Next&OS=ref/5247059&RS=REF/5247059,"7,678,742",2010
1519576506-817,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,Drill-in fluids and associated methods,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=53&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5247059.UREF.&Page=Next&OS=ref/5247059&RS=REF/5247059,"7,678,743",2010
1519576511-818,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,Acid-generating fluid loss control additives and associated methods,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=52&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5247059.UREF.&Page=Next&OS=ref/5247059&RS=REF/5247059,"7,686,080",2010
1519576517-819,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,Drill-in fluids and associated methods,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=51&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=2&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&S1=5247059.UREF.&Page=Next&OS=ref/5247059&RS=REF/5247059,"7,687,438",2010
1519576524-820,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,Orthoester-based surfactants and associated methods,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=50&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,,"7,700,525",2010
1519576528-821,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,Methods for controlling particulate migration,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=49&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,,"7,712,531",2010
1519576534-822,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,Orthoester-based surfactants and associated methods,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=48&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,,"7,713,916",2010
1519576538-823,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,Polymer synthesis from macrocycles,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=47&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,,"7,714,097",2010
1519576543-824,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,Polymeric materials from renewable resources,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=46&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,,"7,723,461",2010
1519576549-825,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,"Method and composition for enhancing coverage and displacement of
     treatment fluids into subterranean formations",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=45&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,,"7,757,768",2010
1519576553-826,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,Consolidating agent emulsions and associated methods,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=44&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,,"7,819,192",2010
1519576557-827,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,"Subterranean treatment fluids comprising a degradable bridging agent and
     methods of treating subterranean formations",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=43&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,,"7,829,507",2010
1519576560-828,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,Microemulsifiers and methods of making and using same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=42&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,,"7,833,943",2010
1519576564-829,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,"Methods and compositions using crosslinked aliphatic polyesters in well
     bore applications",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=41&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,,"7,833,944",2010
1519576569-830,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,"Low-quality particulates and methods of making and using improved
     low-quality particulates",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=40&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,,"7,883,740",2011
1519576573-831,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,Compositions and methods for the removal of oil-based filtercakes,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=39&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,,"7,906,464",2011
1519576577-832,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,"Aqueous-based emulsified consolidating agents suitable for use in drill-in
     applications",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=38&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,,"7,926,591",2011
1519576581-833,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,"Method and composition for enhancing coverage and displacement of
     treatment fluids into subterranean formations",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=37&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,,"7,938,181",2011
1519576591-834,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,Microemulsifiers and methods of making and using same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=36&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,,"7,960,314",2011
1519576600-835,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,"Resin compositions and methods of using resin compositions to control
     proppant flow-back",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=35&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,,"7,963,330",2011
1519576606-836,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,Photobioreactor systems positioned on bodies of water,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=34&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,,"7,980,024",2011
1519576617-837,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,"Treatment fluids comprising relative permeability modifiers and methods of
     use",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=33&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,,"7,998,910",2011
1519576624-838,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,Clean fluid systems for partial monolayer fracturing,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=32&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,,"8,006,760",2011
1519576630-839,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,"Resin compositions and methods of using such resin compositions in
     subterranean applications",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=31&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,,"8,017,561",2011
1519576633-840,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,"Methods and compositions relating to the hydrolysis of water-hydrolysable
     materials",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=30&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,,"8,030,249",2011
1519576636-841,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,"Methods and compositions relating to the hydrolysis of water-hydrolysable
     materials",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=29&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,,"8,030,251",2011
1519576640-842,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,Methods of fluid-controlled geometry stimulation,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=28&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,,"8,082,992",2011
1519576651-843,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,"Photobioreactor systems and methods for treating CO.sub.2-enriched gas and
     producing biomass",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=27&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,,"8,110,395",2012
1519576661-844,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,Self-degrading fibers and associated methods of use and manufacture,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=26&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,,"8,188,013",2012
1519576669-845,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,Surfactant wash treatment fluids and associated methods,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=25&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,,"8,220,548",2012
1519576674-846,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,"Catalyst for direct conversion of esters of lactic acid to lactide and the
     method for producing lactide using the same",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=24&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,,"8,258,317",2012
1519576681-847,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,Degradable particulates and associated methods,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=23&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,,"8,329,621",2012
1519576685-848,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,"Methods of tracking fluids produced from various zones in a subterranean
     well",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=22&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,,"8,354,279",2013
1519576691-849,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,Consolidating agent emulsions and associated methods,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=21&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,,"8,443,885",2013
1519576698-850,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,"Photobioreactor cell culture systems, methods for preconditioning
     photosynthetic organisms, and cultures of photosynthetic organisms
     produced thereby",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=20&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,,"8,507,253",2013
1519576701-851,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,"Photobioreactor systems and methods for treating CO.sub.2-enriched gas and
     producing biomass",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=19&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,,"8,507,264",2013
1519576708-852,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,"On-the fly coating of acid-releasing degradable material onto a
     particulate",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=18&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,,"8,541,051",2013
1519576711-853,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,"Methods of preparing degradable materials and methods of use in
     subterranean formations",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=17&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,,"8,598,092",2013
1519576715-854,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,Process for producing aqueous dispersions of thermoplastic polyesters,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=16&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,,"8,604,101",2013
1519576724-855,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,"Compositions and applications of resins in treating subterranean
     formations",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=15&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,,"8,613,320",2013
1519576729-856,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,"Methods and compositions for controlling formation fines and reducing
     proppant flow-back",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=14&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,,"8,689,872",2014
1519576737-857,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,Photobioreactor systems positioned on bodies of water,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=13&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,,"8,859,262",2014
1519576745-858,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,"Photobioreactor systems and methods for treating CO2-enriched gas and
     producing biomass",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=12&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,,"8,877,488",2014
1519576751-859,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,Array for processing materials,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=11&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,,"9,334,518",2016
1519576757-860,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,Processing materials,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=10&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,,"9,371,550",2016
1519576763-861,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,Reconfigureable processing enclosures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=9&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,,"9,388,442",2016
1519576770-862,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,Array for processing materials,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=8&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,,"9,464,334",2016
1519576779-863,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,Methods for treating lignocellulosic materials,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=7&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,,"9,493,851",2016
1519576785-864,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,Controlling process gases,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=6&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,,"9,611,516",2017
1519576794-865,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,Methods for treating lignocellulosic materials,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=5&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,,"9,631,246",2017
1519576805-866,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,Methods for treating lignocellulosic materials,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=4&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,,"9,650,687",2017
1519576813-867,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,Array for processing materials,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=3&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,,"9,708,761",2017
1519576822-868,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,Methods for treating lignocellulosic materials,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=2&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,,"9,783,861",2017
1519576827-869,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for the manufacture of a purified lactide from esters
     of lactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=602&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of substantially purified lactide
     and lactide polymers from an ester of lactic acid including the steps of
     forming crude lactide in the presence of a catalyst means to form a
     condensation reaction by-product and polylactic acid and depolymerizing
     the polylactic acid molecules followed by subsequent purification of the
     crude lactide in a distillation system. A purified lactide is then
     polymerized.","5,247,059","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5247059,Processing materials,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=1&f=G&l=50&d=PALL&S1=5247059.UREF.&OS=ref/5247059&RS=REF/5247059,,,"9,816,231",2017
1519576848-870,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=601&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,258,488","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5258488,Lactide polymerization,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=43&f=G&l=50&d=PALL&S1=5258488.UREF.&OS=ref/5258488&RS=REF/5258488,,,"5,357,034",1994
1519576855-871,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=601&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,258,488","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5258488,"Continuous process for manufacture of lactide polymers with purification
     by distillation",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=42&f=G&l=50&d=PALL&S1=5258488.UREF.&OS=ref/5258488&RS=REF/5258488,,,"5,357,035",1994
1519576860-872,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=601&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,258,488","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5258488,Poly(lactic acid) composition having improved physical properties,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=41&f=G&l=50&d=PALL&S1=5258488.UREF.&OS=ref/5258488&RS=REF/5258488,,,"5,498,650",1996
1519576870-873,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=601&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,258,488","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5258488,Integrated process for the manufacture of lactide,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=40&f=G&l=50&d=PALL&S1=5258488.UREF.&OS=ref/5258488&RS=REF/5258488,,,"5,521,278",1996
1519576878-874,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=601&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,258,488","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5258488,"Impact modified melt-stable lactide polymer compositions and processes
     for manufacture thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=39&f=G&l=50&d=PALL&S1=5258488.UREF.&OS=ref/5258488&RS=REF/5258488,,,"5,714,573",1998
1519576884-875,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=601&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,258,488","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5258488,"Impact modified melt-stable lactide polymer compositions and processes
     for manufacture thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=38&f=G&l=50&d=PALL&S1=5258488.UREF.&OS=ref/5258488&RS=REF/5258488,,,"5,922,832",1999
1519576890-876,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=601&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,258,488","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5258488,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=37&f=G&l=50&d=PALL&S1=5258488.UREF.&OS=ref/5258488&RS=REF/5258488,,,"6,005,067",1999
1519576895-877,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=601&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,258,488","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5258488,Environmentally friendly chewing gum bases,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=36&f=G&l=50&d=PALL&S1=5258488.UREF.&OS=ref/5258488&RS=REF/5258488,,,"6,153,231",2000
1519576905-878,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=601&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,258,488","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5258488,Lactic acid processing methods arrangements and products,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=35&f=G&l=50&d=PALL&S1=5258488.UREF.&OS=ref/5258488&RS=REF/5258488,,,"6,229,046",2001
1519576909-879,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=601&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,258,488","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5258488,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=34&f=G&l=50&d=PALL&S1=5258488.UREF.&OS=ref/5258488&RS=REF/5258488,,,"6,277,951",2001
1519576914-880,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=601&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,258,488","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5258488,"Lactic acid processing; methods; arrangements; and, product",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=33&f=G&l=50&d=PALL&S1=5258488.UREF.&OS=ref/5258488&RS=REF/5258488,,,"6,320,077",2001
1519576920-881,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=601&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,258,488","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5258488,Low PH lactic acid fermentation,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=32&f=G&l=50&d=PALL&S1=5258488.UREF.&OS=ref/5258488&RS=REF/5258488,,,"6,475,759",2002
1519576925-882,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=601&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,258,488","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5258488,"Impact modified melt-stable lactide polymer compositions and processes for
     manufacture thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=31&f=G&l=50&d=PALL&S1=5258488.UREF.&OS=ref/5258488&RS=REF/5258488,,,"6,495,631",2002
1519576930-883,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=601&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,258,488","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5258488,"Lactic acid processing; methods; arrangements; and, products",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=30&f=G&l=50&d=PALL&S1=5258488.UREF.&OS=ref/5258488&RS=REF/5258488,,,"6,534,679",2003
1519576939-884,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=601&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,258,488","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5258488,"Biodegradable chewing gum bases including plasticized poly(D,L-lactic acid)
     and copolymers thereof",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=29&f=G&l=50&d=PALL&S1=5258488.UREF.&OS=ref/5258488&RS=REF/5258488,,,"6,613,363",2003
1519576948-885,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=601&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,258,488","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5258488,"Lactic acid processing; methods; arrangements; and, products",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=28&f=G&l=50&d=PALL&S1=5258488.UREF.&OS=ref/5258488&RS=REF/5258488,,,"7,144,977",2006
1519576959-886,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=601&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,258,488","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5258488,"Lactobacillus strains and use thereof in fermentation for L-lactic acid
     production",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=27&f=G&l=50&d=PALL&S1=5258488.UREF.&OS=ref/5258488&RS=REF/5258488,,,"7,300,787",2007
1519576971-887,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=601&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,258,488","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5258488,Biodegradable netting,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=26&f=G&l=50&d=PALL&S1=5258488.UREF.&OS=ref/5258488&RS=REF/5258488,,,"7,326,659",2008
1519576979-888,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=601&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,258,488","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5258488,Polymeric materials from renewable resources,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=25&f=G&l=50&d=PALL&S1=5258488.UREF.&OS=ref/5258488&RS=REF/5258488,,,"7,723,461",2010
1519576987-889,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=601&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,258,488","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5258488,Dryer sheet and methods for manufacturing and using a dryer sheet,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=24&f=G&l=50&d=PALL&S1=5258488.UREF.&OS=ref/5258488&RS=REF/5258488,,,"7,943,566",2011
1519576991-890,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=601&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,258,488","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5258488,Dryer sheet and methods for manufacturing and using a dryer sheet,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=23&f=G&l=50&d=PALL&S1=5258488.UREF.&OS=ref/5258488&RS=REF/5258488,,,"7,947,644",2011
1519577004-891,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=601&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,258,488","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5258488,Photobioreactor systems positioned on bodies of water,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=22&f=G&l=50&d=PALL&S1=5258488.UREF.&OS=ref/5258488&RS=REF/5258488,,,"7,980,024",2011
1519577012-892,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=601&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,258,488","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5258488,"Photobioreactor systems and methods for treating CO.sub.2-enriched gas and
     producing biomass",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=21&f=G&l=50&d=PALL&S1=5258488.UREF.&OS=ref/5258488&RS=REF/5258488,,,"8,110,395",2012
1519577017-893,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=601&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,258,488","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5258488,"Photobioreactor cell culture systems, methods for preconditioning
     photosynthetic organisms, and cultures of photosynthetic organisms
     produced thereby",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=20&f=G&l=50&d=PALL&S1=5258488.UREF.&OS=ref/5258488&RS=REF/5258488,,,"8,507,253",2013
1519577025-894,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=601&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,258,488","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5258488,"Photobioreactor systems and methods for treating CO.sub.2-enriched gas and
     producing biomass",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=19&f=G&l=50&d=PALL&S1=5258488.UREF.&OS=ref/5258488&RS=REF/5258488,,,"8,507,264",2013
1519577031-895,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=601&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,258,488","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5258488,Recovery of lactic acid values from a meso-lactide stream,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=18&f=G&l=50&d=PALL&S1=5258488.UREF.&OS=ref/5258488&RS=REF/5258488,,,"8,552,209",2013
1519577036-896,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=601&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,258,488","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5258488,Methods for producing lactide with recycle of meso-lactide,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=17&f=G&l=50&d=PALL&S1=5258488.UREF.&OS=ref/5258488&RS=REF/5258488,,,"8,674,056",2014
1519577046-897,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=601&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,258,488","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5258488,Process for manufacturing lactic acid,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=16&f=G&l=50&d=PALL&S1=5258488.UREF.&OS=ref/5258488&RS=REF/5258488,,,"8,772,440",2014
1519577053-898,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=601&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,258,488","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5258488,Photobioreactor systems positioned on bodies of water,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=15&f=G&l=50&d=PALL&S1=5258488.UREF.&OS=ref/5258488&RS=REF/5258488,,,"8,859,262",2014
1519577061-899,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=601&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,258,488","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5258488,"Photobioreactor systems and methods for treating CO2-enriched gas and
     producing biomass",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=14&f=G&l=50&d=PALL&S1=5258488.UREF.&OS=ref/5258488&RS=REF/5258488,,,"8,877,488",2014
1519577068-900,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=601&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,258,488","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5258488,Recovery of lactic acid values from a meso-lactide stream,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=13&f=G&l=50&d=PALL&S1=5258488.UREF.&OS=ref/5258488&RS=REF/5258488,,,"9,035,076",2015
1519577073-901,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=601&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,258,488","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5258488,"Polylactic acid preparation method, polylactic acid resin prepared using
     the method, resin composition comprising the polylactic acid resin, and
     catalyst system for preparing polylactic acid",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=12&f=G&l=50&d=PALL&S1=5258488.UREF.&OS=ref/5258488&RS=REF/5258488,,,"9,234,075",2016
1519577078-902,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=601&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,258,488","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5258488,Array for processing materials,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=11&f=G&l=50&d=PALL&S1=5258488.UREF.&OS=ref/5258488&RS=REF/5258488,,,"9,334,518",2016
1519577082-903,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=601&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,258,488","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5258488,Processing materials,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=10&f=G&l=50&d=PALL&S1=5258488.UREF.&OS=ref/5258488&RS=REF/5258488,,,"9,371,550",2016
1519577086-904,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=601&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,258,488","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5258488,Reconfigureable processing enclosures,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=9&f=G&l=50&d=PALL&S1=5258488.UREF.&OS=ref/5258488&RS=REF/5258488,,,"9,388,442",2016
1519577092-905,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=601&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,258,488","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5258488,Array for processing materials,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=8&f=G&l=50&d=PALL&S1=5258488.UREF.&OS=ref/5258488&RS=REF/5258488,,,"9,464,334",2016
1519577097-906,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=601&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,258,488","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5258488,Methods for treating lignocellulosic materials,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=7&f=G&l=50&d=PALL&S1=5258488.UREF.&OS=ref/5258488&RS=REF/5258488,,,"9,493,851",2016
1519577103-907,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=601&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,258,488","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5258488,Controlling process gases,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=6&f=G&l=50&d=PALL&S1=5258488.UREF.&OS=ref/5258488&RS=REF/5258488,,,"9,611,516",2017
1519577109-908,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=601&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,258,488","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5258488,Methods for treating lignocellulosic materials,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=5&f=G&l=50&d=PALL&S1=5258488.UREF.&OS=ref/5258488&RS=REF/5258488,,,"9,631,246",2017
1519577114-909,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=601&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,258,488","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5258488,Methods for treating lignocellulosic materials,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=4&f=G&l=50&d=PALL&S1=5258488.UREF.&OS=ref/5258488&RS=REF/5258488,,,"9,650,687",2017
1519577118-910,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=601&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,258,488","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5258488,Array for processing materials,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=3&f=G&l=50&d=PALL&S1=5258488.UREF.&OS=ref/5258488&RS=REF/5258488,,,"9,708,761",2017
1519577125-911,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=601&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,258,488","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5258488,Methods for treating lignocellulosic materials,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=2&f=G&l=50&d=PALL&S1=5258488.UREF.&OS=ref/5258488&RS=REF/5258488,,,"9,783,861",2017
1519577129-912,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=ABST%2F%22polylactic+acid%22&Query=ABST%2F%22polylactic+acid%22&TD=621&Srch1=%22polylactic+acid%22.ABTX.&StartAt=Jump+To&StartNum=615,"Continuous process for manufacture of lactide polymers with controlled
     optical purity",http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=601&f=G&l=50&d=PTXT&s1=%22polylactic+acid%22.ABTX.&p=13&OS=ABST/%22polylactic+acid%22&RS=ABST/%22polylactic+acid%22,1993,"A process for the continuous production of polylactide polymers from lactic
     acid which incorporates removal of water or a solvent carrier to
     concentrate the lactic acid feed followed by polymerization to a
     low-molecular-weight prepolymer. This prepolymer is fed to a reactor in
     which a catalyst is added to facilitate generation of lactide, the
     depolymerization product of polylactic acid. The lactide generated is
     continuously fed to a distillation system as a liquid or vapor wherein
     water and other impurities are removed. The resultant purified liquid
     lactide is fed directly to a polymerization process.","5,258,488","Cargill, Incorporated
 (Minneapolis, 
MN)",[Referenced By],http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/5258488,Processing materials,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=1&f=G&l=50&d=PALL&S1=5258488.UREF.&OS=ref/5258488&RS=REF/5258488,,,"9,816,231",2017
